Polpharma Group Corporate Social Responsibility Report 2013–2014

Ethics, Innovation, Partnership CSR HISTORY OF POLPHARMA GROUP

2015 Drawing up of the Polpharma Group Supplier Code of Conduct and initiation of the implementation process TABLE OF CONTENTS

2015 Publication of the first university textbook on following medical advice by patients correctly in Poland by the Polpharma Scientific Foundation

2015 The 80th anniversary of Polpharma. On that occasion, Polpharma is holding the POLRUN relay – a unique race where more than 700 employees cover a 960 km long route, owing to which the company sends 524 children from Children’s Homes in Polpharma Group • 2 SERVING PATIENTS ETHICAL CONDUCT 4 provinces to summer camps Introduction • 4 AND THE SOCIETY BUSINESS INNOVATION AND ADVANCING CSR Strategy • 6 2015 Development of the new corporate social responsibility strategy of Polpharma Group KNOWLEDGE for the years from 2015 to 2018 Materiality Analysis • 8 Stakeholders • 10 Overview • 14 Overview • 36 Overview • 74 2015 Signing of the Diversity Charter Management Systems • 11 1. We ensure pharmaceutical 5. We reinforce corporate 12. We implement innovative 2015 Award of the CSR Golden Leaf by Polityka weekly security in Poland • 16 ethics • 39 solutions • 76 2. We promote principles of 6. We ensure high product 13. We bridge science 2015 Third place in the Responsible Business Ranking and title of industry CSR leader quality and safe with business • 80 in the Pharmacy & Medicine category preventive care among patients and employees • 17 pharmacotherapy • 43 14. We educate medical 2014 Contributing to the establishment of the Ethics Officers Coalition under the auspices 3. We support patients to follow 7. We ensure and promote and pharmaceutical elevated standards of work of the Global Compact Initiative of the UN Secretary-General in Poland medical advice correctly • 22 professionals • 84 safety • 47 4. We are engaged in community 2014 Completion of the first milestone in the development of the Ethics Programme 8. We nurture employee growth development • Adoption of the Polpharma Group Ethics Programme 27 and commitment • 51 9. We build a culture 2014 The first stakeholder panel in the history of the company held as a voice in the of diversity • 59 planning of the new CSR strategy 10. We care about the 2014 Signing of the Declaration of Polish Businesses for Sustainable Development during environment • 61 the launch of the 3rd stage of Vision 2050 – the New Agenda for Business in Poland 11. We build a sustainable supply chain • 70 GRI Content Index • 88 2014 Joining, as a partner, the Development Initiatives Forum (FIR) and the FIR Grants Fund, with the objective to develop intersectoral cooperation in Pomerania

2014 Social Campaign of the Year 2013 award for the Pressure for Life campaign

2014 Employee-Friendly Employer Award received from a jury chaired by Piotr Duda, head of the National Commission of the NSZZ Solidarność trade union

2013 Publication of the first Corporate Social Responsibility Report in line with GRI guidance

2013 Launch of the Polpharma Group Employee Volunteering Programme ABOUT THE REPORT This publication is aimed at meeting our The CSR indicators provided in the Report cov- The Report is based on information retrieved 2013 Launch of the Get Ready for a Shock (Przygotuj się na wstrząs) campaign to educate commitment to deliver cyclical reports on CSR er the period from 2013 to 2014, however due from Polpharma Group’s internal systems. about anaphylaxis and anaphylactic shock topics in accordance with international Global to the timing of reporting work (second half of No significant changes were observed in the Reporting Initiative guidelines. The report 2015) and significant events finalised in 2015 reporting period. 2013 Joining the Responsible Business Forum, a strategic partnership covers our performance between 1 January (such as the CSR report, entry into force of the 2012 Launch of Pressure for Life (Ciśnienie na życie), the largest education campaign 2013 and 31 December 2014 across all Polish Code of Ethics and Polpharma Group Supplier GRI Guidelines were used to define the content in Poland on hypertension companies and manufacturing divisions of Code of Conduct, etc.), the report contains of the Report. The company’s stakeholders were Polpharma Group (for more information see some additional information on events which involved in the process of selection of the topics 2012 Implementation of the Let’s Go Cycling (Wszyscy na rowery) programme to promote pp. 2 and 3). It is noteworthy that we declared occurred in 2015. covered by the report during a special panel bike commuting our intention to report on an annual basis in meeting (for more information, see page 10). the previous Report (published in December The report has been prepared in accordance 2012 The first edition of the Stop Accidents Programme (Stop Wypadkom) which 2013). However, considering the complexity with the G4 Core Global Reporting Initiative Should you have any opinions or questions promotes proactive employee safety attitudes and encourages reporting of near and the long duration of key projects (which guidelines and has undergone an external regarding the Report, please contact misses often take years to complete), such as the review. Magdalena Rzeszotalska 2011 Establishing cooperation with the European Blood Donor Foundation, where part preparation of the Ethics Programme, we have Corporate Communication and CSR Manager; of revenue from the sale of one of Polpharma’s products supports the Krewniacy decided to publish reports every two years, to No significant limitations as regards the Polpharma S.A. Pharmaceutical Works, (Blood Relatives) campaign promoting voluntary blood donation give an exhaustive account of our actions and coverage of the Report were noted during the ul. Pelplińska 19, 83-200 Starogard Gdański; outcomes. preparation of the Report. email: [email protected] POLPHARMA GROUP POLPHARMA GROUP’S LOCATIONS IN POLAND GDAŃSK

We are the leading drug manufacturer in Poland and one of the largest groups of pharmaceutical companies in Central and Eastern Europe. We are one of the top twenty generics companies globally. For 80 years, our overarching objective has invariably been STAROGARD GDAŃSKI : head offi ce to serve patients and the community, in accordance with our motto which is “People Helping People”. WARSAW: offi ce DUCHNICE WARSAW: manufacturing plant SIERADZ KEY FACTS CORE PRODUCTS AND SERVICES

Leading Polish manufacturer of drugs Prescription drugs NOWA DĘBA and pharmaceutical substances OTC drugs Medical devices Polish market leader in terms of sales volume and value Dietary foods for special medical purposes Cosmetics 80-year track record Food supplements POLPHARMA GROUP’S LOCATIONS ABROAD Biologics 7 manufacturing plants AND MAIN MARKETS FOR MEDICINES Pharmaceutical substances (of which 5 in Poland)

7 R&D centres B2B MARKET: (of which 4 in Poland) Licensing of Polpharma Group products About 7500 employees (of whom 4224 in Poland) Selling substances to other pharmaceutical groups

PLN 1952 million in revenue* Contract manufacturing services from Polish operations in 2014

643 products** across the POLPHARMA GROUP COMPANIES AND DIVISIONS IN POLAND Group’s portfolio, including COVERED BY THE REPORT 346 products offered on the • Polpharma S.A. Pharmaceutical Works domestic market and exported by in Starogard Gdański* Polish companies • Polpharma S.A. Pharmaceutical Works, More than PLN 560 million Biotechnology Division in Gdańsk • Polpharma S.A. Pharmaceutical Works, invested in fi xed assets and R&D Polpharma Group in Poland Manufacturing Division in Duchnice • in Poland in 2013 and 2014 Geographical range of representative offi ces • Polpharma S.A. Pharmaceutical Works, • Sales of pharmaceutical Manufacturing Division in Nowa Dęba substances by continents * Revenue information is retrieved from Pol- Akrihin company in Russia • Polpharma Trade Offi ce Sp. z o.o. in Warsaw • pharma Group consolidated accounts for 2014. Santo, Member of Polpharma Group in Kazakhstan Europe: 47% Revenue from Polish operations is calculated • Polfa Warszawa SA in Warsaw • by means of eliminating revenues generated Asia: 23% • Medana Pharma SA in Sieradz Farmaprojects, strategic partner in Spain by companies operating outside the territory of • North America: 23% the Republic of Poland from the Group result. * Polpharma S.A. Pharmaceutical Works are the sole Africa: 5% or majority shareholder in other Polpharma Group Polpharma Group customers on foreign markets include drug distributors (in the case of medicinal products) companies in Poland South America: 2% ** As at December 2014 and other pharmaceutical companies (in the case pharmaceutical substances and B2B services)

2 Polpharma Group Corporate Social Responsibility Report 2013–2014 3 Polpharma Group Corporate Social Responsibility Report 2013–2014 introduction

This is your second report. What key CSR accom- underpin all our activities. The engagement of maximise access to effective and safe treat- want to proactively reach out to patients plishments can Polpharma Group boast since its almost 2,000 employees in the development ment. In the context of the recent problems with education and engage in the right ETHICS, INNOVATION AND last CSR report? of the Ethics Programme and consultation with the availability of important drugs in programmes to achieve a genuine change PARTNERSHIP of the provisions of the Code of Ethics was Poland, we should speak up about the need in health attitudes of the Poles in the long The previous report was published in late 2013 extremely important to us, refl ecting the sig- to ensure the pharmaceutical security of term. In the short term, we intend to focus and it only covered two companies: Polpharma Ethics, innovation and partnership nifi cance of the process for our organisation. the country. Pharmaceutical security must on continued reinforcement of the culture S.A. Pharmaceutical Works and Polpharma are the key themes that align our be guaranteed by the local pharmaceutical of ethics within our company through Trade Offi ce, as well as the Manufacturing action across a range of areas. We are What key challenges have been faced by phar- industry which prioritises the Polish market active communication and education of Division in Duchnice. In that report, we de- convinced that the interpenetration maceutical companies within the last three years? and is able to ensure continued supplies in our employees, both in Poland and in our clared that we would start applying the same of those features makes us, as a compa- case of manufacturing problems or a politi- foreign companies. Our challenge for the standards to all Polpharma Group compa- Apart from product and service innovations, ny, ready to face the today’s challenges cal and economic crisis. Access to treat- upcoming year will be to implement a nies in Poland and abroad. We are gradually the growth of the pharmaceutical sector war- of the pharmaceutical sector in Poland ment additionally means offering a wide sustainable supply chain strategy, a diffi cult implementing a common approach to various rants the continued modernisation of manu- and globally. range of innovative products at affordable process which requires some additional ac- CSR issues, partly because of our Ethics Pro- facturing facilities and investments in new prices. This is also the domain of domestic tion from certain suppliers. However, we are gramme, which covers the entire Group, but manufacturing areas. This is more and more ETHICS – shared ethical values and generics companies, with Polpharma as the glad that many of our partners understand also owing to some other important initiatives. challenging due to, among other things, fre- agreed rules of ethical conduct support leader. The cost of treatment is particularly the need to raise our standards and see it as The current report demonstrates progress in quent legislation changes at the national and us in the reinforcement of our business important in the case of biologics, which a business opportunity. relation to the previous publication, disclos- international level. In addition, over the last position while keeping to the highest are too expensive for the average Polish ing GRI indicators for our four companies years, we have been witnessing the progressive standards and adding value to all stake- patient. For that reason, we have decided to What do Ethics, Innovation and Partnership and three divisions in Poland. The creation consolidation of the global pharmaceutical holders. develop less expensive follow-on biologics mean to Polpharma Group, as the key themes JERZY STARAK, of the Polpharma Group’s Corporate Social industry, which makes it diffi cult to compete CHAIRMAN which will allow more patients to afford the and prime considerations of the report? Responsibility Strategy has been a signifi cant on the market for smaller players, without INNOVATION – aside from develop- OF THE SUPERVISORY BOARD treatment. POLPHARMA SA achievement lately, which has structured signifi cant economies of scale. Additionally, Those features describe the initiatives we ing innovative drugs, we improve every and prioritised our actions. The key pillars of the economic pressure from governments undertake. In our business, we are guided aspect of our operations every day to What are the key challenges and objectives our strategy are: serving the patients and the and healthcare systems has forced busi- by ethical values and certain standards of better serve the patients and the com- ahead of Polpharma Group in the short term community, ethical business conduct and nesses to look for savings and new ways to ethical conduct. We implement innova- munity. (1 year) and in the long term (3 to 5 years) in innovation and advancing knowledge. We improve performance. Also health care itself is tive solutions in all business areas in order the context of the announced CSR Strategy? have grown in all those key areas, developing changing at a rapid pace. Therapy is becoming to continuously improve our organisation PARTNERSHIP – we integrate differ- our standards on our own. The success of our more personalised and patient-specifi c, and The key challenge we intend to face in the and to better serve the patients and the ent people and entities who do care efforts is evidenced by our fi rst rank in the ICT solutions are more and more common in long term is to maximise the potential of community. We believe that the best results about sustained positive change around medical and pharmaceutical business category diagnostics. Along with demographic change, science, our own intellectual and technol- are obtained through partnerships and important health, scientifi c, social and and third rank in the general classifi cation of low fertility rates in women and more effective ogy resources and third party fi nancing, collaboration rather than working alone. economic objectives. the Responsible Business Ranking 2015. This treatments for many diseases, the popula- such as EU funds, to deliver innovative solu- Therefore, we unite a range of players shows us that Polish businesses should not feel tion is ageing. The demand for products and tions that improve the effi cacy of treatment around important objectives to maximise inferior to global companies where the CSR services for seniors in developed countries has and, consequently, the quality of life for our motto “People Helping People”. concept caught on many years before, and risen, posing a challenge to entire economies. patients. Those solutions involve not only it is also an important commitment to keep The role of biologics in the treatment of seri- new products, but also developments to improving our activities. ous illnesses has increased, as they are more existing ones, aimed at improving follow- effective and have less side effects. They will ing medical advice by patients correctly. How important is the Ethics Programme become even more signifi cant with the launch Non-compliance is one of the main barriers to Polpharma Group? of new, cheaper follow-on biologics. Already to the effective delivery of therapies, which today, 7 out of 10 bestselling drugs in the is stressed by the World Health Organisa- Establishment of the Ethics Programme world are biological products. However, their tion. Although the Polpharma Scientifi c confi rms that we are a trustworthy company development entails a high risk and immense Foundation has been giving publicity to which operates based on respect for the law, investments. this subject for a long time, there is still applicable procedures and highest standards much left to do. We hope that a university of conduct. Further, it refl ects our responsi- Against the backdrop of those challenges, what is textbook published on the initiative of our bility as a pharmaceutical company whose your view on the corporate social responsibility of Foundation will contribute to a greater products infl uence patient health and quality pharmaceutical companies? awareness of that subject by medicine of life. The Programme promotes a strong and students and will help alleviate the problem coherent culture of ethics across the Group, The biggest responsibility pharmaceutical of patient non-compliance. Additionally, we with shared ethical values which guide us and companies have towards the community is to

4 Polpharma Group Corporate Social Responsibility Report 2013–2014 5 Polpharma Group Corporate Social Responsibility Report 2013–2014 OUR COMMITMENTS TO THE SOCIETY 1. THE CSR STRATEGY POLPHARMA GROUP SOCIAL RESPONSIBILITY STRATEGY

e have been on the market to work on the Polpharma Group’s Social for 80 years and we respected Responsibility Strategy in the second half Wthe rules of corporate social of 2014, we were mainly looking for the an- The resulting Polpharma Group’s Social Responsibility Strategy corresponds to responsibility when no one had even used swer to the question how to better respond BUSINESS 5. We reinforce corporate ethics the CSR acronym yet. We have intensified to stakeholder needs while developing our the long-term challenges faced not only L CO 6. We ensure high product quality by the pharmaceutical industry, but also A N and safe pharmacotherapy our efforts in this field after the year 2000, business activities based on a system of val- IC D when our company was privatised relying ues. Key stakeholders and decision-makers by the Polish economy as a whole. Our H U 7. We ensure and promote elevated on Polish capital. For the last decade and responsible for our most important busi- strategy has a lot in common with such T C standards of work safety T more, we have been proving that it is ness areas took part in the time-consuming important documents as Vision 2050 – the E 8. We nurture employee growth worthwhile to act in line with the principle process of strategy development. New Agenda for Business in Poland and the → In our business, we are and commitment of sustainable development, balancing associated Declaration of Polish Businesses guided by high ethical 9. We build a culture of diversity standards, we respect business objectives and interests of stake- We selected three key pillars of social for Sustainable Development (we are one 10. We care about the environment of the signatories of the Declaration and we the needs of employees, 11. We build a sustainable supply holders: employees, patients, the medical responsibility: serving the patients and the patients and healthcare participate in working groups in connection chain and scientific community, customers, community, ethical conduct of business stakeholders, and we care suppliers and local communities (for more and innovation and advancing knowledge. with successive stages of Vision 2050). about the environment. information, see the CSR background Within those three intertwined areas, we of Polpharma Group on inside covers). made 14 commitments which we intend to We also used the social responsibility pursue until 2018. guidance provided in the international In 2014, we made a decision to put more standard ISO 26000 as a reference. Y ET structure into our CSR initiatives. Starting CI → O IN S N O E V H A T We improve our 1. For the sake of patient T organisation, I D health and quality of O respond to key medical N life, we provide access to N I am happy that after many years of company, for example in the procurement challenges and provide

A important therapies, health

implementing projects and measures in area, where we have launched efforts to space for the advancement A S education and preventive

individual CSR areas we have managed to draw up the Polpharma Group Supplier of knowledge by N

T care. Through dialogue and

structure our approach and assign strate- Code of Conduct. The strategy develop- implementing innovative D N partnership, we respond

solutions and cooperating

A

gic priorities to our actions. We realised ment process engaged all key business E to the needs of our local

I with scientists.

that it was a tough process already during functions in CSR activities, owing to communities. D T

V

A

the stakeholder panel meeting, where we which today we are able to involve fully A

E

P

N

G

had the opportunity to see the very differ- informed managers in the implementation G

C

D

N

I

E

I N

ent expectations of medical and business process, people for whom CSR objectives L G V

W

R K O N → E S communities or social organisations are an important aspect in all operating during the hours spent on discussions. areas. It is my personal satisfaction that we have managed to create a long-term framework Magdalena for our CSR activities, in which we have Rzeszotalska, 12. We implement innovative formulated specific commitments to the Corporate 1. We ensure pharmaceutical security in Poland solutions community and the actions to implement Communication 2. We promote principles of preventive care among 13. We bridge science with business by 2018. I can see already today how and CSR Manager, patients and employees 14. We educate medical and much the strategy has influenced our Polpharma SA 3. We support patients to follow medical advice pharmaceutical professionals correctly 4. We are engaged in community development

6 Polpharma Group Corporate Social Responsibility Report 2013–2014 7 Polpharma Group Corporate Social Responsibility Report 2013–2014 THE MATERIALITY PROCESS

We learnt about social responsibility and responsibility, responsibility for others, The Responsible Business Forum is business ethics in Poland from the global grows decidedly when one’s children are extremely satisfi ed with its cooperation perspective. Relevant standards came to born. Few private companies in Poland with companies that have a mature and 1 2 3 us from the headquarters of the biggest have managed to reach the stage where strategic approach to the implementa- Selection of topics Prioritising Conclusion multinational corporations. CSR was an they would acquire major companies from tion of corporate social responsibility. imported product that originated from other markets and integrate them into their Polpharma is an example of a company The list of topics was created Stages of the process: • Final approval of the matrix a completely different environment and groups. Polpharma has recently managed which places a lot of emphasis on social relying on: • Preselection (the current list) stemmed from a long-standing tradition to defi nitely improve the quality of its and environmental considerations, • Internal policies and strategies • Analysis by the CSR Team of well-established democracy and mature comprehensive CSR management system, combining its 80 years of tradition with • Previous corporate reports • External stakeholder panel markets. Although imported products which is evidenced, among other things, an innovative business approach. The • Peer CSR reports • Matrix preparation had been highly esteemed in Poland, few by the title of industry CSR leader in the development of the CSR concept seen in • Industry hot topics – research people believed that standards of ethical Responsible Business Ranking 2015, per- Polpharma further serves as a proof that and rankings, trends corporate culture could be developed haps because it has had no option but to Polish companies are able to compete • Topics discussed by the media within the Polish private business commu- maximise the public good. How could we against international corporations in this nity. Therefore, Polpharma is an interesting not set a good example when we already fi eld and should not feel inferior to them. case for everyone who will ever research have ‘children’. The important issues tackled by the the evolution of ethics and responsibility in company include health education, MATERIAL TOPICS SELECTED IN THE ANALYSIS PROCESS Poland. We all agree that CSR is a particular such as its Pressure for Life (Ciśnienie na refl ection of business maturity. Respon- Professor Bolesław Rok, życie) campaign which attracted KEY TOPICS KEY TOPICS sibility does not become important until Director of the Business a lot of interest during the CSR Expo FOR EXTERNAL STAKEHOLDERS FOR INTERNAL STAKEHOLDERS a certain stage of business development Ethics and Social in 2014. Polpharma pays considerable is achieved, like in the case of personal Availability of treatment Innovation Centre at attention to the development of the Health education development, where the sense of social the Kozminski University Pomeranian region, engaging in a number Education on health and medicines Promotion of healthy life styles of initiatives and activities as the CSR Promotion of healthy life styles Code of ethics and values Ambassador in Pomerania. The local Community involvement, cooperation with social partners activities demonstrate how important Equality and diversity the issues of community involvement are Code of ethics and values Communication with employees for the company. It is also noteworthy to Marketing and advertising ethics Employee learning and development 2. MATERIALITY highlight the importance of Polpharma’s Quality of raw materials employees in its CSR strategy. Diversity ANALYSIS at work is an element of the manage- Product safety ment process, and the complexity of Strategic environmental management actions confi rms that the employees are Sustainable supply chain he culture of openness to stakehold- The topics were identifi ed using a staged the company’s greatest asset. er needs, which has been developed approach: Scientifi c cooperation with research institutes for years, supports multifaceted long- • drawing up a list of topics specifi c T Marzena Strzelczak, Cooperation with the medical and pharmaceutical community term cooperation and delivery of solutions to the pharmaceutical industry, General Director, to tackle the most relevant topics for par- • analysis of the company’s business Member of the ticular stakeholder groups. We consider the operations to date, Management Board analysis of materiality of the topics brought • inclusion of stakeholders in the of the Responsible forward by internal and external stakehold- identifi cation of key subjects, Business Forum ers to be a very important process, as it • developing a list of subjects of allows us to prioritise the topics and – indi- particular importance to Polpharma. rectly – to actively engage the stakeholders 2.in the defi nition and implementation of CSR strategies.

8 Polpharma Group Corporate Social Responsibility Report 2013–2014 9 Polpharma Group Corporate Social Responsibility Report 2013–2014 STAKEHOLDER MAP 3. STAKEHOLDERS

ocial responsibility is not an end in sory boards or memberships in associations itself. Its most important role is to and organisations. We have been relying Sensure that the company considers on the model of close win-win cooperation the needs and expectations of internal and with stakeholders for years, recognising its Scientists and Competing Media Patients Doctors Pharmacists external stakeholders in its business. To numerous advantages. Feedback from our opinion leaders companies remain faithful to this philosophy, we need business environment has more than once to maintain relations with a wide range inspired us to implement organisational For the purposes of the dialogue, we of stakeholders, which gives us a better changes and to create new solutions owing identifi ed key stakeholder groups and understanding of the complexity of our en- to which we are well-equipped to address their representatives, and then, conside- vironment and allows us to include relevant future challenges and opportunities. ring their importance and infl uence on the company, we selected the most important groups and entities in our activities. This Suppliers stakeholders and invited them to a dialo- Employees dialogue can take a number of forms: direct gue session. 3.meetings with stakeholders, leveraging the experience and knowledge of external advi- The panel for external stakeholders was attended by representatives of: • UN Global Compact in Poland Public administration, Business Local • Polish Confederation Lewiatan regulators, organisations Social Customers communities • Polish Association of Pharmaceutical health care payer organisations – drug distributors Industry Employers MEMBERSHIPS • Polish Association of Self Medication Industry (PASMI) IN ASSOCIATIONS • Main Pharmaceutical Inspectorate • Supreme Pharmaceutical Council 4. MANAGEMENT SYSTEMS • Polish Pharmaceutical Society We seek to actively participate in the • London Benchmarking Group (LBG) • Polpharma Scientifi c Foundation olpharma Group is constantly developing and improv- COMPOSITION OF THE MANAGEMENT BOARD activities of various organisations and • Responsible Business Forum (strategic • academic community ing its management systems. Risk management within OF POLPHARMA S.A. PHARMACEUTICAL WORKS associations to share our knowledge and partner) • practising profession AS AT THE END OF 2014 the company is carried out on the basis of a dedicated experience, and – through joint action – • Declaration of Polish Businesses for • drug distributors P Peter Prock – Member of the Supervisory Board delegated to act as the • Ministry of the Economy policy, Under which a model has been designed to defi ne the to maximise the social effects of our Sustainable Development linked to President of the Management Board • WWF risk areas and levels for individual business processes. An update activities. We are members of such organ- Vision 2050 – the New Agenda for Busi- Jan Faryaszewski – Vice President of the Management Board • patient organisations process, carried out on a regular basis relying on special forms isations as: ness in Poland (signatory and member Bożenna Kozakiewicz – Vice President of the Management Board of sustainable manufacturing and • Łukasiewicz Institute, which and a system of metrics, allows to track changes in the business promotes awareness of Rajmund Ireneusz Martyniuk – Vice President of the Management Board • EGA European Generic Association consumption working group and social environment and to take mitigating measures. demographic challenges Francois Menard – Vice President of the Management Board • Polish Association of Pharmaceutical innovation working group) Tomasz Moys – Vice President of the Management Board Industry Employers (PZPPF) In connection with the establishment of the new CSR strategy Andrzej Dziuban – Member of the Management Board • Polish Association of Self Medication for the entire Polpharma Group in Poland, work is under way to Sebastian Szymanek – Member of the Management Board O STAKEHOLDER PANEL Industry (PASMI) build a coherent management structure for the implementation Hannes Teissl – Member of the Management Board Stakeholder dialogue is an important form • Business Centre Club of the strategy, both at the level of individual companies and COMPOSITION OF THE MANAGEMENT BOARD • Polish Confederation Lewiatan (through of cooperation between a business and its corporate functions. In 2014, as the efforts in particular areas OF MEDANA PHARMA SA environment, and an expression of maturity of the strategy intensifi ed, dedicated teams were appointed. PZPPF) Anna Durdyn – President of the Management Board • Polish Business Roundtable, with the in CSR strategy management. Therefore, For example, there is the Ethics Programme Establishment COMPOSITION OF THE MANAGEMENT BOARD participation of Jerzy Starak, Chairman of preparing ourselves for the development of Team at Polpharma Group or the Sustainable Supply Chain OF POLFA WARSZAWA S.A. the Supervisory Board of Polpharma SA a new CSR strategy, we organised a stake- Team. Both teams are led by a representative of the Supervisory • Programme Board of the Polish National holder panel in November 2014. The goal Board, and Management Board representatives and top execu- Tomasz Moys – President of the Management Board Małgorzata Cegielska-Matysiak – Member of the Management Board Sales Award, which promotes ethical of the meeting was to listen to insights from tives sit on the steering committees. Team members represent Katarzyna Goławska – Member of the Management Board selling principles, etc. (Rajmund Ireneusz groups that are important to our business on all key functions. Members of management bodies are Martyniuk, Vice President of the Man- relevant topics which should be covered by regularly updated on the progress in the implementation COMPOSITION OF THE MANAGEMENT BOARD OF POLPHARMA TRADE OFFICE SPÓŁKA Z O.O. agement Board of Polpharma SA is our CSR strategy. Several hours of discussions of each strategic programme and action carried out as part with representatives of various organisations 4. Rajmund Ireneusz Martyniuk – President of the Management Board a member of the Programme Board) of the CSR strategy. • Ethics Offi cers Coalition (a project helped us notice a range of new aspects and Grzegorz Chełmicki – Member of the Management Board Bożenna Kozakiewicz – Member of the Management Board under the Global Compact Initiative of dimensions of corporate social responsibility. Sebastian Szymanek – Member of the Management Board the UN Secretary-General (member of We have taken many of them into consider- the initiative group) ation in the preparation of the new strategy.

10 Polpharma Group Corporate Social Responsibility Report 2013–2014 11 Polpharma Group Corporate Social Responsibility Report 2013–2014 2013 2014

All All STAFF COMPOSITION BY AGE AND GENDER AND MINORITIES TOTAL NUMBER OF EMPLOYEES (G4-10) 2 286 1 887 4 173 2 289 1 935 4 224 NUMBER OF EMPLOYEES BY AGE AGED ≤ 29 298 243 541 272 239 511 AGED 30 TO 50 1 600 1 282 2 882 1 599 1 321 2 920 AGED 51 ≥ 388 362 750 418 375 793 PERCENTAGE OF EMPLOYEES BY AGE [%] AGED ≤ 29 7% 6% 13% 6% 6% 12% AGED 30 TO 50 38% 31% 69% 38% 31% 69% AGED 51 ≥ 9% 9% 18% 10% 9% 19% NUMBER OF FOREIGNERS 7 12 19 8 14 22 RATIO OF FOREIGNERS TO ALL EMPLOYEES 0,17% 0,29% 0,46% 0,19% 0,33% 1%

2013 2014

Managers and executives Individual contributors Managers and executives Individual contributors

STAFF COMPOSITION BY EMPLOYEE CATEGORY, AGE

AND GENDER Wszyscy Wszyscy Wszyscy Wszyscy NUMBER OF EMPLOYEES BY AGE AGED ≤ 29 5 3 8 293 240 533 6 2 8 266 237 503 serving patients AGED 30 TO 50 170 240 410 1 430 1 042 2 472 191 247 438 1 408 1 074 2 482 AGED 51 ≥ 31 44 75 357 318 675 32 50 82 386 325 711 TOTAL 206 287 493 2 080 1 600 3 680 229 299 528 2 060 1 636 3 696 and the society PERCENTAGE OF EMPLOYEES BY AGE AND EMPLOYEE CATEGORY AGED ≤ 29 2% 1% 1% 98% 99% 99% 2% 1% 2% 98% 99% 98% AGED 30 TO 50 11% 19% 14% 89% 81% 86% 12% 19% 15% 88% 81% 85% AGED 51 ≥ 8% 12% 10% 92% 88% 90% 8% 13% 10% 92% 87% 90% TOTAL 9% 15% 12% 91% 85% 88% 10% 15% 13% 90% 85% 88%

MOST IMPORTANT AWARDS IN 2013 AND 2014: Innovation the economic development of Valued products Marketing, sales, PR • Award of the President of the the Pomeranian region (2014) • Teraz Polska Emblem for Acard • numerous awards, such as Republic of Poland for the devel- • Medals for Supporting the Devel- (2013) the Golden Paperclip (Złoty opment and implementation of opment of Enterprise for Jerzy Ecology Spinacz), Health Care Success innovative technologies (2013) Starak and Elżbieta Dzikowska • Patron of Ecological Education of the Year (Sukces Roku • Innowator Wprost (2014) (Mecenas Edukacji Ekologicznej) w Ochronie Zdrowia) for (2013 and 2014) Attractive employe (2013 and 2014) Polpharma’s education Impact on development • Second place in the Science • Environmentally Responsible programmes We seek to offer the best possible response to the needs of patients • Pearl of Polish Economy category in the Universum Business (Eko-odpowiedzialni • Polish National Sales Awards (Perła Polskiej Gospodarki) in the Student Survey (2014) w Biznesie) (2013) in Sales Force and Excellent and our local communities. For the sake of patient health, category “promulgation of social • Reliable Employer of the • Sustainable Development Salesperson categories values” for Jerzy Starak (2014) Decade (2014) Leaders (Liderzy we engage in health education and preventive care. • Economic Griffin (Gryf Gospodar- • Employee-Friendly Employer Zrównoważonego Rozwoju) czy) for the positive impact on (2014) (honourable mention, 2013)

12 Polpharma Group Corporate Social Responsibility Report 2013–2014 13 Polpharma Group Corporate Social Responsibility Report 2013–2014 serving patients Rajmund Ireneusz Martyniuk, Vice President of the Management Board of Polpharma SA and President of the Management Board and the society of Polpharma Trade Office, Commercial Director at Polpharma Group Polpharma was born in Poland and most of its products are manufactured here. Poland is also our largest market. We believe that the success and development of our company are indissolubly linked to the quality and efficiency of the local health care system. As a market We are the largest manufacturer of drugs in Poland. For us, the leading position means mostly a commitment to guarantee pharmaceutical leader, we believe that it is our role to actively support the reinforcement of the social health system, and to raise awareness and ensure security for the Polish population. Manufacturing our products locally, we ensure continued supplies and access to required therapies for the right care for millions of Polish citizens. Poland is and will be our priority as regards ensuring the availability of Polpharma’s medica- patients. We maintain the production of a range of unprofitable medications, including life-saving products, for which there are no substitutes tions. We manufacture a wide range of life-saving drugs and we are the only company which ensures access to such drugs. We never on the market. We reinvest our profits in Poland, allocating money to socially important innovations, including biologics. Preventive care compromise on quality requirements, while maintaining price levels allowing patients to buy their prescription drugs. and health education are of critical importance to us. We carry out a range of awareness-raising education campaigns and programmes covering We support scientific and educational activities of most medical and pharmaceutical scientific associations, and we provide grants to such conditions as hypertension or anaphylactic shock. We need to keep in mind that medicines work only as long as we take them. a large number of scientific studies in the field of pharmacy and medicine through the Polpharma Scientific Foundation. We run a number of countrywide education programmes and epidemiology screening tests, and we improve patient access to advanced diagnostics. Therefore, we have been the first company in Poland to give publicity to the issue of correct following medical advice by patients Polpharma employees participate in social activities in all our locations. We support local health-related and environmental initiatives, as a key factor of therapeutic success. We have strong ties with the regions where we operate. We feel responsible for the development employee volunteering and charity projects carried out by our partners. of those areas and for the jobs created not just within our facilities, but also by our subcontractors. We are involved in initiatives supporting the improvement of quality of life and intersectoral cooperation within local communities.

people took free heart follow-on biologics OUR SUCCESSES people received training blood pressure tests and and eye checks in hours were spent projects are almost as part of the Get Ready more than 126,000 heart age tests by our employees carried out by our 326,000 for a Shock programme 6 400 29 campaigns of the were taken in the Pressure 15,000 10 000 volunteering in the 6 Biotechnology (of whom 6,000 Health Zone (Strefa for Life campaign local communities Division in Gdańsk in 2013–2014) na Zdrowie) campaign

OUR COMMITMENTS We also created the firstalgorithms in Poland to be used by 1. We ensure 2. We promote principles of 3. We support patients 4. We are engaged doctors in case of patients with anaphylaxis. pharmaceutical security preventive care among to follow medical advice in community patients and employees. development. • We offered comprehensive preventive care programmes in Poland. correctly. to our employees, including an anti-tobacco programme, and we encouraged them to take up sport. KEY METRICS • Together with the Polpharma Scientific Foundation, • BWe will manufacture drugs needed • We will reach out with education or • We will run a campaign in all • We will establish a good we prepared the textbook “Nieprzestrzeganie zaleceń by Polish patients with a particular prevention activities to one million medical universities in Poland to neighbourliness policy covering terapeutycznych. Od przyczyn do praktycznych rozwiązań” focus on those that are not supplied Poles. promote the textbook “Therapeutic all Polpharma Group locations in to the Polish market by anyone but Non-Compliance. From Reasons to Poland. (Therapeutic Non-Compliance. From Reasons to Practical Polpharma. • We will provide access to extended Practical Solutions” to students. Solutions.) health care services to employees • We will implement a regular KEY ACTIVITIES IN 2013–2014: • We will develop follow-on biologics across all Polpharma Group • We will reach out to pulmonary, community dialogue. • We organised the annual Open Day in our Starogard facility, and improved generic forms to locations in Poland. diabetes and heart disease speciali- which supports integration between our company and the ensure that Polish patients can sts through daily promotion of • We will expand the employee • We carried out the biggest education campaign in Poland on • We will arrange health initiatives volunteering programme to new inhabitants of the Kociewie region. access the most advanced therapies Polpharma medications with hypertension prevention. The most important outcome of the at affordable prices. for employees across all Polpharma a leaflet to support patients in areas. • We joined the activities of the Development Initiatives Group locations in Poland at least Pressure for Life campaign was a change in the attitudes of therapeutic compliance. Forum (FIR), which promotes intersectoral cooperation • We will make it possible to maintain once a year. the Poles towards heart disease prevention. an acceptable cost level in drug • By providing regular training, we will in the Pomerania region. • We will implement a model to • The Get Ready for a Shock campaign raised the important manufacturing, despite increasing ensure that all our representatives • We developed the Employee Volunteering Programme component prices and other cost measure short- and long-term are prepared to talk to doctors topic of anaphylaxis. We provided training to numerous effectiveness of activities for major of Polpharma Group across all sites. drivers, by scaling up our business about following medical advice patient groups that could be affected by the problem. and investments in innovative education programmes. by patients correctly. technologies

14 Polpharma Group Corporate Social Responsibility Report 2013–2014 15 Polpharma Group Corporate Social Responsibility Report 2013–2014 1. we ensure 2. we promote principles pharmaceutical security of preventive care in poland among patients

The presence of a strong pharmaceutical and employees Education programmes are very im- eing the largest pharmaceutical military reserves, supplying medications. sector in Poland guarantees that revenue portant to our business, giving patients group in Poland, we play a key role in The large share of domestic manufacturers can be reinvested in the most profi table the opportunity for early diagnosis and e live longer and longer (almost tion of preventive care and early diagnosis. Bensuring the security of drug supplies in the generic market helps reduce the costs way: in innovation. This improves the helping them avoid grave and often 77 years on average), but still Aiming to reach as many people as possible to the public. We allocate most of our profi t of pharmacotherapy for patients and gene- potential of the economy as a whole, life-threatening complications. So far, we to the development of new drug formula- rates savings for the state budget. Owing to increases the receipts of the state budget Wmore than 2 years less than with our expertise, we strive to make our have educated the Poles on herpes, sex- tions and socially important innovations that, the National Health Fund (NFZ) can and reinforces the position of Poland on a statistical European Union citizen education campaigns exceptional, remark- ual health and glaucoma, and for a few which improve health and quality of life. We extend its reimbursement scheme to new the international scene, but most of all, (79.2 years), according to the OECD’s able, but most of all, comprehensible and years we have been encouraging people keep the domestic market, our key market, groups of drugs, helping more and more it guarantees human safety, an invalu- Health at Glance 2014 report. Preventive practical. The campaigns have a very good to take care of their hearts and raising supplied with 220 products responding to patients. According to data provided by able priority. medicine plays a key role in maintaining a reception. Both strong attendance and the awareness of anaphylactic shocks. the most common health problems. We Sequence HC Partners, an analytical service The security of drug supplies is one of good quality of life and health. Its signifi - participant feedback confi rm the success of Designing our education campaigns, we provide broad access to treatment with our provider, drugs from domestic manufactu- the elements of the security of the state cance is bound to increase over the next our approach to promoting the principles plan our actions so that we do not only extensive offering and reasonable pricing. rers cover 44.3% of all reimbursed therapy and its citizens. It is important not only years, because of the population ageing of preventive care. The outcomes of our speak to patients using our authority, we We have a 12.3% share in the Rx drug days, however the share of domestic drugs in a state of emergency or war, but also, process and extension of retirement age. actions are also recognised in the most reach out to them and facilitate preven- market and only 5.03% in reimbursement in the total amount of reimbursement is or even mostly, in peacetime. 2.Being aware of the gravity of this challenge, important industry competitions. tive measures in practice. We believe payments. For the sake of health and lives of much lower (they only account for 27% of we place strong emphasis on the promo- that a permanent change of attitudes our patients, we maintain the production of the total amount of reimbursement). Reso- is only possible with many years of hard a range of unprofi table products, including urces spent to reimburse drugs manufactu- and persistent work. life-saving products, for which there are no red in Poland (PLN 2.5 billion in 2014) are in Dr Bohdan substitutes on the market. We manufacture fact offset by budget income in the form of Wyżnikiewicz, Vice Chairman the only generic drugs for 47 molecules. We taxes, social security contributions and other 1. of the Institute for countrywide health Dominika also participate in the provision of strategic payments (PLN 2.4 billion). Market Economics Bandurska, campaigns – from junior Brand PR Manager, Polpharma to senior Trade Offi ce THE NATIONAL PHARMACEUTICAL we invest in socially SECTOR GENERATES: In 2013 and 2014, we ran a few extensive important innovation • almost 1% of Poland’s GNP education and prevention campaigns ad- dressed to patients. They included: Health Zone (Strefa na Zdrowie), a programme • jobs Biologics are undoubtedly the future of investments, mostly due to the costly clini- 105k organised together with Caritas Polska (direct, indirect and induced effect) modern pharmacy. They mimic the func- cal trials, as well as the time and expertise aimed at facilitating access to medical We performed more than tests, specialist consultations and health tions of human proteins (such as insulin or needed. The development of follow-on free tests in total • PLN in budget education for people aged 50+, most of 458,000 growth hormone), offering hope to patients biologics takes from 7 to 9 years and costs 2.4 billion as part of a range of education and receipts them living in small towns. In 2013–2014, suffering from serious illnesses (such as between 80 and 100 million euro. Currently prevention campaigns. some cancers, leukemia, asthma, cystic there are six projects involving that type of * based on DELab UW, PZPPF 2015 report: Makroeko- we checked the hearts and eyes of 6,400 nomiczne aspekty znaczenia sektora farmaceutycznego people from 29 small towns as part of fi brosis, psoriasis and rheumatoid arthritis). drugs under way at our laboratory in Gdańsk dla polskiej gospodarki; the domestic pharmaceutical Biologics are effective and safe, but access Science and Technology Park. sector is understood as Polish and foreign operators the Health Zone initiative. to therapy is hindered by its cost: they are manufacturing their products in Poland Your Sight campaign (Wykryj jaskrę – ocal more than 25 times more expensive than Our commitment to the development of POLPHARMA GROUP We are engaged in important local commu- wzrok), and to become voluntary blood chemical drugs. biologics is also an opportunity for top IN POLAND GENERATES: nity events throughout Poland (such as the donors as part of the Your Blood Has Great Polish scientists and exceptionally gifted Days of Starogard), arranging ‘white’ cam- Power initiative (Twoja krew ma wielką Polpharma decided to develop follow-on graduates to develop their talents in Po- • 20k jobs paigns during which citizens have the op- moc) in our Nowa Dęba location. biologics, which are drugs marketed after land (for more information, see page 81). (direct, indirect and induced effect) portunity to get free medical consultations the expiry of patents for original medica- and preventive health checks. Furthermore, In 2013 and 2014, the two largest tions. Owing to their lower price, they will • 20 of budget infl ows from the whole we encouraged people to take advantage campaigns were: Pressure for Life and allow more patients to use the treatments. sector (2014 data) of eye disease prevention opportunities Get Ready for a Shock. Their results are as part of the Test for Glaucoma – Save discussed in detail in the LBG model. However, even those drugs require immense * Calculation based on the same methodology as in the DELab UW report

16 Polpharma Group Corporate Social Responsibility Report 2013–2014 17 Polpharma Group Corporate Social Responsibility Report 2013–2014 Anaphylaxis is a severe, life-threatening, generalised The campaign earned us Meanwhile, paramedics stress that lack of response from accident witnesses often or systemic rapid hypersensitivity reaction. It is O PRESSURE FOR LIFE In 2013 and 2014, our campaign reached a number of prestigious awards: a generalised response of the organism to an allergen results from fear of the consequences of Pressure for Life is the biggest educational 100 towns and villages. We checked the blood • 2013 Magellan Award, or other factors (such as physical effort). It is char- giving incompetent aid – hence the need acterised by a rapid onset of symptoms, including campaign on hypertension in Poland. It was pressure of 326,000 Poles and distributed • 2014 Golden Paperclip (Złoty Spinacz), to provide extensive education. respiratory deterioration and/or cardiovascular symp- initiated in late 2012 in response to alarm- 750,000 copies of educational materials. • Effi e Award, toms (hypotension as a leading symptom, increased ing fi gures: cardiovascular diseases, despite • 2014 Stevie Award, heart rate, feeling faint or loss of consciousness). The points of departure for the campaign the increased effi cacy of treatment, We arranged numerous events to accom- • Social Campaign of the Year 2013 Usually, skin symptoms occur as well, in the form of were surveys on public awareness of ana- urticaria and itching. Anaphylaxis develops within are the most common cause of death in pany the campaign, such as the “Seniors (Kampania Społeczna Roku 2013), phylactic shock and a medical community minutes and usually no later than several hours after Poland, but are still often disregarded by make their dreams come true with Acard” • Leader of the Year 2014 in Health Care O GET READY FOR A SHOCK debate which allowed to develop specifi c coming int contact with an allergen. The most severe patients. One in three adult Poles suffer contest organised in cooperation with the (Lider Roku 2014 w Ochronie Zdrowia). form of anaphylaxis is the anaphylactic shock, which Get Ready for a Shock (Przygotuj się na messages addressed to doctors. from hypertension (NATPOL study 2011). Przyjaciółka weekly. During an initia- can lead to death. wstrząs) is a comprehensive countrywide Still, 70% of the Poles do not take their tive carried out in 2013, we donated one Where only a fast response will save education and information programme on Initiatives carried out as part of the blood pressure on a regular basis, and zloty for each blood pressure check to the The campaign was recognised and awarded: someone’s life, there is no time for anaphylaxis, an issue which is poorly un- programme were addressed to various 95% are unaware of the rules of correct Healthy Heart Clinic (Klinika Zdrowego the Golden Stevie Awards 2015, ignorance or hesitation. derstood in Poland, despite being a severe audiences – allergy patients and their fami- measurements (PBS study 2012). We were Serca) in Zabrze. Owing to that, the Clinic The Golden Paperclip (Złoty Spinacz) 2015, The Get Ready for a Shock programme and potentially life-threatening condition. lies, allergology experts, media, as well as committed to change the pattern among received a total of PLN 200,000. and it received a honourable mention in prepares people to take the right The campaign was aimed at promulgating beekeepers and public transport employ- the Poles which was that they did not the Social Campaign of the Year 2014 action when human life is in danger. knowledge about the causes, consequences ees. We also provided a number of training care about their health until they fell ill. As part of the campaign, we also initiated competition. Our programme raised the awareness and handling of anaphylactic shock. We sessions, outdoor events and lectures for Therefore, the focus in our campaign was the fi rst heart age study on such a scale of anaphylaxis, and media fi nally started additionally developed innovative algo- the medical community. The Anaphylaxis on preventive care, early diagnosis and edu- in Europe. During the fi rst two editions of to link the topic of allergy with its most rithms for doctors and patients showing, Education Week, which involved free aller- EDUCATIONAL ACTIVITIES cation – not only in risk groups, but the campaign (2013 and 2014), the study severe form, the anaphylactic shock. in a straightforward manner, the steps that gist consultations in dozens of Polish towns ADDRESSED TO THE MEDICAL also within their families. covered more than 126,000 people. Owing to that, we could reach a consid- COMMUNITY AND GENERAL must be taken in the event of anaphylaxis and cities, was very popular. Owing to PUBLIC IN THE GET READY erable proportion of the population with (for more information, see p. 85). a campaign carried out in means of public FOR A SHOCK CAMPAIGN OUTCOMES OF THE CAMPAIGNS our educational content. This resulted transport in several Polish towns and cities, IN 2013–2014 in a perceptible change in the awareness Experts stress that the main problem with more than 2 million passengers could ac- The Pressure for Life campaign con- of the Poles (as confi rmed by a survey anaphylactic shock is the very low public cess educational materials produced in the • innovative anaphylaxis algorithms tributed to permanent changes in the carried out together with the medonet. awareness of the condition. Still few people campaign. for patients and doctors attitudes of its participants, as shown by • as much as 28% of people who pl web portal after the fi rst year of the know that allergy is not only about runny campaign). Furthermore, according to the results of a PBS study carried out after had heard about the campaign declared nose and watery eyes. In the event of an • training for 5000 public transport media reports, public transport drivers the fi rst year of the campaign: that they had checked their blood acute allergic reaction – anaphylaxis and employees who participated in our fi rst aid training pressure over the last week – almost anaphylactic shock – rapid aid is critical are more willing to give fi rst aid to pas- • people who had heard about the twice more than in the group of people and often saves lives. • education campaign addressed to campaign demonstrated, on average, who had not heard about the campaign sengers and passers-by. Those outcomes REAKCJA NA CZAS are recognised by independent experts, 5$78-(Ģ<&,( a higher awareness of the (15%); 2 million 15pp which is evidenced by the awards we OUTCOMES OF THE CAMPAIGNS public transport passengers risk factors of cardiovascular diseases • as much as of the respon- 76% have earned for our past activities. than people who were unaware of the dents expected that the campaign • training and lectures for doctors – A very important part of the campaign We have identifi ed a problem and built PRZYGOTUJ SIĘ NA WSTRZĄS! campaign; would be continued. UCZULAMY ALERGIKÓW involved close cooperation between a lasting system. We have marked out 18 conferences, more than 5000 Polpharma employees and allergology new life-saving paths within the soci- FREQUENCY OF BLOOD PRESSURE CHECKS DEPENDING www.odetchnijspokojnie.pl doctors trained ON THE AWARENESS OF THE PRESSURE FOR LIFE CAMPAIGN experts, which resulted in the production ety and in medicine. Our actions have of the current anaphylaxis guidelines for doubled the number of Poles who have When did you last take your blood pressure or have your blood pressure taken? • expert forum: ~ 30k users doctors. heard about anaphylaxis! After one year of the campaign, 42% *** 64% of Poles declared that • more than 6000 people trained 28% 30% Before the campaign, only 27%* (33%**) Yes, I have heard about they knew the term ‘anaphylaxis’. during workshops accompanying 18% 22% of Poles declared that they knew the term 15% 17% 15% the Pressure for Life campaign 12 events (picnics, festivals, marathons); 10% ‘anaphylaxis’ and only 11%* (28%**) of According to a TNS study from January 2014 and 2% No, I have not heard about Anna more than 20k items distributed to Poles declared that they knew how to **a survey carried out in collaboration with medonet.pl the Pressure for Life campaign Robak-Reczek, participants (fi rst-aid kits, bracelets, this week this month this year earlier I don’t help someone in the event of anaphylactic (January 2014). *** A study carried out in collaboration Senior Specialist algorithms) remember shock. with medonet.pl (December 2014). for Brand PR

18 Polpharma Group Corporate Social Responsibility Report 2013–2014 19 Polpharma Group Corporate Social Responsibility Report 2013–2014 The Power Of The World Wide Web We Care about the Health EDUCATIONAL WEBSITES We support employee initiatives involv- AND PREVENTIVE CARE O SMOKING IS PASSÉ The Poles tend to look for advice online of our Employees ing the promotion of leisure activities. I am delighted that Polpharma offers the CAMPAIGNS OF POLPHARMA For many years, we have run health very often, including health-related advice. We provide a good package of preventive We also act as a partner for bike events opportunity to participate and assists awareness campaigns promoting healthy Unfortunately, the multitude of informa- care as well as general and specialist medi- and competitions, and we encourage our its employees in participating in major lifestyles to our employees. In 2013, we tion available on the internet does not cal services to current and retired employ- employees to participate in them (the Ko- sports events. I am on three Polpharma decided to support our employees from always result in good quality. Therefore, ees of Polpharma. The medical services are ciewie Kołem marathon, Kociewie Szlakiem teams myself. Polpharma Run Team Trade Offi ce in Warsaw in quitting smok- we create education websites dedicated provided by MEDPHARMA Zakład Opieki MTB competition or Polish Medical and brings together people who are pas- www.odetchnijspokojnie.pl to the most common health conditions. Zdrowotnej S.A. and Centrum Medyczne Pharmaceutical MTB Championship). ing. In 2014, we did the same for Pharma- sionate about running, both beginners The content published on those websites Lux-Med. ceutical Works in Starogard. We organised and advanced runners. One of the major is up-to-date, exhaustive, reliable, and – We take pride in our company sports the Quit Smoking programme, offering a running events is the DOZ Marathon in full-day anti-tobacco session to each par- most of all – very practical. We additionally run free fl u vaccination www.abcmigrena.pl teams: Polpharma Ski Team, Polpharma Łódź, where we regularly enter a large campaigns and sanatorium programmes, Bike Team, Polpharma Tri Team and ticipant, followed by two reinforcing ses- team for the 10k and marathon races. For example, at www.odetchnijspokojnie. and we subsidise meals at work. Our Polpharma Run Team, established in 2014. sions. What about the effects? They were I have met a lot of awesome crazy pl, allergy and asthma sufferers will fi nd employees are also an important target Our triathletes enter major triathlon com- amazing! 56% of programme participants people there, from our company and a current pollen map or dietary advice, but audience for our education campaigns. www.mojeoczy.pl petitions, including Ironman events. The in Warsaw and 62.5% of programme par- beyond. Polpharma Bike Team, on the also a Symptom Diary to assist them in the The Pressure for Life van visited our facili- Polpharma Ski Team has been in the top of ticipants in Starogard broke free for good. other hand, are those who enjoy preparation for the next appointment with ties in Starogard Gdański, Polfa Warszawa Alpine Ski Championships of Pharmaceuti- Many of them persuaded their friends and working the pedals on and off the road. families to quit, too. their allergist. Additionally, the website is and Trade Offi ce, while the Get Ready for www.leczpaznokcie.pl cal Companies for several years, and our I found out myself that there are plenty equipped with a nearest medical facility a Shock workshop was on the agenda of Bike Team keeps winning medals in the of them among our staff. However, the locator and a function allowing to call the the Polpharma Open Day. Polish Medical and Pharmaceutical MTB 62,5% of participants of anti- Polpharma Tri Team is my favourite. This facility of your choice. Furthermore, the ap- Championship. Our runners are not wast- tobacco sessions in Starogard Gdański year, together with three colleagues, plication provides support to patients from The subjects of health, the right diet and www.21plus7.pl ing their time away, either. In the fi rst edi- I have represented our company in Gdy- the anaphylactic shock risk group, not only keeping fi t are regularly featured in Pana- tion of the Tricity Business Relay, as many and 56%of participants in Warsaw nia in the biggest Ironman 70.3 event in by means a set of practical advice on how ceum, our in-house magazine. There is as two Polpharma teams climbed the po- have beaten the nicotine addiction. Poland. It was fantastic. Thank you very much, and I hope that our company will to proceed in the event of an anaphylactic a fi tness studio in the building where Trade www.bezopryszczki.pl dium in their respective categories. In turn, shock, but also with an extremely impor- Offi ce is located in Warsaw. The Multi- 55 runners entered the DOZ Marathon in continue supporting the participation of tant ‘emergency call’ feature, which allows Sport programme, which offers convenient Łódź, including 9 marathon runners. our colleagues in various sports-related PRODUCT ADVICE initiatives. the user to immediately contact a doctor or access to sports and recreation activities WEBSITES FOR PATIENTS a preselected person. throughout Poland, is very popular with our For many years, we have had a Yachting employees and their families. Club in our Starogard facility, operating The www.abcmigrena.pl website features under the auspices of Polpharma. Robert Czerwiak, a Migraine Diary. At www.mojanowafi gura. We promote daily exercise, especially bike Team Leader at the pl, in turn, we prepared a lot of advice on commuting. As part of the Let’s Go Cycling www.mojanowafi gura.pl Our yachtsmen, wearing the colours of the Waste Treatment and Incineration nutrition, health, fashion and beauty for (Wszyscy na rowery) programme, we have Farmacja Praktyczna magazine, participate Plant Unit, diet- and wellbeing-conscious people. taken care of bike-friendly infrastructure in the Sailing Championship of Poland for Polpharma SA Teddy-bear Stories (Misiowe Opowieści, on our premises (bike shelters, speed limits Journalists. www.misioweopowiesci.o2.pl (www.misioweopowiesci.o2.pl), on the other for cars). We also reward employees who hand, is a mine of knowledge on child health prefer this environmentally-friendly means for parents, accompanied by inspiring games of transport. Credit is awarded for each and fun for children in different ages. registered bike commute, which can then www.dbajonerki.pl POLPHARMA SPORTS TEAMS be exchanged to prizes in the MyBenefi t IN 2013–2014: In our education activities, we take advan- cafeteria system. Before the implementa- • Polpharma Ski Team (skiing) tage of the fact that the Poles are keen to tion of the programme within the Group, www.fosidal.pl • Polpharma Run Team (running) use the features of advanced telephone only 20 employees of our Starogard facility • Polpharma Bike Team (cycling) devices. Dedicated smartphone apps biked to work. However, when the On Your • Polpharma Tri Team (triathlon) accompany a number of our campaigns Bikes, Everyone campaign was launched, and initiatives. For example, the Pink Mir- the number of bike commuters across all ror (Różowe Lusterko) application offers Polish locations increased to 480. There are convenient support in the regular use of many brave souls among them who ride contraceptives. their bikes all year round, in all weathers.

20 Polpharma Group Corporate Social Responsibility Report 2013–2014 21 Polpharma Group Corporate Social Responsibility Report 2013–2014 3. we support patients to follow medical advice In 2015, a professional textbook was correctly I think it should be underlined that since O LOOKING FOR CAUSES published for students and doctors during 2007, the Polpharma Scientifi c Founda- AND SOLUTIONS specialisation courses: “Therapeutic Non- tion has demonstrated great commit- We were the fi rst ones in Poland to bring Compliance. From Reasons to Practical or the sake of patient health, we have order). Results of this study and other ment, consistently supporting the com- therapeutic compliance to the attention Solutions”, with Prof. Zbigniew Gaciong been the fi rst pharmaceutical com- studies on the subject as well as conclu- munity of health care professionals and of the scientifi c and medical community and Prof. Przemysław Kardas as scientifi c F pany in Poland to raise awareness sions and recommendations are published patients in the elimination of barriers to as well as society. In 2007, the Polpharma editors. Soon-to-be doctors obtained not of the fact that therapeutic success relies in the textbook “Therapeutic Non-Compli- therapeutic compliance of persons with Scientifi c Foundation held a competition only a rich compendium of information on the degree of following medical advice ance. From Reasons to Practical Solutions.” chronic diseases. During the 8 years of for the best research project on barriers to on the scale, causes and consequences of correctly. In a report on that subject The work on the book started in 2014, work, we have observed a major change therapeutic compliance and ways to over- non-compliance, but also a source of valu- published in 2003, the World Health and the book was published in 2015. in the awareness of doctors and patients, come them. In recognition of the fact that able advice. The textbook consists of three Organisation recognised non-compliance who better understand the impact of the awareness of therapeutic non-compli- parts: a general section (defi nitions, causes, as a serious barrier preventing patients The consequences of patient non-compli- therapeutic compliance on therapeutic ance in the medical community was rela- assessment of the status quo, ways of from taking advantage from the continuing ance vary extensively, from deteriorated success. I am convinced that the Founda- tively low, in 2008 the Foundation issued tackling the problem, emphasising the role advancements in medicine and pharmacy. therapeutic results, through the need for tion should get some credit for that. a publication on that subject addressed of nurses and pharmacists), a more specifi c additional diagnostics, further medications, to doctors entitled “Współpraca lekarza section on therapeutic non-compliance in Equally disturbing conclusions can be more medical appointments or hospitalisa- z pacjentem w chorobach przewlekłych – particular chronic conditions and a practi- drawn from a study carried out by a team tion to death. Prof. Piotr Kuna, compliance, adherence, persistence. Stan cal section (recommendations for general Lack of doctor-patient cooperation is led by Prof. Przemysław Kardas from the Chairman of the obecny i możliwość poprawy” (Doctor- practitioners, ready-made scripts for con- a major problem in the therapy of Medical University of Łódź on a group of According to conservative estimates, the Scientifi c Council Patient Cooperation in Chronic Diseases versations with patients, tips on alternative chronic diseases. So far, the focus has of the Polpharma 60,000 patients with chronic diseases. annual costs of therapeutic non-compli- – Compliance, Adherence, Persistence. solutions if a patient does not comply, for been only on whether the patient should Scientifi c take drug A or drug B, while the problem More than 83% of the study subjects did ance amount to PLN 6 billion. This imposes Status Quo and Room for Improvement). example, for economic reasons). Foundation lies somewhere else: a high percentage not follow the recommendations to a vary- a burden not only on patients and families, The publication, issued in 30,000 copies, of patients do not take medications at ing degree (for example, even when a pa- but also on the National Health Fund, was the fi rst Polish monograph addressing all. 3.tient took medications, he would take them and thus, indirectly, on the society. this issue. It turns out that the best way to ensure at the wrong time of day or in a wrong “THERAPEUTIC NON-COMPLI- • During the fi rst year, treatment is therapeutic compliance is to simplify the Earlier publications available in Poland ANCE. FROM REASONS discontinued by at least one in three TO PRACTICAL SOLUTIONS” therapies and to improve patient moni- mentioned the issue of therapeutic non- – patients taking hypolipidemic drugs or a textbook for doctors and medical toring: increased frequency of appoint- compliance relying on research carried out treated for type 2 diabetes with oral students, scientifi c editors: ments, provision of care by nurses and in Western countries and in the United hypoglycemics. Prof. Zbigniew Gaciong, MD, PhD pharmacists. A nurse may call a patient (NON)COMPLIANCE States, and the knowledge of how Polish • Every seventh patient discontinues the and Prof. Przemysław Kardas, MD, PhD. to ask if he remembers that he has an people treated themselves was fragmen- recommended therapy within a month appointment or has to take medications, tary, random, or even intuitive. • Only 65% of chronically ill from the implantation of a stent in a pharmacist may remind him to collect The Foundation decided to look for the • 22 authors – outstanding scientists, patients declare that they always take coronary arteries, resulting in a 9-fold a new prescription. answer to that question and commissioned clinicians, doctors, experts in various all recommended doses. • Chronically ill patients, despite the increase in the risk of death. With our latest textbook “Therapeutic some qualitative and quantitative studies. fi elds of medical and social sciences, declarations about medication adheren- • 4 million Poles suffer from asthma Non-Compliance. From Reasons to Prac- The results were published in the report • chronical- ce, admit that sometimes they come off and 2 million Poles suffer from the tical Solutions”, we want to highlight an One in four “The Polish Patient – a Self-Portrait”. • editors – professors and doctors ly ill patients has failed to comply with the drugs (most often because of feeling chronic obstructive pulmonary disease 8 important problem, because in the case The report was provided to medical profes- from the Medical University of Warsaw doctor’s advice and happened to use unwell or a temporary improvement) or (COPD). Only some 50% of them com- of many diseases, although there are sionals and to the media. It also became and the Medical University of Łódź, as only a part of the prescribed packaging modify their therapies without seeking ply with therapeutic guidelines. effective drugs, therapeutic results are a point of departure for a number of well as scientists cooperating with the or only some or one of the prescribed medical advice. • Almost 80% asthma and COPD suffer- still poor. discussions and public debates on the Polpharma Scientifi c Foundation, drugs. ers use poor inhalation techniques, re- signifi cance of proper doctor-patient • Ca. PLN 6 billion sulting in therapeutic non-compliance. annually – these are the losses of the cooperation. It is noteworthy that no other • copies – distributed to 3000 Prof. Zbigniew Polish health care system due to patient Source: “Therapeutic Non-Compliance. From research has been done on such a scale so libraries at medical universities and sci- Gaciong, Reasons to Practical Solutions”, scientifi c editors: far and that the study is quoted in most ence institutes, scientifi c associations non-compliance. Chairman of the Prof. Zbigniew Gaciong and Prof. Przemysław Kardas, papers on therapeutic non-compliance. and directly to students and doctors. Source: “Polskiego pacjenta portret własny” 2015 Foundation’s (The Polish Patient – a Self-Portrait), 2010 Scientifi c Council

22 Polpharma Group Corporate Social Responsibility Report 2013–2014 23 Polpharma Group Corporate Social Responsibility Report 2013–2014 WE RAISE AWARENESS OF THE NEED FOR FOLLOWING MEDICAL ADVICE BY PATIENTS CORRECTLY

Various sources (clinical trials, pharmacy records) show an alarming picture: a high percentage of Polish patients do not take me- Partnership in Treatment The objective of the Partnership in Treat- dications at all. That is why activities raising the awareness of the need to comply with therapeutic recommendations in patients, Recognising that the problem of therapeu- ment campaign was to: Treatment, and especially long-term including the principles of safe self-medication (using OTC drugs), are so important. tic non-compliance affects all of us, we are • raise the awareness of the role of coop- treatment, requires patients to be initiating a series of activities which – like eration and therapeutic compliance in educated about the disease itself, We pursue this objective not only through education initiatives, but also through innovation which makes therapies more convenient the Partnerstwo w leczeniu (Partnership in the treatment process among doctors, benefi ts of treatment and consequences and supports therapeutic adherence. Treatment) campaign – are meant to raise patients and their families, of therapeutic non-compliance, and it public awareness of the problem and to in- • emphasise the role of sound communica- calls for trust in specialists, confi dence tegrate patients, their families and doctors tion between doctors and patients, in therapeutic success and self-discipline. around the need to comply. • educate on barriers to and drivers of Many factors make it diffi cult for patients therapeutic compliance, to meet those requirements. That is why We also support and educate the medical • promoting good doctor-patient coopera- good cooperation between health care community, as surveys carried out by the tion practices in the treatment process. professionals, patients and their families Polpharma Scientifi c Foundation show that is so important. During debates held trust in physicians is the strongest driver of as part of the campaign, we arranged • We improve our tech- • We share our expertise • We educate and • We promote the prin- therapeutic compliance. In May 2013, the O BREAKING THE TABOO a meeting of all participants of the nology processes, to with the medical support patients ciples of safe and Polpharma Scientifi c Foundation together Partnership between the doctor, patient treatment process and we discussed the make our drugs more conve- community for example by: responsible self- with the Wygrajmy Zdrowie Foundation and family plays a critical role in ensur- requirements for successful cooperation. nient to use. An example of for example through: – a leafl et supporting medication for example launched a nationwide education campaign ing therapeutic compliance. Therefore, We also talked about educating on barri- such a solution could be our – conferences and workshops therapeutic adherence; through the www.odpowie- called “Partnership in Treatment. especially in sensitive areas such as sexual ers to and drivers of therapeutic compli- double-layer tablet combining dedicated to therapeutic dzialneleczenie.pl website Doctor – Patient – Family” (Partnerstwo health care, we need to address our activi- ance. Our debates were accompanied by two APIs, improved drugs for compliance, such as the – a media campaign carried run by the Polish Association w leczeniu. Lekarz – Pacjent – Rodzina) ties to all people who have an impact on presentations of good and effective prac- children which taste better countrywide education out in 2013 together with of Self Medication Industry under the slogan “I treat myself success- therapeutic success. The unprecedented tices of cooperation between health care (such as Ibufen) or have campaign “Partnership in the Wygrajmy Zdrowie (PASMI), of which we are an fully – I follow the doctor’s advice”. The ob- National Sexual Health Programme, carried professionals, patients and their families. a better form (minicapsules Treatment. Doctor – Patient Foundation and TVP2 chan- active member. jective of the campaign was to emphasise out already for seven years, could serve as In our view, a similar education campaign that can be administered with – Family” carried out under nel as part of the initiative the signifi cance of cooperation between an example of such a holistic approach. As addressed to the general public should meals), or the heart-shaped the slogan “I treat myself “Partnership in Treatment. health care professionals and patients and part of the campaign, we break the com- be carried out on a continuing basis in tablet of Acard which makes successfully – I follow the Doctor – Patient – Family”; their families in the therapeutic process. munity taboo still associated with sexual the framework of preventive care, for the drug easily distinguishable doctor’s advice”, carried out Telewizja Polska (Polish Television) was the health care in Poland. The embarrassment example by the National Health Fund. and facilitates regular use. together with the Wygrajmy – specialised mobile apps media sponsor of the campaign. More- barrier applies to patients and doctors Zdrowie Foundation; which remind patients to over, the marshals of the Wielkopolskie, alike: 73% of patients have never been Szymon take a specifi c dosage at Małopolskie, Łódzkie, Dolnośląskie, Śląskie asked about their sexual health by a doc- Chrostowski, President of the – pioneering publications on a predefi ned time or support and Pomorskie provinces were engaged in tor. Through educational measures, some Management the Polish market (for more patient treatment (such as the campaign. also addressed to seniors and people with Board of the information, see p. 87); the Odetchnij Spokojnie disabilities, we encourage Polish people Wygrajmy Zdrowie (Breathe Easily) applica- As part of campaign activities, we carried to be more open about their sexual lives Foundation, – including the issue of fol- tion for allergy and asthma out debates in various regions of Poland, and to consult a specialist if they have any co-organiser of lowing medical advice by patients and persons at risk such as Poznań, Łódź, Krakow, Katowice, problems. the Partnership patients correctly in the of anaphylactic shock, which Wrocław and Gdańsk (www.partnerstwo- in Treatment Knowledge Pharm educa- is described on page 20). wleczeniu.pl). We invited opinion leaders campaign. tion programme (Pharma to take part in our discussion, including Wiedzy) for pharmacy and provincial family medicine and labour medicine students. medicine consultants, representatives of local Chambers (of Physicians, Pharmacists approx. 300 people attended and Nurses) and patient organisations, to regional meetings as part of the discuss the issue of building partnerships Partnership in Treatment campaign. in treatment together. The debates were attended by Prof. Przemysław Kardas, Prof. Piotr Kuna, Prof. Ewa Sewerynek, 73%of patients have never Prof. Jerzy Wordliczek and many others. been asked about their sexual health by a doctor

24 Polpharma Group Corporate Social Responsibility Report 2013–2014 25 Polpharma Group Corporate Social Responsibility Report 2013–2014 4. we are engaged in community development Patient information leafl et ease control for conscious consumers. Em- phasising the advantages of self-medication, PASMI, as an organisation representing The community involvement model of ommunity engagement is a natural We reinforce those ties, engaging in impor- we promote the principles of responsible manufacturers of OTC drugs, focuses Polpharma Group covers a diversity of

8ORWNDSRZVWDâD]LQLFMDW\Z\ element of our responsibility, in tant local community events. Once a year, 5DG\1DXNRZHM)XQGDFML OTC drug use, for example by participating mostly on education aimed at the areas and types of community activi- /(&=Ċ6,Ċ in the development of the www.odpowie- accordance with the motto “People during the Open Day of our Starogard facil- SKUTECZNIE responsible use of drugs. To this end, C ties, from preventive care to employee Helping People”. We are an important part ity, we unveil the mysteries of chemistry 2GSRZLHG]QDQDVWċSXMĆFHS\WDQLD  dzialneleczenie.pl website. the website www.odpowiedzialnelecze- volunteering, local charity initiatives or &]\NLHG\NROZLHN]DSRPQLDâHğZ]LĆýVZRMHOHNDUVWZR" &]\]GDU]D&LVLċQLHSU]HVWU]HJDýJRG]LQSU]\MPRZDQLDOHNyZ" nie.pl was established, which features of local communities and we believe that and pharmacy to citizens, giving them the support for culture. In the event of such &]\SRPLMDV]NROHMQĆGDZNċOHNXMHğOLVLċGREU]HF]XMHV]" -HīHOLF]XMHV]VLċĩOHLZLĆīHV]WR]OHNLHPF]\SU]HVWDMHV]JRSU]\MPRZDý" information on the safe use of OTC good neighbourliness is an important driver opportunity to see how advanced and safe large scale activities, the challenge is to -HīHOLRGSRZLHG]LDâHğWZLHUG]ĆFRFKRFLDīQDMHGQRS\WDQLHSRUR]PDZLDMRW\P]OHNDU]HP OXESLHOċJQLDUNĆ O OUR PERSPECTIVE &]DVDPLFKRU]\]DSRPLQDMĆRSU]\MċFLXOHNX &]\ ZLHV] F]\P JUR]L QLHSU]HVWU]HJDQLH of sustainable growth. We feel that our re- our manufacturing processes are. QLHELRUĆOHNXRZâDğFLZHMSRU]HDOER]PLH- ]DOHFHĕOHNDU]DOXESLHOċJQLDUNL" drugs, pain management and diagnosis measure the outcomes and effects which QLDMĆMHJRGDZNċ=GDU]DVLċīHSU]HGZF]HğQLH NRĕF]ĆWHUDSLċDQW\ELRW\NLHPOXELQQ\PLOHND- :WHG\ 7ZRMH ]GURZLH PRīH XOHF QDJâHPX PLXZDīDMĆFīHMXīMHMQLHSRWU]HEXMĆ SRJRUV]HQLX E\ý PRīH EċG]LHV] PXVLDâ E\ý ON AN IMPORTANT SUBJECT OHF]RQ\ZV]SLWDOXSRGGDýVLċGRGDWNRZ\P sponsibility is not restricted to the jobs cre- EDGDQLRP GLDJQRVW\F]Q\P L ]Dī\ZDý ZLċFHM 3DPLċWDMīHZDUWR OHNyZ :]URVQĆ WHī 7ZRMH Z\GDWNL QD OHF]HQLH advice, and many other insights. The lat- are the foundation for far-sighted plan- SU]HVWU]HJDý]DVDGOHF]HQLD 5R]ZDī ZV]\VWNLH NRQVHNZHQFMH L ]DVWDQyZ VLċ GOD7ZRMHJRGREUD MDN E\ý V\VWHPDW\F]Q\P Z OHF]HQLX 3RSURğ RSRPRFOHNDU]DLQDMEOLīV]\FK As a PASMI member, our company is est education campaign, Treat Yourself ated within a region. We additionally try to Projects involving our employees are ning and management 'RZLHG]VLċZLċFHMRVZRMHMWHUDSLL]DS\WDMOHNDU]DOXESLHOċJQLDUNċ

1. 'ODF]HJRSRZLQLHQHPSU]\MPRZDýOHNL" 2. -DNLNLHG\SRZLQLHQHPMHSU]\MPRZDý" 3. &RVLċVWDQLHMHīHOLRSXV]F]ċGDZNċ" involved, inter alia, in activities aimed at promote the growth of local communities particularly important to us. Already today, 4. *G\SRF]XMċVLċOHSLHMWRF]\PRJċSU]HUZDýOHF]HQLH RGVWDZLýOHNL " Responsibly (Lecz się odpowiedzialnie), is of community involvement. I am glad 5. &]\SRZLQLHQHPVSRG]LHZDýVLċHIHNWyZXERF]Q\FKFRZWHG\URELý"

7HVW0RULVN\·HJR*UHHQDVDPRRFHQ\VWRSQLDZVSyâSUDF\  ĨUyGâR0RULVN\'(*UHHQ/:/HYLQH0&RQFXUUHQWDQGSUHGLFWLYHYDOLGLW\RIDVHOIUHSRUWHGPHDVXUHRIPHGLFDWLRQDGKHUHQFH0HG&DUH 8ORWNDMHVWGRVWċSQDQDVWURQLHZZZSROSKDUPDSOIXQGDFMD improving the control over the non-medi- also published on the website as a series by means of numerous social, education, employee volunteering plays a major role that we, at Polpharma, have this oppor- cal use of prescription stimulants by young of videos showing the most common health, cultural or sports initiatives taken in our community activities. In 2013 and tunity to be part of this process another people. In 2014, together with other PASMI patient mistakes relating to medication. across all locations. We have particularly 2014, the Group’s employees worked year in a row, joining the LBG network. Our leafl et supporting patients in medi- members, we requested that a minimum The campaign is additionally sup- strong roots in the Kociewie region, Staro- almost 10,000 hours to support people in Owing to the LBG methodology, cation adherence has a very practical age limit of 18 years be established for pur- ported by member companies, including gard Gdański in particular, where we have need in their local communities. We would information on community initiatives, dimension to it – space is provided on the chasing products containing pseudoephed- Polpharma, which is actively involved in been growing with successive generations like to continue reinforcing this area, add- and especially their outcomes and ef- front page for a doctor or nurse to enter rine, dextromethorphan or codeine and PASMI’s ongoing educational activities. of inhabitants for eight decades. We have ing our own ‘building block’ to the social fects, is more and more complete year the date and time of the next appointment that a maximum level for those substances The activity of Polpharma and other strong neighbourhood relationships with capital, so much needed in Poland. by year, allowing to track the social and the treatment plan (drug name, route in OTC drugs be introduced. Those require- member companies in the promotion 4.local communities around all our offi ces effects of our activities and to take more of administration, number of tablets and ments are taken into consideration of responsible treatment supports the and facilities. strategic action in the future. It is a long time of administration). The reverse side of in the revised drug abuse law, which has idea of self-medication as the fi rst step and complicated journey, and Polpharma the leafl et, on the other hand, encourages been in force since July 2015. towards health maintenance and disease Group is enjoying it with confi dence, as self-refl ection on the degree of medica- management. Owing to the availability one of few Polish companies. tion adherence. The simple four-question of OTC drugs outside of the pharmacy Morisky-Green test serves as an aid in the channel, Polish citizens can satisfy their helping even evaluation. The leafl et encourages patients health care demand at the right time, in to talk to a doctor or nurse about the the right form and place. more diversely Małgorzata short-term and long-term consequences of Greszta, non-compliance even if they only answer One more time, we decided to summarise Charitable gifts Sustainability ‘no’ once. Ewa Jankowska, our community involvement using the Services Manager, LBG approach. We chose this particular Community President of the investment SGS Polska Responsible Self-Medication Polish Association international social reporting standard not Self-medication, understood as using OTC of Self Medication just because we wanted to promote the Commercial initiatives drugs, is a common practice today and an Industry (PASMI) most valuable CSR solutions as the market important element of comprehensive health leader. Most of all, we appreciate the care. According to the European Parliament, practical dimension of LBG and we believe Charitable gifts the growing popularity of self-medication that owing to LBG, we will leverage our re- Helping Wisely is a consequence of the increasing aware- sources even better and extend our support We have been involved in charity work for ness and maturity of patients, as well as to more people in need. years, establishing deep and lasting rela- civilisation. tions with people and institutions that are not indifferent to the needs of others. This view is shared by the members of PAS- We seek to help wisely, not only by provid- MI, the Polish Association of Self Medication ing fi nancial assistance or drugs, but also Industry, including our Group companies. by sharing our resources – such as our free PASMI members perceive self-medication as time, know-how and positive energy – a fundamental value in the maintenance and with people in need. protection of consumer health and the fi rst step towards health maintenance and dis-

26 Polpharma Group Corporate Social Responsibility Report 2013–2014 27 Polpharma Group Corporate Social Responsibility Report 2013–2014 Our actions are very diverse in terms of pate in the 10k run along the streets of KEY CHARITY PROJECTS a unique event in the region and nation- gard (lecturers try to motivate young people IMPLEMENTED IN 2013–2014 their nature and range, which can be local, Starogard, organised already for more wide. It offers space for dialogue and action to take action and believe in their dreams), nationwide or international. The nature of than two decades by the Sports and in support of the development of construc- • supporting the Starogard Volunteering Day our involvement is best refl ected by such Recreation Centre in Starogard. International reach tive and practical solutions for Pomerania. organised by the Można Inaczej Association, • provision of Polpharma’s bike safety town for projects as: • support to Kasisi Foundation in Zambia, However, the Forum is ‘alive’ all year the purposes of local events, distribution of • Support for the Kasisi Foundation 23. The Kociewie Run in October 2014 • drugs donated to Caritas Ukraine, Caritas round, not only during the meetings. Belarus and Caritas Kazakhstan, refl ectors and educational books on safety, established by Szymon Hołownia, which was fi nished by 313 people, and the win- It is a comprehensive project for the sus- • organisation of conferences and training • many years of support from Medana Farma assists the largest children’s home in ner was Joel Kosgei Komen from Kenia. for the Ukrainian Emergency Medical Ser- tainable development of the region, based to the Światełko Dzikuska Day-Care Centre Zambia, in the heart of African bush, vices together with the Polish Emergency on a durable and cherished partnership. in Sieradz. run by Sister Mariola from Poland. We Medical Services, purchase of a fi rst aid The fi rst edition of the FIR Grant Competi- provided necessary medicines to the training manikin, tion took place in 2014, awarding a total of Foundation several times in 2013 and • fi nancial support to missionaries in Asia PLN 140,000 to fi ve intersectoral projects. Charitable and South America, 2014. Assistance for the foundation is an gifts We were one of the sponsors of the grants. • arrangement of transport for Polish people example of international aid, in which For Polpharma, the “People Helping Community in Kazakhstan. we have been involved for many years. investment People” motto is extremely relevant, We support Polish missionaries in various Countrywide reach very justifi ed and multifaceted. The value corners of the globe and aid organisa- Commercial of every company is measured by its initiatives • cooperation with Caritas Dioceses all over tions at times of natural disasters. We Poland (provision of drugs, for example, for contribution to social development, also provide drugs to teams going on mother and child care centres and Brother and also by whether and to what extent missions to the poorest regions of the Community investment Albert centres, support for the Christmas it is engaged in community life at the world. We are committed to ensuring that our present campaign for the poor, fi nancial • Grupa Kolarska Starogard Gdański As- local or national level. • Second life for IT hardware – instead of support brings maximum long-term ben- support for pilgrims), sociation (cycling team) (MTB Kociewie Support for preventive care initiatives, • Strefa na Zdrowie (Health Zone) – free destroying old company computers and efi ts to local communities. Therefore, one Szlakiem Marathon) – organisation of valuable educational and cultural proj- medical checks and specialist consulta- PROJECTS AWARDED IN THE 1ST ects, as well as socially important charity printers, we sell them, and we use the of the assumptions behind our CSR strate- tions provided in cooperation with Caritas a sports event with the objective to pro- proceeds for social purposes. Owing to gy is that we are shifting from fragmentary, Dioceses in Polish small towns – almost EDITION OF THE GRANT mote the Kociewie region and its tourism projects is embedded in our CSR strat- that collection and sale of IT hardware, often one-time initiatives towards com- 30 parishes in 2013 and 2014 (for more COMPETITION OF THE DEVEL- potential, as well as mountain biking and egy. For many years, our company has we could provide funds for computer munity investment – structured, strategic information, see p. 17), OPMENT INITIATIVES FORUM: family bike tours. been helping people, expecting nothing room equipment in the Social Welfare and recurring activities with a sustainable • cooperation with the Dzieło Nowego • DALBA Social Cooperative in Puck • Social Cooperation Cooperative in in return. Our benefi ciaries include House in Damaszka. With the modern impact on regional development and qual- Tysiąclecia foundation (a scholarship (The project “A Cooperative That Sopot (Luk Luk charity shop in Sopot) people who have used our preventive hardware connected to the internet, pa- ity of life. We join forces with other actors scheme for gifted children from poor Brews More”) – establishment of a non- – launch of the fi rst charity shop in care programmes, scholarship schemes families all over Poland), tients can now educate themselves and to maximise our response to the needs of profi t Brewery Cooperative employing Pomerania, providing jobs and education or emergency assistance in the recent • cooperation with the Catholic Informa- contact their families. Our volunteers the Pomeranian population and – through 12 people with intellectual disabilities; to long-term unemployed. years, such as war or natural disaster tion Agency in the area of annual Bishop victims. Such aid, the good deeds we do, took part in repair work and conversion intersectoral cooperation – to create a Chrabek Awards “Ślad” (Trace) for media this is the sixth company of that kind are immeasurable. But I would like to un- of a storeroom into a computer room. climate for positive change and build the people who contribute to a culture of globally and the fi rst one in Poland. The Development Initiatives Forum sup- derscore that help is important not only New computer hardware was also pur- identity of the region. truth, understanding and dialogue, • Mamy z Morza Foundation in Gdynia ports the reinforcement of the local social to its benefi ciaries. Experience tells us chased for a school computer laboratory • cooperation with the Order of Malta on (Pomeranian Parenting Clubs) – fabric and social capital of the region. that we enjoy helping and giving to oth- in Gymnasium No 3 and the Centre of Together We Can Do More: the Opłatek Maltański, a nationwide annual creating space for parents to meet Projects awarded in the 1st edition of the ers much more than we enjoy receiving. Psychology and Pastoral Care “Więź” in Development Initiatives Forum Christmas charity event. and for children to have fun in Kartuzy, Grant Competition, despite being so differ- Starogard Gdański. Proceeds from the (Razem możemy więcej: Forum Puck and Kościerzyna. ent, have one thing in common: they show Local reach sale of computer hardware from Polfa Inicjowania Rozwoju) • provision of the lecture theatre in the • Kashubian Business Incubator in that joint involvement produces amazing Warszawa, on the other hand, were used We want to bring the three worlds of busi- Starogard facility for the purposes of Kościerzyna – a series of training ses- outcomes in terms of equal opportunities, to buy specialist sensory integration ness, local authorities and NGOs together important local initiatives, such as the edu- sions and consultations provided in the social and professional empowerment of Krystyna Nitecka, therapy equipment for the Children’s to improve our response to local needs. cation and prevention programme Be Safe framework of the Kashubian Academy of excluded groups, as well as promotion of Key Public Home at ul. Dalibora in Warsaw. This concept is implemented in an excel- on the Road (Bezpieczni na drodze) carried Enterprise to promote entrepreneurship, entrepreneurship or physical activity. We Relations Expert, • The Kociewie Run with Polpharma – lent way by the Development Initiatives out by the Starogard District Authority for encourage people to establish small and are happy that the initiatives of Pomera- Polpharma SA can serve as an example of an initiative Forum (FIR), established in 2012. It engages secondary school students (the training medium-sized companies and stimulate nians are innovative – the awarded projects covered a total of 1691 students in 2013 which promotes both physical activity representatives of the largest Pomeranian economic activity in the Kościerzyna include some initiatives that are unique not and 2014), or the Future Is Coming confer- and the tourism assets of a region which companies (Polpharma, Lotos, Energa), ence organised, in the framework of the District. only in Poland, but also globally. is close to our hearts. A few hundred NGOs and provincial authorities. Theory Exemption Olympics (Olimpiada runners from Poland and beyond partici- The annual meeting of the Forum is “Zwolnieni z teorii”) by youth from Staro-

28 Polpharma Group Corporate Social Responsibility Report 2013–2014 29 Polpharma Group Corporate Social Responsibility Report 2013–2014 A Close Neighbour (the Open Day) project participants returned to see ‘their’ volunteers and the patients of the Social Christmas Charity We celebrate one day of the year in a spe- patients for a long time after the project The Development Initiatives Forum is Welfare House, which were as important as Every year, our employees play Santa cial way, together with our employees and had been completed. a partnership between the Pomeranian the outcomes of repair works. We addition- Claus, making the wishes of children from the local community. It is the Polpharma business community, NGOs and local ally invited young disabled participants of childcare facilities and day-care centres Open Day, organised for years on the oc- • Employee Volunteering Programme authorities aimed at introducing positive occupational therapy to our picnic, whom come true. We prepared a total of 540 casion of the International Earth Day. The The Employee Volunteering Programme changes. Polpharma plays a major role in we helped during the same initiative in Christmas presents in 2013 and 2014. In agenda is full of attractions. Employees carried out by our company since 2013 it. They are a proven partner that we can 2012. It was a great opportunity for an 2014, we established cooperation with the and Starogard citizens visiting our facility supports grassroots initiatives of our always rely on. The forum is a Pomera- unprecedented integration between the promoters of Szlachetna Paczka (the Noble can see for themselves that we operate in employees. It takes the form of a grant nian initiative, yet it is unique in Poland. two institutions occupying neighbouring Box campaign). In 2015, we again want to a safe and environmentally friendly way. competition aimed at choosing 20 most We act to support the innovativeness of parcels. bring the Christmas spirit to those in need Therefore, many of the Open Day activities interesting projects entered by our the communities which can contribute by means of our programme. are related with environmental and safety employees every year. They receive a to increasing the potential of Pomerania. education. We swap waste for ecological PLN 3000 grant each from the company. We inspire people and entities to take souvenirs. We encourage people to partici- Projects can be submitted in the following joint action, because we truly believe in pate in sessions showing the second lives categories: health and preventive care, the idea of sustainable development. of various products. We run contests and improvement of quality of life, education We are convinced that the feasibility of THE AID MAP – LOCATIONS OF VOLUNTEERING PROJECTS IN 2013 AND 2014 cycling licence examinations in cooperation and equal opportunities, humanitarian socio-economic changes depends on the with the local police. aid, local development and ecology. Proj- social capital of Pomerania. Our aim is to ects rewarded in 2013 and 2014 involved, create the right conditions to build social GDYNIA We are committed to making our Open among other things, renovations of child- confi dence between people who offer GDAŃSK Day a means to promote healthy lifestyles care facilities and education workshops a signifi cant potential for those changes. TCZEW STAROGARD GD. MIŁOCIN and physical activity. For that reason, our delivered by our employees. LUBICHOWO SZCZECIN EŁK agenda includes education activities carried BORZECHOWO NARKOWY OSIEK out in the framework of our campaigns: • Managers as volunteers We talked to the patients and we also Pressure for Life (Ciśnienie na życie) and We included community involvement in Monika Hinc, some moments of silence with them. Get Ready for a Shock (Przygotuj się na the process of improvement of compe- Coordinator at BIAŁYSTOK There were people who would not talk wstrząs). We encourage people to join the tences of marketing and sales managers. the Development to us, but having someone to accompany WARSAW bone marrow registry. We also organise As part of the annual Train the Trainer Initiatives Forum PRUSZKÓW them in the disease was very impor- special campaigns, for example Cycling for meeting, some 200 managers are engaged OTRĘBUSY LASKI ŻYRARDÓW tant to them, our presence or holding a Good Cause (Pedałujemy na szczytny cel), in team building exercises which include KALISZ ŁÓDŹ TOMASZÓW MAZ. hands was enough. We knew that they owing to which we bought new bicycles for a joint action for a selected institution SIERADZ expected us and needed us, because not students from poor families in Gymnasium that needs support. During the 2013 and The innovativeness of a business is everyone was visited by their families or No 2 in Starogard. 2014 campaigns, we managed to complete measured not only by its products, but CZĘSTOCHOWA NOWA DĘBA friends. fi nishing works in the newly built Mother also by the quality of human resources Employee Volunteering and Child Care Centre in Ełk, to renovate management and responsibility for the TARNOBRZEG ZWIERZYNIEC (reminiscences of 18 Medana The involvement of our employees in the the Social Welfare House in Tomaszów local community in which the business employees, who spent a total CHMIELNIK of 1700 hours of their free time Employee Volunteering Programme shows Mazowiecki and to restore its surround- operates. Polpharma is certainly a very KRAKOW in 2014 to help the patients of how important the motto “People Helping ings, and to prepare additional activities for conscious and reliable employer. I am the Social Welfare House and People” is to our team. Offering support, the benefi ciaries. We take care to ensure glad to have this stable company as one of the key economic pillars of the Star- the Hospice at the Provincial we help those in need, but we also help that our aid not only meets the current Hospital in Sieradz) ourselves. The employees of Medana, who economic needs, but also adds some more ogard Gdański town and the Starogard spent a total of 1700 hours of their free value, giving the opportunity to establish District. time in 2014 to help the patients of the relationships, to be together. Therefore, Social Welfare House and the Hospice at we organised additional screening checks the Provincial Hospital in Sieradz empha- in the Social Welfare House in Tomaszów, sised this fact many times. “Voluntary work performed by our employees with medical helped me discover the values that are education, and a picnic with a lot of attrac- Janusz Stankowiak, really worth pursuing in my life”, one of the tions. This stirred very positive emotions Mayor of Starogard volunteers pointed out. Many volunteering in all participants of the meeting, both the Gdański

30 Polpharma Group Corporate Social Responsibility Report 2013–2014 31 Polpharma Group Corporate Social Responsibility Report 2013–2014 Promoting Amateur Sport Activities Sport Without Barriers SUMMARY OF THE EMPLOYEE We created a unique place in the Warsaw SPONSORING PROJECTS VOLUNTEERING PROGRAMME IN LOCAL COMMUNITIES: Physical activity is a great way to take care There is more to sport – it makes us more offi ce of Polpharma: the Spectra Art Space, AT POLPHARMA GROUP of your health, but most of all, it is about sensitive to the needs of persons with dis- Charitable where art coexists with corporate space. gifts Sport-related projects: great pleasure. There are many physi- abilities and encourages us to eliminate the The experimental space inspires creative Community • sponsoring a men’s basketball team cal activity enthusiasts on our team. We barriers that they must face every day. 22013013 22014014 thinking and acting in our employees on investment from Starogard Gdański, which has support them in sport competitions (p. 21) GGRANTRANT CCOMPETITIONOMPETITION a daily basis, and serves as a venue for Commercial been playing in the premier league and we promote bike commuting (p. 20). We have already helped disabled persons NNUMBERUMBER monthly meetings with Warsaw citizens. initiatives since 2004 Our interest in bicycles is not an accident. in our local community many times. As OOFF VOLUNTEERSVOLUNTEERS 9977 115757 • sponsoring of the Cycling School estab- By promoting sustainable transport, we members of the Polpharma Association They have the opportunity to see works of HHOURSOURS lished in 2014 by the Grupa Kolarska contribute to the improvement for Physical Education Development and WWORKEDORKED Culture for Everyone – Commercial art from the private collection of Jerzy Sta- Starogard Gdański Association, of the natural environment. Sport, our employees are involved in a 11855855 33946946 Initiatives rak, which give a representative overview of • sponsoring of Kociewie Kołem, a bicycle range of activities, including charity events NNUMBERUMBER mmoreore Many years ago, André Malraux, a French Polish art from 1945 to the present. They road racing marathon, and the MTB Our employees have established the Pol- with proceeds going to disabled children. In OOFF BENEFICIARIESBENEFICIARIES tthanhan 33865865 writer and statesman, said: “Culture is what include works by Magdalena Abakanowicz, Marathon Kociewie Szlakiem, pharma Association for Physical Education 2014, we were one of the partners engaged 11000000 made a man become more than just an Jerzy Nowosielski or Leon Tarasewicz. The • providing support to the Kociewie Run Development and Sport which organises in the organisation of the Special Olympics incident in nature”. We sponsor notewor- Spectra Art Space also features works by with Polpharma for many years, sport competitions in a range of disciplines. European Basketball Week. The world’s big- thy national and local cultural initiatives. young talented artists supported by the SSHORT-TERMHORT-TERM VOLUNTEERINGVOLUNTEERING • sponsoring the International Children’s We support those activities and we instill gest sport event promoting basketball We acquaint the Polish people with works Starak Family Foundation under its Soon ((SALESSALES AANDND MMARKETINGARKETING Football Tournament organised by the our passion for sport in local communities, for people with disabilities was held be- MMANAGERS)ANAGERS) of famous award-winning artists, and we program. Beniaminek 03 Sport Club in Starogard seeing active leisure as an additional op- tween 29 November and 7 December help young talents develop their potential. NNUMBERUMBER Gdański in 2013. portunity to bring citizens together. 2014 in ten provinces. It had 18,500 OOFF VOLUNTEERSVOLUNTEERS 118282 220808 We make sure our employees have direct Since 2013, in cooperation with the Rower participants from 33 European countries. contact with art in their place of work, and HHOURSOURS Cultural projects: Over Association, we support the organisa- WWORKEDORKED 11790790 22068068 we host workshops, symposia and other • sponsoring the Gdańsk Music Festival, tion of the Kociewie Kołem bike marathon, art-related events. ACCOMPLISHED NNUMBERUMBER IN 2015 • sponsoring a series of jazz concerts titled whose route runs through a number of OOFF BENEFICIARIESBENEFICIARIES ook.k. 100100 112020 municipalities in the Kociewie region. The “Muzyka z Polpharmą w kościele” O WWW: EVERYONE KNOWS travel time is less important here, the focus (Music in Church with Polpharma), MORE is on the unique culture, cuisine, habits and • sponsoring the exhibitions “Oblicza In 2014, we established cooperation with architecture of Kociewie experienced along CCHRISTMASHRISTMAS CCAMPAIGNAMPAIGN fi guracji” (the Faces of Figuration, 2013) the Integracja Foundation. As a result, an the route. We also support the Kociewie ““POLPHARMAPOLPHARMA GROUPGROUP EMPLOYEESEMPLOYEES and “Polskie malarstwo XIX wieku” architecture audit was carried out in our FFOROR CCHILDREN”HILDREN” Szlakiem MTB marathon organised by the (Polish 19th century painting) (2014) Warsaw offi ce in 2015, and our website was Grupa Kolarska Starogard Gdański As- PPRESENTSRESENTS in the Starogard Centre of Culture, also audited. Experts from the Foundation BBOUGHTOUGHT 225050 229090 sociation, and a cycling school run by the • sponsoring the adaptation of tales from advised us on how to create and develop Group which provides a special training Kociewie for the screen. internet sites to make them attractive and programme to the most talented young fully accessible to a range of user groups, people of the region. Currently, the school including blind persons. We have already is taking care of the development of seven implemented a number of recommenda- young cyclists from Kociewie. tions from the Foundation, providing train- ing to our corporate website editors.

Visit Polpharma’s YouTube channel for videos showing employee volunteering campaigns at Polpharma Group.

32 Polpharma Group Corporate Social Responsibility Report 2013–2014 33 Polpharma Group Corporate Social Responsibility Report 2013–2014 ethical business conduct

In our business, we apply high ethical standards, we respect the needs of employees, patients and healthcare stakeholders, and we care about the environment.

34 Polpharma Group Corporate Social Responsibility Report 2013–2014 35 Polpharma Group Corporate Social Responsibility Report 2013–2014 ethical OUR COMMITMENTS 5. We reinforce corporate 6. We ensure high product 7. We ensure and promote 8. We nurture employee ethics. quality and safe elevated standards growth and commitment. business pharmacotherapy. of work. KEY METRICS

• Every employee will receive • We will implement a • 0 severe accidents at work • We will implement a new ethics training at least once programme to increase by 2018 competency model at every two years the commitment of our • Through education Polpharma Group. conduct • We will actively involve employees to the continual activities, we will reduce • 100% of the Group’s high- and mid-level improvement of quality of the contribution of the employees in Poland will managers in the promotion our products and services. human factor to accidents be covered by performance of the principles of ethics • We will implement an at work in connection with reviews aligned with the We believe that ethics should be the cornerstone of any business. This requirement is particularly relevant for the pharmaceutical across the company international database of industrial operations by new competency model. industry, due to its exceptional importance for the health and lives of patients. Let’s demonstrate this in our daily activities, continuing • We will develop a system registered medical inquiries 50%. • We will increase the to reinforce the culture of ethics at Polpharma Group. We share the same ethical values: respect, integrity, responsibility, solidarity to track ethics compliance to improve the forms of number of employees and cooperation, which frame and guide our activities in every area. For us, commitment to the highest standards means fi rst and within the company response to health care engaged in internal initia- foremost a focus on product quality and safety and safe working conditions, providing optimum conditions for employee development, professionals and patients. tives (including innovation, embracing diversity and protecting the environment. We promote good practices in our environment, especially along the supply chain • We will implement a pa- community involvement, and in local communities. We also participate in such initiatives as the Ethics Offi cers Coalition under the auspices of the UN Secretary- tient education programme safety, etc.) by at least General Global Compact Initiative in Poland, aimed at sharing knowledge and promulgation of business ethics management standards. to raise the awareness of 30%. safe pharmacotherapy.

OUR SUCCESSES meetings with employees eemployees were involved in in Poland and abroad almost tthe consultation process for nearly wwere held as part of tthe Polpharma Group Code 2000 20 tthe effort to prepare oof Ethics tthe Code 9. We build a culture of 10. We care about the 11. We build a sustainable diversity. environment. supply chain.

KEY METRICS

• We will establish policies • We will reduce energy • 100% of our suppliers will and set agendas for consumption by 6%. receive the Polpharma • We encouraged employees to report near misses under different diversity areas. • We will reduce water Group Supplier Code of the Stop Accidents (Stop Wypadkom) programme. • 100% of Polpharma Group withdrawal by 10%. Conduct. • We educated our employees and external contractor staff managers in Poland will • We will increase the use • 100% of liable suppliers will working for Polpharma on work safety. be covered by diversity of recycled packaging sign an acknowledgement • We conducted the Employee Feedback Survey accompanied education activities. materials to 50%. that they read and understood the Code of by in-depth dialogue with the employees and new initiatives • We will recycle 80% Conduct. to drive commitment. of the waste generated. • 70% of key suppliers will • We ensured employee development according to the • We will reduce waste meet all the requirements 70/20/10 model, proven by the world’s best companies. volume by 10%. of the Code of Conduct. KEY ACTIVITIES IN 2013–2014: • We developed the Let’s Go Cycling (Wszyscy na Rowery) • We will implement solutions to support and Green Ticket (Zielony Bilet) programmes, encouraging the reduction of CO2 • By means of extensive internal consultation, we implemented our employees to use sustainable means of transport. emissions from passenger the Ethics Programme, with the Polpharma Group Code of • We launched a unique project to identify APIs in wastewater. transport (promoting carpooling, regular Ethics as a key feature. • We started working on a sustainable supply chain strategy eco-driving training, CO2 • We joined the initiative group of the Ethics Offi cers Coalition, and the Polpharma Group Supplier Code of Conduct. emissions as a criterion with one of our goals being to develop an ethics management when purchasing fl eet standard for Polish companies and institutions. vehicles).

36 Polpharma Group Corporate Social Responsibility Report 2013–2014 37 Polpharma Group Corporate Social Responsibility Report 2013–2014 5. we reinforce corporate

Tomasz Moys, ethics Vice President of the Management Board of Polpharma SA, President of the Management Board of Polfa Warszawa SA, Member of the Steering Committee of the Ethics Programme hared ethical values and predefi ned The remaining elements of the Ethics Establishment Team at Polpharma Group standards of conduct set the tone for Programme are: ethical education, Sour daily choices and activities. a whistleblowing system, institutional solutions associated with ensuring the In a wide and diverse corporate structure like the one at Polpharma Group, a foundation made of shared ethical values is critical. Despite In order to continually improve our culture proper functioning of regulations, the often differing traditions which shaped the individual companies in the past and the diverse business cultures of the countries where of ethics, we initiated efforts in 2013 to as well as ethics-related external we operate, we feel that they are an universal feature which integrates the entire group. The system of ethical values established by develop a comprehensive Polpharma Group and internal communication activities. the Polpharma Group Code of Ethics consists of: respect, integrity, responsibility, solidarity and cooperation. It guides us, showing how Ethics Programme. Consultations with em- to build relationships in and outside the organisation. The values show our attitude towards colleagues and business partners. They also ployees, an important part of the process, determine our attitude towards key issues such as product quality assurance, ensuring a safe work environment, respecting the dignity of demonstrated that our team perceived a all employees or a focus on environmental protection. set of shared ethical values as an important Ethical values and the standards of conduct set out in the Code give assurance to Polpharma Group stakeholders as to the diligence business growth driver. and integrity of our operations. This helps us achieve competitive advantage and set good practices in our broadly defi ned impact zone. We feel responsible for our surroundings, including their social, economic and environmental dimensions. Therefore, we promulgate our The most important element of the Ethics principles along the entire supply chain and we participate in initiatives aimed at raising the standards of economic life in Poland. Programme is the Polpharma Group Code of Ethics, drawn up in an extensive internal 5.consultation process in 2014 and effective from 1 January 2015. employee initiatives risky situations and wasw the response rate were entered for the behaviours were iin the 2014 Employee more than Green Process Award, eeliminated owing Feedback Survey ETHICS FIRST 30 generating almost 1100 tto the Stop Accidents 81% (Polpharma( Group programme ini Poland, without PLN 7 million in savings Results of consultations with Polpharma PolfaP Warszawa) Group employees preceding the creation of the Code O THE CODE OF ETHICS The key to the proper functioning of stage, the employees had the opportunity 98% believe that the culture the Code of Ethics is to ensure that its to review the proposed provisions of the of ethics is important in daily work. THE POLPHARMA GROUP CODE OF ETHICS IS BASED ON ETHICAL VALUES SHARED BY ALL GROUP EMPLOYEES: provisions are consistent with employee Code, express their opinion or suggest attitudes and expectations as well as our changes, either at meetings or through the 98% are of the opinion organisational culture. Therefore, the work intranet. The work was accompanied by that the standards of conduct and was based on extensive social consultations intensive communication and education ethical values adopted by the company and involvement of representatives of all activities. Almost 20 meetings with em- should apply to employees at all levels, areas in the development and subsequent ployees in Poland and abroad were held in including managers, executives and implementation of the provisions of the total. members of the Management Board. Code. Owing to the common involvement, the are positive that an ethical The work on the Code of Ethics took a year document was created and subsequently 97% business attitude is a must for any and a half and it engaged almost 2000 approved by the Management Board of socially responsible company. employees across the Polpharma Group Polpharma in December 2014. It has been locations, including top executives. in force since 1 January 2015. It sets out The fi rst stage of the consultation process a system of values, norms and principles 96% believe that unethical was an opinion poll, where employees were which the Polpharma team intends to live behaviours may affect relationships with asked to evaluate the existing culture of by every day. It is also a joint commitment business partners and thus performance. ethics at Polpharma Group and to identify to follow the highest standards in our the issues which should be covered by the relations with colleagues, business partners, 95% admit that the company’s Code of Ethics and the emerging customers and the broadly defi ned busi- culture of ethics should refer to values Ethics Programme. During the second ness environment. and not only to rules.

38 Polpharma Group Corporate Social Responsibility Report 2013–2014 39 Polpharma Group Corporate Social Responsibility Report 2013–2014 The rules laid down in the Code apply to • an Ethics Programme information package • All promotional material contains clear HOW TO CONTACT all employees, independently of their posi- being part of the induction programme The past two years were marked by ef- information helping doctors and patients We as employees are proud that Polfa THE COMPLIANCE OFFICER: tions and nature of their responsibilities, for new employees. forts geared towards the establishment make informed choices with respect to Warszawa was able to participate in across all Polpharma Group companies in of a comprehensive Ethics Programme at medicines or other products. the drawing up of the Code of Eth- Poland and other markets. Each employee In parallel, we worked to harmonise the Polpharma Group. – face-to-face meeting, • We established e-Medical Legal (e-ML), ics alongside other Polpharma Group has received a copy of the Code from his ethical standards in our foreign companies The key task in the framework of the Pro- – telephone call to 22 364 60 29, a special system which assures that each companies. The implementation of the or her line manager and has signed an and representative offi ces of Polpharma gramme was to establish the Polpharma – email to [email protected] product is presented in a fair and ethical Code was preceded by extensive social acknowledgement. Group. Group Code of Ethics. We wanted this – or by traditional post to Compliance way; all promotional material: TV and consultations. This process included document to be unique, to refl ect the Offi cer, Polpharma Trade Offi ce Sp. z o.o., radio commercials, online advertising, surveys and face-to-face meetings. We The Polpharma Group Code of Ethics gov- Advice on ethical questions character of our organisation and the ul. Bobrowiecka 6, 00-728 Warszawa printed material (folders, brochures, were updated on successive work stages erns such areas as the role of line manag- and whistleblowing ethical values common to all of us. posters), mobile content, etc. are verifi ed and outcomes on an ongoing basis. ers in the reinforcement of the desirable The general rule in our Ethics Programme Therefore, we engaged employees from and approved through that system. During the activities, we became the co- culture of ethics, relationships with col- is that managers are engaged in the promo- all our companies in the development authors of a document laying down the leagues and business partners, addressing tion of ethical conduct and addressing of the Code of Ethics, encouraging them Recognised and Rewarded principles and values that guide us every ethically doubtful situations and whistle- ethical concerns. This applies not only to to be open and active in the joint effort. Polpharma’s observance of high standards day. Respect, integrity, responsibility, blowing. The Code additionally addresses executives, but also to mid-level manag- The signifi cance of ethics for our organ- in selling activities is confi rmed by the Ethi- solidarity and cooperation are all embed- our fundamental rules, such as respect for ers. Therefore, the line manager is the fi rst isation was confi rmed by the involve- cal Sales and Customer Service Manage- ded in our professional and private lives. human rights, ban on use of child labour point of contact for an employee with any ment of the company’s top executives ment Certifi cate awarded in the 6th edition Our suggestions and ideas are refl ected or forced labour, compliance with the rules ethics-related issues, including whistle- in the proceedings of the Steering Com- of the Polish National Sales Awards (2014), in the Code of Ethics, helping us identify of fair competition, including compliance blowing. Only where it is impossible to mittee and by the appointment of an whose objectives include the reinforcement with its content. The standards laid of the ethos of a professional seller. of advertising and promotion activities contact the line manager, each Polpharma interdisciplinary project team composed down in the Code are not strange to us, with the law, counteracting corruption and Group employee may contact the Pol- of managers. they were created by us and for us. We confl icts of interest, and environmental pharma Group Compliance Offi cer directly. We treat the Ethics Programme as Ethical Marketing and Sales are perfectly aware how important it is protection. As a socially responsible com- External stakeholders of Polpharma Group a sign of business maturity and also Nasze wartości, charakter działalności to respect them, especially considering pany, Polpharma requires its suppliers and may also report ethics violations. as an approach to the development of oraz prawo farmaceutyczne nakładają the substantial value we create for our na nas szczególne zobowiązania w zakresie trade partners to conform to high ethical a culture of ethics based on common customers, people who are ill and need komunikacji z otoczeniem, zwłaszcza standards, too. The Compliance Offi cer appointed under values. A Polpharma Group Compliance help. the Ethics Programme monitors the appli- Offi cer was appointed as part of the w odniesieniu do wiarygodnej, rzetelnej ACCOMPLISHED cation of the Code of Ethics and employee Programme to safeguard the adopted reklamy i promocji. IN 2015 compliance with the law and certain proce- rules of conduct. We place a lot of O ETHICS – OUR JOINT dures. He or she offers advice to employ- emphasis on employee communications We respect the applicable legal standards RESPONSIBILITY ees, helping them tackle ethical concerns, and ethical education. Ethical counseling and industry guidance on marketing The creation of the Code of Ethics for all and additionally carries out education and for employees and a whistleblowing pro- communications, such as the Code of employees to identify with provides a solid training activities. The Compliance Offi cer gramme which protects whistleblowers Pharmaceutical Marketing Ethics of the conducts investigations on own account or Polish Union of Pharmaceutical Employ- foundation for many years. Importantly, its against any potential retaliation are also Renata Zań Marta Zwierzyńska individual provisions have to be expanded in cooperation with Ethics Teams estab- important elements of the programme. ers (replaced in June 2015 by the European on in practice in the form of effective lished within Polpharma Group companies. Generic Medicines Association (EGA) Those teams are made up of people having procedures and mechanisms supporting the Marcin Musiał, Code of Conduct for Healthcare Interac- the experience and competence required to Polpharma Group continued reinforcement of the culture of tions), as well as the Code of Ethics of the decide on violations of the law or ethics. Compliance Offi cer, ethics, including response to and clarifi ca- Polish Association of Self Medication In- Leader of the tion of situations which may raise ethical dustry (PASMI). They are complemented Ethics Programme by restrictive internal procedures on com- concerns. In 2015, as part of Programme Establishment development activities, our focus areas munication with patients and the medical Team at Polpharma and pharmaceutical professionals. Medical Representatives, Pharmaceu- Michał Chudy Mariusz Staruk included: Group • the whistleblowing and non-compliance tical Representatives and Hospital We approve more than 3000 pieces of Representatives at Polpharma need to Employees of Polfa Warszawa S.A., investigation procedure, a Polpharma Group company since advertising and promotional material for complete an e-learning course on the • the anti-corruption procedure and 2012 medicinal products, medical devices, cos- procedure on gifts and other advantages, legal standards applicable to their jobs metics, food supplements and dietary foods • a system of regular training covering as representatives and to pass a test with for special medical purposes every year. all employees, maximum score.

40 Polpharma Group Corporate Social Responsibility Report 2013–2014 41 Polpharma Group Corporate Social Responsibility Report 2013–2014 6. we ensure high product quality and safe EGA Code of Conduct We regard our involvement in the estab- In the reporting period: As a member of EGA (the European lishment and work of the Coalition as a – we did not record any material inci- pharmacotherapy We are subject to a range of inspections Generic and Biosimilar Medicines Associa- responsible form of sharing our ethics ex- dents of non-compliance with laws and as a medicinal product manufacturer. tion), an organisation of top European pertise. We hope that the activities of the regulations concerning the provision e are responsible for human and confi rming the quality of our subsup- The process itself is extremely important manufacturers of generics and follow-on Coalition will contribute to the improve- and use of products and services which to the organisation, offering the op- health and life, therefore we do pliers. supply chain, verifying and confi rm- biologics, we committed to respect the ment of standards of economic life in our would result in a fi ne imposed on our portunity for continuous development. not compromise on the quality ing the quality of our subsuppliers. rules of the Code of Conduct for Health- part of Europe. company. W The results of audits and inspections and safety of our products. These are the care Interactions adopted by EGA in late are communicated to the Management priorities at every stage of product life – Moreover, it is the responsibility of each 2014. This document contains specifi c – there were no incidents of non-compli- Board level. A successful outcome, espe- from development through manufacturing marketing authorisation holder to evaluate guidance on relations with the medical ance with voluntary codes concerning cially in the case of certifi cation bodies, and storage to distribution and sales. the advantages and risks of pharmacother- community, regulating not only market- marketing communications, including is always a priority for all employees. ing communications, but also interactions advertising, determined in a judgment apy for all medicinal products. On behalf of We are also responsible for ensuring the Polpharma Group, this requirement is met with patient organisations and medical or decision of a state authority, disci- We are subject to regular inspections compliance of our activities with the by the Corporate Medical Unit. experts, education of the medical com- plinary court or an ethics committee carried out by the Chief Pharmaceutical munity or community involvement. of an industry organisation. provisions of the Pharmaceutical Law and Inspector, regulatory bodies in the coun- related provisions as well as European Pharmacovigilance involves the ongoing tries where we distribute our products, ACCOMPLISHED directives. We are obliged to adapt our assessment of the drug safety profi le and certifi cation bodies and fi nally custom- IN 2015 organisation to the changing law, placing mitigation of therapy risk by providing ers. On average, approximately 50 audits Business practice in Europe and globally the right emphasis on provisions governing up-to-date information about the drug to and inspections take place annually at places increasing emphasis on the trans- the prevention of drug counterfeiting. We health care professionals and end custom- the Pharmaceutical Works in Starogard parency of activities and corporate social 6. control the entire supply chain, verifying ers – patients and their families. Gdański. It means that in every working responsibility. This applies in particular to week in 2013 and 2014 there was at the pharmaceutical industry. Internation- least one audit or inspection day in a al organisations of drug manufacturers given manufacturing area. The number O IN THE ETHICS OFFICERS set high ethical standards for themselves of audits and inspections in the other COALITION in an environmental self-regulation pro- Polpharma Group businesses is also high. cess with respect to their commercial and We are a member of the initiative group quality management It is noteworthy that we, as Polpharma marketing activities. EGA is headed in the of the Ethics Offi cers Coalition, which Group, carry out almost 150 audits same direction, having published its Code is aligned with the objectives of the annually on our suppliers. This is in line of Conduct for Healthcare Interactions, All our drugs and pharmaceutical substan- employee is aware that his or her actions UN Secretary-General Global Compact with the pattern of ensuring thorough designed to cover that kind of coopera- ces are manufactured in accordance may have a direct or indirect impact on the Initiative in Poland. The Coalition was supervision over the supply chain and tion to the widest extent possible. The with the standards of the Good Manufac- quality of our products. established on 10 December 2014 as part maintaining the right quality of produc- Polish Association of Pharmaceutical turing Practice (GMP), which is confi rmed of the Programme Business and Human tion materials. We also audit analytical, Industry Employers, as an EGA member, by certifi cates issued by the Chief Pharma- Considering the very wide product range, Rights. Implementation of the UN Guiding manufacturing and manufacturing-relat- has adopted the solutions and obligated ceutical Inspector. Conformity to the most which – aside from drugs – includes me- Principles on Business and Human Rights ed service providers. All those activities its members (including Polpharma) to stringent quality standards in the manu- dical devices, food supplements, dietary 2014–2020. The inaugural meeting of require a great deal of effort and can apply them. facturing of APIs is additionally evidenced foods for special medical purposes and the Ethics Offi cers Coalition was held on only be carried out by experts. Each of by the results of scrutiny carried out by the cosmetics, relevant manufacturing divisions 8 April 2015 and gathered more than 70 our auditors undergoes a preparation Wojciech US Food and Drug Administration (FDA). are additionally subject to inspections by participants. programme ending with certifi cation in Kuźmierkiewicz, All FDA inspections so far (in 2004, 2009, Certifi cation Bodies and District Sanitary the respective area. Vice President 2012 and 2015) were successful. Inspectorates (Sanepid). The main objective of the Coalition is to of the Polish jointly develop a standard for ethics pro- Association of Reproducible top quality necessitates not gramme management for businesses and Pharmaceutical only advanced technologies and com- institutions in line with the UN Guiding Industry Employers, prehensive quality control and assurance Principles on Business and Human Rights. representing Polish systems, but also responsible employee Marcin Turzyński, Additionally, the Coalition serves as a plat- employers at EGA attitudes. Therefore, through an appro- Polpharma Group form for sharing best ethics management priately selected and implemented training Quality Manager practices based on Polish and international scheme and predefi ned daily communi- business experience. cation standards, we ensure that each

42 Polpharma Group Corporate Social Responsibility Report 2013–2014 43 Polpharma Group Corporate Social Responsibility Report 2013–2014 Well-planned pharmaceutical forms We ensure that our drugs meet the most All complaints are recorded in detail. We ○ Adequate quality stringent quality standards throughout carry out an individual investigation of of registration dossiers When I was implementing the phar- QUALITY STEP BY STEP their shelf life. We carry out long-term sta- every incident. We always maintain regular macovigilance system at Polpharma bility testing to control long-term product contacts with the patient. for the fi rst time, I did not expect it to behaviour. We look at even the slightest become a corporate system covering so deviations from specifi cations with utmost The acceptable complaint rate is clearly many countries a few years later. I am concern, with respect to both products defi ned in every organisation. The happy that patients speaking different and packaging materials. In 2013–2014, complaint rate in the Group is one of languages can go to us for support and Polish Polpharma Group companies fi led our closely monitored predefi ned quality expertise in their mother tongue needed Disposal education applications for 9 product withdrawals, indicators. The value varies depending on to ensure a successful and safe therapy. ○ safe product ‘end of life’ which demonstrates our conscious and the specifi c nature of the manufacturing It is a pleasure to look at the Medical responsible quality management, and is area concerned. For example, the indicator Department Team – a group of profes- also a preventive measure taken by the value for Pharmaceutical Manufacturing Qualifi ed and regularly sionals, reliable and open people who organisation. Plant in Starogard Gdański is set at 0.65 audited suppliers share their experience to others and ppm (0.000065%). It means that the ○ top quality of raw materials consistently improve their knowledge. Complaint as an Important acceptable complaint rate is less than I am confi dent that the pharmacovigi- Change Trigger one defective packaging per million. lance system and medical information Education on therapeutic Each customer making a complaint is This value is reviewed and evaluated on an system built in Polpharma over the years compliance, monitoring treated on a case-by-case basis. We annual basis. offers good support to patients. But, as of complaints and adverse do not ignore any information or reports. Winston Churchill said, “now this is not reactions the end. It is not even the beginning of R&D expertise and We encourage our patients to share their ○ therapy safety the end. But it is, perhaps, the end of implementation of systemic observations, expectations and reserva- and effectiveness the beginning.” The pharmacovigilance solutions tions. Feedback on product quality is system is a quality-based system and ○ product design refi ned with critical to us, offering an opportunity to as such, it requires continuous improve- great attention to detail implement corrective measures and for continuous improvement. ment and development. Our entire team is committed to that development. We have one common goal: to live up to the safety of pharmacotherapy big challenge of “People Helping People”.

Qualifi ed and audited carriers Thorough monitoring of manufactu- and medical inquiries ○ full safety in transit ring processes, control of changes and Izabela Słowik, deviations, analysis of fi nished products For many years, we have focused on comorbidities on the development of Medical and ○ reproducible top manufacturing ensuring the best possible pharmacother- an adverse reaction and effect of other Pharmacotherapy quality apy-related protection to our patients and medications taken in parallel. On the basis Safety Director, on minimising the side effects of use of of the known adverse reactions, we carry Polpharma Group medicinal products, which translates into out the fi nal evaluation of the benefi t-risk improved safety of treatment. balance of drug use. The results of the assessment form the basis for measures We keep a steady level of investment We invest in quality on many levels. solutions, while promoting innovative ap- Seeking to minimise the risk associated aimed at improving product safety. For across all businesses to maintain top pro- We develop and upgrade our machinery, proaches. Finally, we invest in our people, with the use of our drugs, we carry out example, we implement recommendations duct quality while preserving our competi- auxiliary systems and control systems developing the competences of subject- continuous pharmacovigilance activities. from competent European Union author- tive advantage. (for the visual inspection of fi nished -matter experts and specialists. We place a particular emphasis on the anal- ities relating to information provided in products). We implement new IT systems, ysis of any information we receive about printed information material and other providing support for the available quality adverse reactions. The medical evaluation measures aimed at minimising the risk of of such insights includes the analysis of pharmacotherapy. causes, severity assessment, impact of

44 Polpharma Group Corporate Social Responsibility Report 2013–2014 45 Polpharma Group Corporate Social Responsibility Report 2013–2014 7. we ensure and promote elevated standards of work Medical Inquiries Patients can ask questions and obtain in- Provision of reliable drug information to formation in all countries where Polpharma The number of medical inquiries an- safety The safety of our employees is our prior- patients is an equally important element of Group’s drugs are sold. For that purpose, swered is growing every year. Patients are ity. We make efforts to provide safe and the protection system, involving the com- we also provide a telephone line and often concerned about how they should e always put people and their Prevention is of critical importance to us. ergonomic work places and innovative munication of all new hazards identifi ed as a contact form available at www.polphar- take their medication in relation to protective equipment and tools to re- health and safety fi rst. OHS Through a variety of education activities a result of the analysis of available data. ma.pl which diverts inquiries directly to meals, what and how much they should duce the occurrence of accidents at work means much more to us than and internal communication tools (regu- This important role has been assigned to the inboxes of the staff of the Medical drink to wash it down, or even about the W and occupational diseases. Only healthy just adapting our work places to current larly published BeHaPoskop and Safety info the Medical Department. To ensure that Information Unit. We additionally launched temperature of the beverage. Parents and satisfi ed employees can be commit- regulations. We keep looking for ways to serwis guides, corporate newsletters our patients can access the latest knowl- a help line owing to which a patient who wonder how they should administer the ted to their responsibilities. Therefore, make the work environment, tools and Panaceum and Remedium), we make our edge on our medicinal products, already calls a telephone number provided on drug to their child – can they add it to his we make every effort to encourage our conditions even safer, more comfortable employees aware that their daily behav- a few years ago we implemented a medical a leafl et has a choice to make a quick call favourite juice or meal, can they crush employees to lead healthy lives and take and friendly. A mandatory OHS training iours, habits and attitudes are of crucial inquiry management system covering all relating to a medical inquiry or an adverse a pill or break it into halves, empty a care of their safety. We are convinced scheme covers not only our employees, importance to their health and safety, not Polpharma Group companies and foreign reaction report. capsule and mix the contents with liquid? that thinking of one’s own safety and but also external contractor staff working just in the work place. representative offi ces. Moreover, patients tend to have concerns the safety of others can only be effective about combinations of drugs, their po- on our premises. if it is ‘in your blood’. We are making it tential interactions. We usually respond Conformity to the most stringent stan- happen, promoting safe behaviours at on the basis of offi cially approved docu- In 2013, we joined Healthy Workplaces dards of safety is evidenced by a honour- work, during commuting, at home and ments, but in most cases more thorough – Working together for risk prevention, able mention in the 2014 edition of the beyond. Building such a broadly defi ned product labelling research in other sources is also necessary a campaign of the European Agency for Culture of Safety competition held by the culture of safety is a time-consuming (current guidance, publications). We are Safety and Health at Work (EU-OSHA) Central Institute for Labour Protection and tough process, but the effects are also supported by our Quality, R&D and which promotes this aspect of professional – National Research Institute, European worth any effort. Information on Polpharma Group medica- conditions, availability category and 7. Regulatory Units. and personal life. Agency for Safety and Health at Work tions is provided in the summary of the marketing authorisation holder. Our greatest satisfaction comes from and Kirschstein & Partner, a consulting Sylwia Janowicz, product characteristics (information for positive feedback and such remarks as company. The jury recognises companies Head of the health care professionals), patient infor- We address the needs of the blind and “now I understand, thank you”. which successfully balance business activi- Department for mation leafl et and on product packaging. visually impaired. In accordance with EU ties and work safety. Environmental The type of information, its content and requirements, we put Braille information Protection and placement are governed by national and EU on our product packagings (a tactile writing Dorota Work Safety, medicinal product registration procedures. system for people who are blind or visually Kucharska-Pacho, Polpharma SA Legible packaging information and product impaired) and we publish audio versions Senior Medical leafl ets are an important factor in the ef- of our product leafl ets. The Ulotka Audio Information fectiveness and safety of therapy. They meet system provided by MEDsynC was devised Manager, Polpharma Group the requirements of the pharmaceutical law in close cooperation with the Polish Associa- for health and safety and EU guidelines. Patient information leaf- tion of the Blind, and it is recommended lets are subject to readability testing, which by the organisation as a product which is means that they are consulted with the friendly to the visually impaired. Selected initiatives carried out in 2013 and 2014 target users of the medicinal product con- In 2013 and 2014, the Polpharma cerned. This assures that patients can locate Responding to patient needs and listening Medical Unit answered • special work zone • Safe Driving Day In 2014, we created a special zone in our We promote safe driving all year round, the information provided in the leafl et and to the recommendations of pharmacists, 2960 medical inquiries. understand how to handle the product. The we have established a communication win- Pharmaceutical Analysis Development but on 25 July, the Safe Driving Day, patient information leafl et provides key in- dow which plays a major role in therapeutic Unit of the R&D Department to work the issue receives more attention than formation, such as ingredients, pharmaceuti- compliance. It is placed on the packaging of with substances which, in accordance ever. On that day, we run an information cal form, indications and contraindications, selected Rx drugs and comprises two boxes. with the Safety Data Sheet and classifi ca- campaign motivating car users to employ dosage and route of administration, neces- One of them is dedicated for the pharmacy tion by the OHS Unit, require the use of the right attitudes and demonstrate safe sary precautions, potential interactions with price tag, so that the tag does not obscure more stringent safety precautions. Work behaviours on the road. safety in the zone is guaranteed by the other drugs, adverse reactions or storage other important information. The other fi eld The box for the price tag conditions. Permanent elements of labelling is for the dosage regimen. personal protective equipment used, but also by the zone design and equipment as include the name, dosage, pharmaceutical The box for the well as appropriate work organisation. form and ingredients, packaging contents, dosage regimen route of administration, expiry date, storage

46 Polpharma Group Corporate Social Responsibility Report 2013–2014 47 Polpharma Group Corporate Social Responsibility Report 2013–2014 THE STOP ACCIDENTS A Diffi cult Lesson PROGRAMME IN FIGURES In 2013, there was an accident in our Staro- Our focus on work safety includes all gard Gdański facility involving an employee persons supervised by the organisation, 2013 • Safe Fleet (Bezpieczna Flota) • The Stop Accidents (Stop Wypadkom) of an external contractor, resulting in both our staff and employees of compa-

We have one of the largest vehicle fl eets programme severe bodily injuries. We performed a thor- nies working on our premises. Training on the market, mostly to support our The programme promotes and rewards 547 the stop accidents ough analysis of this tough incident and sessions, fi eld meetings with employees sales force. The programme, initiated in the engagement of employees in safety programme in fi gures we applied the lessons learnt, covering the and supervisory authorities, audits and 2012, includes a range of interrelated and prevention at work. The desirable employees of external contractors working inspections are our daily routine, as part elements which considerably improve the proactive attitude is demonstrated, 75% of reports on our premises with additional procedural of the promotion of a culture of safety safety of company car drivers. Safe Fleet for example, by watching out for and concerned technical issues activities and continuous improvement, at work. Each incident representing a involves, among other things: the Safe reporting of all hazards, near misses or also as part of the training provided to violation or deviation of the generally ap- Driving Code, promoting the principles dangerous situations. The most active them. Additionally, we implemented a pilot plicable rules is scrutinised in order to take of reports of eco-driving and sustainable transport, employees get attractive rewards. 17% Lock Out Tag Out system, whose purpose corrective and preventive measures so concerned human issues training and practice to improve on safe is to prevent accidental operation of equip- that similar incidents do not occur in the driving techniques and fi rst aid skills and • Medical rescue competitions ment during its maintenance. This way, future. Incidents posing a potentially high implementation of corporate standards In May 2014, we held a medical and 8% of reports we want to prevent such situations from risk of accidents are reported in corporate for company car equipment. The safest chemical rescue competition for the concerned organisation issues reoccurring in the future. newsletters. During training provided to company car drivers are rewarded with employees of the API facility. The On-Site subcontractor staff, we play our corporate attractive prizes. Fire Brigade supported us in the organisa- 2014 OHS-themed videos, we discuss the rules tion of the event. Teams competed in four of safety at work and we answer ques- • First aid training fi elds, which included the rules of fi rst tions. We spare no efforts to make every 580 risky incidents, TRAINING FOR We would like fi rst aid to be a natural aid, fi refi ghting and chemical rescue. situations and behaviours eliminated SUBCONTRACTORS participant of the meeting convinced that instinct for our employees and associates. they will be satisfi ed with working on our premises and will not suffer any unpleas- Therefore, we take advantage of some of reports 67% ant consequences. meetings organised on our premises – such concerned technical issues 1. Every non-employee working on the 4. During the training, the subcontractor as the Week of Work Safety and Health premises of Polpharma must complete fi lls out an individual safety statement events – to provide fi rst aid training. During additional induction training on OHS and receives our Bezpieczadło safety of reports the Open Day, we additionally promote 21% and fi re safety. brochure. concerned human issues and teach fi rst aid to our visitors. Rafał Peta, 2. The training is valid for two years. 5. Once the subcontractor delivers Senior OHS • OHS competitions 12% of reports After that time, it must be refreshed. the documents and completes the Manager, Chief OHS Specialist, We organise a wide range of competitions concerned human issues training, he or she can proceed to Polpharma SA with an attractive formula and prizes to 3. Persons bringing subcontractors on work. effectively raise the awareness of behav- site are obliged to deliver a safety iours that improve employee safety. statement and risk assessment for For example, in 2014 we encouraged the work to be carried out. The our staff to take part in Shine and Get subcontractor receives induction Noticed (Zabłyśnij i daj się zauważyć), training from the OHS Unit and a photography contest promoting the On-Site Fire Brigade. SUBCONTRACTORS COVERED BY TRAINING AND HAZARD use of refl ectors in the dark. BRIEFING

22013013 22014014 HHAZARDAZARD BBRIEFINGRIEFING 887575 11084084 TTRAININGRAINING 116161 221313

48 Polpharma Group Corporate Social Responsibility Report 2013–2014 49 Polpharma Group Corporate Social Responsibility Report 2013–2014 8. we nurture employee growth and commitment 2013 2014 For years, the Polpharma Group HR strategy has been based on development Total Total olpharma means people, their We guarantee equal treatment to all em- and optimum use of the potential of our staff. HR processes are designed to offer experience, knowledge and passion. ployees, irrespective of their gender, race, the best possible match between busi- Therefore, we are committed to origin, religion, sexual preferences or dis- P ness expectations and the capabilities Number of work-related fatalities 00 0 01 1 ensuring that our fair and wise HR policy, abilities. We also ensure unbiased perfor- and ambitions of the Group’s employees. Number of minor injuries at work 17 15 32 17 20 37 consistent with our system of values and mance reviews and transparent procedures, We keep improving our HR tools and focused on comprehensive development from internal and external recruitment Number of severe injuries at work 00 0 000 solutions to maximise their user friendli- and engagement, makes a difference and through training and professional develop- Overall injuries 17 15 32 17 21 38 8. ness and align them with the current and gives us the competitive edge. ment to career paths. future strategic development objectives Injury rate 44 8 459 of our organisation. (IR) (all Group employees) In 2014, we initiated work to update our employee competency model. Having a coherent and comprehensible model, Number of cases of occupational diseases 00 0 000 Employment we will harmonise the approach to the assessment and development of key Occupational diseases rate (ODR) 00 0 000 Polpharma Group has 4224 employees Polpharma is a key employer in the Ko- competencies across all job levels. Doz- in Poland. Owing to our employees, their ciewie region. It maintains a stable high ens of people from different companies competence and engagement, we are able level of employment, fully respecting the representing all corporate functions took to achieve ambitious objectives. Therefore, applicable rules of labour law. Polpharma part in the development and testing of Lost days due to accidents and injuries at work 303 244 547 443 579 1 022 it is extremely important for us to attract is also a god example of an employer car- the best talents, and then to create opti- ing for a high level of employee safety. the tool. Severity rate 18 16 17 25 30 28 Suggestions and views of our employees mum conditions for them to make them I hope that Polpharma’s business in are extremely valuable. We carry out an want to stay and grow their potential Starogard Gdański will continue to employee feedback survey on a regular in the long term. develop. basis. Its fi ndings and the resulting Lost days due to diseases 34 859 15 448 50 307 35 225 16 092 51 317 initiatives are developed in a collabora- We provide a friendly and creative work Total lost days (including due to diseases) 40 847 17 409 58 256 41 796 19 355 61 151 tive manner by our organisation and place, competitive remuneration principles, Arkadiusz Banach, are refl ected in the fi nal form of our HR Absentee rate (AR) 7 831 3 337 11 168 8 013 3 711 11 723 broad opportunities for professional de- Director solutions. velopment and a comprehensive employee of the District benefi t scheme. Considering the unique Employment Offi ce in Starogard competence of our staff, each resignation Gdański is a substantial loss. Therefore, we seek to Dorota Piskorska, be the employer of choice, which gives us Corporate a guarantee of maintaining a stable, experi- Development enced and close-knit team. and HR Director, Polpharma Group

50 Polpharma Group Corporate Social Responsibility Report 2013–2014 51 Polpharma Group Corporate Social Responsibility Report 2013–2014 2013 2014 2013 2014

Total Total

TOTAL NUMBER OF EMPLOYEES AGE ≤ 29 30-50 51 ≤ ≤ 29 30-50 51 ≤ AGE ≤ 29 30-50 51 ≤ ≤ 29 30-50 51 ≤ PROBATIONARY PERIOD 00 0 000 Total Total non-permanent 179 202 381 167 201 368 Turnover 51 133 34 24 119 29 390 Turnover 45 99 35 26 84 31 320 permanent 2 055 1 661 3 716 2 050 1 705 3 755 Percentage Percentage replacement 52 24 76 72 29 101 Turnover 1% 3% 1% 1% 3% 1% 9% Turnover 1% 2% 1% 1% 2% 1% 8% to perform a specifi c task 00 0 000 rate rate TOTAL WORKFORCE WITH EMPLOYMENT CONTRACTS 2 286 1 887 4 173 2 289 1 935 4 224 Total Total by gender: New 102 133 10 101 142 9 497 New 100 132 5 93 108 2 440 management contracts 00 0 000 employee employee hires hires self-employed but working for the group as regular employees 00 0 000 Percentage Percentage employees supervised by the group (apt) 00 0 000 Rate of new 2% 3% 0% 2% 3% 0% 12% Rate of new 2% 3% 0% 2% 3% 0% 10% GRAND TOTAL 2 286 1 887 4 173 2 289 1 935 4 224 employee employee hires hires TOTAL NUMBER OF PERMANENT EMPLOYEES full-time basis 2 258 1 866 4 124 2 270 1 913 4 183 part-time basis 28 21 49 19 22 41 70/20/10: Development TOTAL 2 286 1 887 4 173 2 289 1 935 4 224 as a Continuous Process THE 70/20/10 FRAMEWORK We believe that development should be perceived as a continuous, holistic process, the sum of all experience acquired on our of learning and development happens through practical experience Comprehensive Development proach. For many years, we have provided own account and from others in our daily 70% and problem solving. The year 2014 brought a number of impor- We owe our dynamic growth to our staff, an extensive training programme to our jobs, supplemented by knowledge from tant changes in the training area. First and their openness, curiosity, engagement employees, tailored to individual business formal training. We had followed this occurs through receiving and analysing of feedback, observation foremost, the approach to development and constant willingness to improve their needs. Employee development planning approach intuitively for many years until and working with others who serve as role models – line managers, within the Group was structured around 20% qualifi cations. At the same time, we are is based on competency assessment and it was formalised in 2014 through the es- trainers, coaches. the 70/20/10 framework, a clear system of aware that opportunities for comprehen- performance reviews. Each employee can tablishment of the 70/20/10 development career paths was designed, and informa- sive improvement are a great incentive. access the results of the assessment in framework, which had been proven by the happens through formal training, workshops, conferences, seminars tion on available professional growth Our employees appreciate the fact that we the form of a clear graph available online. best companies in Poland and worldwide. 10% or specialist literature. opportunities was disseminated (the HR offer unique development opportunities, Regular assessment discussions with line The implementation was preceded by e- Portal, Training Curriculum). also through participation in revolutionary managers and annual and interim reviews learning which was aimed at emphasizing projects that are often innovative from the of objectives facilitate the refi nement of the signifi cance of employee empower- perspective of the entire region. Therefore, development plans. ment and responsibility for own develop- we place particular emphasis on continuous ment. improvement based on the 70/20/10 ap-

52 Polpharma Group Corporate Social Responsibility Report 2013–2014 53 Polpharma Group Corporate Social Responsibility Report 2013–2014 The Training Curriculum In 2015, new development tools were add- Career Paths We Appreciate Employee Initiative Friendly Workplace KAIZEN: TINY IMPROVEMENTS, In response to the expectations of our em- ed to the Training Curriculum: e-learning The new career path system established We have created a clear and transparent We make every effort to keep our working BIG BENEFITS ployees expressed, for example, in feedback and audiobooks. in the fi rst half of 2013 supports employ- incentive scheme which rewards employees environment free from harassment and surveys, we developed two practical tools: ees who want to fulfi l their professional for outstanding performance, daily discrimination. TTOTALOTAL OUTCOMESOUTCOMES the HR Portal and the Training Curriculum. Furthermore, we continue and develop ambitions through internal promotions. commitment and respecting our system IINN 22013013 ANDAND 20142014 The innovative HR Portal available on the skills management and lifelong learning The system harmonised job titles, providing of values. We focus on open dialogue, encouraging IIDEASDEAS PPUTUT 11359359 intranet is a source of hands-on and up-to- programmes proven in the previous years, clear and transparent promotion criteria. everyone to contribute. FFORWARDORWARD date HR knowledge, including training and that support the continued employability A review of promotion opportunities, com- Considering that our business is driven by IIDEASDEAS 997272 development. The Training Curriculum is of employees: bined with a review of remuneration, continuous improvement and looking for Labour unions, the workers’ council, on-site AACCEPTEDCCEPTED 1 117117 612612 a list of training proposals recommended • Career Engine – a leadership develop- is carried out twice a year. The long-await- innovations in every business area labour inspectors and on-site OHS com- BBENEFITSENEFITS [PLN][PLN] for individual job groups. Every employee ment programme at Polpharma Group, ed changes included the extension of career (for more information, see pp. 76 and mittees are all valuable discussion partners. ((valuevalue ooff 8 keykey iideas)deas) can choose a classroom training from that • LIDER Programme – supporting newly paths in the commercial function. 77), we reward employees for particular We provide a comprehensive employee list during the year in coordination with his hired staff and newly appointed manag- achievements in this fi eld through our benefi ts scheme to our staff. We seek to or her line manager. ers in building engaged and motivated The introduction of new career paths was long-standing programmes and competi- align all benefi ts around the themes of At the Pharmaceutical Works in Starog- teams, preceded by 25 meetings held by the HR tions: health and well-being. For instance, the ard Gdański, the Biotechnology Division In 2014, the fi rst pilot year of the pro- • Polfa Warszawa Manager Academy – Department. The information campaign MultiSport package and extended medical in Gdańsk, Polfa Warszawa and Medana gramme, the Training Curriculum mainly a series of training courses addressed to attracted a lot of interest to career paths, • The Amber Galen Award (Nagroda plans are very popular. Pharma, there are collective bargaining covered managers. The tool received very team managers, helping the system to establish itself in our Bursztynowego Galena) – a key honour agreements covering all workforce in place good feedback, and so starting in 2015, we • subsidies for university studies, includ- company. Its effectiveness is best proven by within Polpharma Group, awarded for 15 All employees with employment contracts, (except management boards). In the remain- extended the self-managed development ing postgraduate studies developing the fact that by the end of 2014, as many years to people and teams demonstrating whether on a full-time or part-time basis, ing companies and divisions of Polpharma system to all employees. To participate in management skills, within the available as 941 changes were made to individual excellent performance and exceptional enjoy the same access to benefi ts and al- Group – Manufacturing Division in Duchnice, Manufacturing Division in Nowa Dęba and a recommended training event, all you budget. terms of employment (including promo- attitudes and meeting our corporate lowances arising from generally applicable Trade Offi ce in Warsaw – remuneration poli- have to do is to consult the timing with tions) owing to the career paths. values to the fullest extent possible. provisions of law in particular locations/ cies are in place. your line manager and accept the selection • Innovation of the Year (Innowacyjność companies. We subsidise employee in the system. Roku) – a competition that rewards the holidays, sport activities and participation best process, product or organisational in cultural events. Employees can take PERCENTAGE OF EMPLOYEES innovations submitted by our employees out housing loans or receive emergency RECEIVING REGULAR 2013 2014 (for more information, see p. 76); assistance. Employees are also covered by PERFORMANCE AND CAREER • Kaizen – a competition supporting an extended private medical plan (in 2014 DEVELOPMENT REVIEWS a culture of continual small improve- this did not apply to the employees of the Total Total ments in daily work; we reward the best Manufacturing Division in Nowa Dęba, who 2013 2014 idea, the most active programme partici- are to be covered by that extended plan L L

pant and the best team; in 2013 and 2014 soon). They can also take out life insurance L L A ALL A ALL Total number of employees 2 286 1 887 4 173 2 289 1 935 4 224 we recorded the highest number of ideas on preferential terms (whether working on put forward and accepted in an edition a full- or part-time basis). Certain benefi ts MMANAGERSANAGERS ANDAND EXECUTIVESEXECUTIVES Managers and executives 206 287 493 229 299 528 ever – key ideas generate benefi ts esti- are also available to persons hired under 992%2% 889%9% 994%4% 994%4% 991%1% 996%6% Individual contributors 2 080 1 600 3 680 2 060 1 636 3 696 mated at over one million PLN annually, civil law contracts or as temporary staff, IINDIVIDUALNDIVIDUAL CCONTRIBUTORSONTRIBUTORS HOURS OF TRAINING PER EMPLOYEE BY EMPLOYEE CATEGORY • The Green Process (Zielony Proces) – depending on the capabilities of the com- 882%2% 779%9% 885%5% 883%3% 881%1% 886%6% a competition promoting environmentally pany concerned. Managers and executives 4 457 6 971 11 428 6 147 9 103 15 250 PPERCENTAGEERCENTAGE OFOF WORKFORCEWORKFORCE friendly initiatives and aligned with the Individual contributors 18 527 12 506 31 033 23 428 15 333 38 761 CCOVEREDOVERED BBYY RREVIEWSEVIEWS concept of sustainable development. Total hours of training 22 984 19 477 42 461 29 575 24 436 54 011 883%3% 880%0% 886%6% 885%5% 882%2% 888%8% AVERAGE HOURS OF TRAINING PER EMPLOYEE Employees are additionally recognised BY EMPLOYEE CATEGORY for their outstanding efforts through the Managers and executives 22 24 23 27 30 29 Rewards Scheme. Credits awarded by line managers can be exchanged to attractive Individual contributors 98 8 11910 prizes through the MyBenefi t platform. In Total hours of training 10 10 10 13 13 13 2014, managers recognised their employees via the Rewards Scheme on 2000 occa- sions.

54 Polpharma Group Corporate Social Responsibility Report 2013–2014 55 Polpharma Group Corporate Social Responsibility Report 2013–2014 Being Close to Employees and Their As an organisation focusing on continu- Employer of Choice ships to the best participants in Warsaw Families ing self-improvement, we are particularly The opinion of our employees matters We understand this ‘choice’ in two ways. (for instance in the HR, IT, Procurement, Polpharma is not a heartless corporation. We organise a range of events, meetings happy about the improvement of results a lot to us. For seven years, we have First of all, we would like young people Rx Marketing Units) and in Starogard It is a Polish company where an individual and team building trips for our employees versus the same survey carried out three conducted the Employee Feedback Sur- who enter the labour market to make Gdański (Controlling and IT). is still important. Jerzy Starak, the com- and their families. Together with them, we years before. vey, one of our key tools in the dialogue conscious employer choices, instead of pany owner, has never taken an easy way celebrate such occasions as the Children’s with our employees. We do not restrict leaving everything to chance, which often Since June 2014, we have been running out. He has never wanted to discontinue Day or St Nicholas’ Day. We also remember EMPLOYEE ENGAGEMENT ourselves to the survey alone. We have determines their future professional life. a traineeship programme at Polfa unprofi table businesses. He has fought about those employees who have already SURVEY 2014 gone one step further. We listen to what Secondly, we would like the most valu- Warszawa addressed to adult graduates for them, restructured and upgraded retired. We stay in touch, celebrate their the people expect, what kind of work able students and graduates to choose of technical secondary schools. As part of them, while maintaining a high level of anniversaries, arrange regular meetings on place they value and what changes they our company as the place to pursue their the cooperation, the students take part in social dialogue. the occasion of the Seniors Day and we of- want. The beginnings were not easy, as professional ambitions. a manufacturing practice, supervised by While junk contracts are attracting a lot

fer special benefi ts (such as medical care). T it is in the case of any new development. experienced staff from the Maintenance of publicity in Poland, Polpharma hires E N C

E However, starting from the fi rst meetings Those objectives are targeted by our in- Unit. This way, we help the young people people under employment contracts and N M A E

Polpharma Open Day, held every spring in D with our employees, we have been striv- house Polpharma Academy programme enter the labour market, while showing our offers stability to many Polish families. G N A E G Starogard Gdański, is a special event where T ing to create a climate of mutual trust. addressed to the most talented university employees how to share knowledge and Polpharma cares about its employees, T N our employees can show their work place A ATTENDANCE E ENGAGEMENT We defi ne clear boundaries and oppor- graduates, which allows them to get an experience. which is confi rmed by the Employee- to their families and friends. This day is tunities for changes. To depict the scale in-depth insight into the business practices Friendly Employer Award (Pracodawca full of attractions, such as shows, process PPOLPHARMAOLPHARMA GGROUPROUP 779%9% 551%1% of the initiative, let me mention that it of a pharmaceutical company from the Together in Tough Moments Przyjazny Pracownikom) received in 2014 ((PolandPoland andand otherother ccountries)ountries) simulations and chemical experiments. It is involves more than 40 meetings for each perspective of tasks performed by a range The responsibility for the economic condi- from the National Commission of the also a unique opportunity to do something PPOLPHARMAOLPHARMA GGROUPROUP 881%1% 448%8% survey. We create a map of action for of units. Owing to that, the participants of tion of our company, and hence for the fate NSZZ Solidarność trade union. IINN PPOLANDOLAND the upcoming years using the ideas put good for your health and for the environ- ((withoutwithout PPolfaolfa Warszawa)Warszawa) the Academy can contrast their university of our employees, sometimes forces us to forward by our employees. It includes ment. During the Open Day in 2014, our knowledge with practice, and in conse- optimise our workforce. We spare no effort Leszek PPOLFAOLFA WWARSZAWAARSZAWA * 776%6% 332%2% activities included testing for heart age both strategic initiatives (such quence, they are able to make informed to make these tough and painful decisions Świeczkowski, as part of the Pressure for Life campaign. as the introduction of the aforemen- choices in respect of their working fi elds in a responsible way, with full respect for Chairman of the We also promoted sustainable transport, * The survey in Polfa Warszawa was carried out for the tioned Training Curriculum or career and development. Our company, in turn, those affected by the process. We always Intercompany inviting the participants to a bike safety fi rst time. The company joined Polpharma Group in paths, the Step Forward HR Portal) and acquires valuable employees, because as try to look for solutions that will offset Commission of town and a bike service station. Automo- 2012 and underwent a diffi cult restructuring process. tiny changes which still have a major shown by experience from the seven edi- the consequences of losing jobs, at least in NSZZ Solidarność The results were calculated separately, in order to tive enthusiasts, on the other hand, were impact on the day-to-day atmosphere tions of the Academy carried out so far, the part. Aside from a package of benefi ts, our get the best possible insights on engagement in that encouraged to join an eco-driving course. and work satisfaction (such as uploading best participants usually stay with us after affected employees have the opportunity company. employee photographs in the company the completion of their traineeship. to retrain themselves to improve their contact database). I am certain that we Every Voice Is Important chances on the labour market. get to know our employees better with AWARDS AND HONOURS Employee opinion expressed in our cyclical In 2014, 15 people participated in the each subsequent survey. Employee Feedback Survey is particu- fi ve-day Academy training. We offered In the recent years, restructuring of work- • Universum Student Survey larly important. The survey, carried out Aleksandra paid 7-month traineeship to the best three force covered mostly Polfa Warszawa and 2013: The Perfect Employer title in the since 2006 using a methodology devised Szafraniec, graduates, which then turned into perma- Sanfarm, a company which was trans- Medicine & Pharmacy category and the by AON Hewitt, covers 20 engagement Head of nent employment – the three of them are formed into the Manufacturing Division of third place in the Sciences category. factors classifi ed into six groups: people, Organisational still with us today. Polpharma SA in Nowa Dęba. Importantly, 2014: the second place in the Sciences rewards, work, practices, opportunities, Development in the case of Polfa Warszawa, we man- category and the seventh place in the quality of life. We extended the range of and Talent We reinforce our position on the ‘employer’ aged to complete this process mostly in Medicine & Pharmacy category. the study location by location every year. Management, market through our presence at major job the framework of Voluntary Redundancy • Universum Poland’s Most Attractive In 2014, employees of all our Polish and Polpharma Group and career fairs in Poland and HR events Programmes (VRP), which included a Employers foreign organisations were invited to par- abroad. We also initiate a range of own ac- range of protective measures, includ- 2015: The Perfect Employer title in the ticipate in the survey. tivities to reach valuable candidates (from ing comprehensive support in the form Sciences category. our perspective). With them in mind, we of activation programmes. The ratio of • Reliable Employer of the Decade The survey enjoyed a great deal of popular- created the ‘Career’ section on our website voluntary redundancies to total reduction (Solidny Pracodawca Dekady) (2014) ity – the average response rate throughout and set up profi les at www.pracuj.pl and of employment was 81.5% in 2012, 50% • Employee-Friendly Employer the Group (Poland and other countries) was LinkedIn. We were involved in the Grasz in 2013 and 31.4% in 2014, respectively. certifi cate (Pracodawca Przyjazny 79%. The average engagement score for o Staż programme (a traineeship competi- The overarching objective of activation Pracownikom) received in 2014 from the entire Group was 50%. tion) organised by the Gazeta Wyborcza programmes was to provide as much sup- the National Commission of the NSZZ daily and PwC. We offered paid trainee- port as possible to the leaving employees, Solidarność trade union (2014)

56 Polpharma Group Corporate Social Responsibility Report 2013–2014 57 Polpharma Group Corporate Social Responsibility Report 2013–2014 9. we build a culture of diversity helping them to prepare to successfully look for new jobs in the highly competitive It is not easy to fi nd a job in our region. s a company with a long-standing is why already today we are intensively Recently, we have initiated education labour market. Participants of vocational Therefore, we appreciate the fact that activities aimed at overcoming stereo- inter-generational tradition and improving our skills in the area of manage- support programmes had the opportunity Polpharma is developing its manufactur- types associated with disabled persons. with a presence on a number of ment and working in diverse teams, for to use such assistance as: ing activities in Nowa Dęba, maintaining A As a company, we are open to employ- international markets, we experience the example through workshops and training • in-house training on innovative job approximately 160 jobs. Even at the time ing people with disabilities. However, power of diversity ourselves. We employ activities. seeking methods, preparation of job ap- when the facility needed restructuring continuous awareness raising activities almost 7500 people in total in Poland and plication documents, preparation for job following its privatisation, the company in this respect are necessary, especially other markets. Each of us is different. In so doing, we acknowledge that we need interviews, self-presentation, etc., made a lot of effort to minimise the among managers. Aside from a work- We differ in terms of gender, age, experi- a diversity lesson more than ever, not only • individual job counselling (psychological extent of potential redundancies, offer- shop organised by the Integracja Founda- ence, family status, lifestyle, and often lan- at the level of individual companies, but support, identifi cation of professional ing employment on a 7/8 FTE basis or tion, we carried out an architecture audit guage and cultural background. However, also for the general public. Demographic capacity, planning of development activi- looking for jobs in other facilities in the to check the accessibility of our offi ce ties, etc.), Podkarpacie region. This demonstrates being able to combine our best assets, we trends, especially the inevitable popula- in Warsaw for people with various kinds • external training, courses, post-graduate responsible thinking and concern about form a creative and close-knit team, ready tion ageing, clearly indicate that the art of of disabilities. Intergenerational com- studies and other forms of development the social effects of the company’s to face the greatest challenges. Our goal is bridging gaps between generations could munication and age management are allowing to change or improve profes- activities. Currently, the Manufacturing to create a work environment in which ev- be a critical skill for the economic and further important aspects of diversity. sional qualifi cations, subsidised up to PLN Division in Nowa Dęba is an example of ery employee is respected and appreciated, social future of Poland. Being aware of Here, we started with education too, 4000. a well-functioning and modern facility and is able to maximise his or her potential. that challenge, we take an active part in especially in the case of team managers with a signifi cant potential for further efforts aimed at supporting and promoting of different ages. We have also obtained In our Nowa Dęba Division, on the other growth. We give priority to the issue of equal diversity in Poland. We additionally address funding from the National Training Fund hand, we implemented job sharing activi- treatment and providing equal career op- this important subject in the public debate for a training scheme for employees aged ties to reduce the scale of required redun- portunities to all employees. Building on during conferences and other events. 45+. With that funding and additional dancies. The entire crew switched to a 7/8 a foundation which has been developed for resources allocated by Polpharma, we FTE basis, and the pay was reduced accord- years and is valued by our employees, we plan to provide foreign language classes would like to go further and make diversity (English and Russian) and training on ingly. To this end, terms of employment Wiesław Ordon, 9. one of our key development drivers. That cooperation within multi-generational had to be consulted with all employees and Mayor of Nowa teams, managing multi-generational labour unions. We also searched for jobs for Dęba the affected employees in other companies teams, MS Word, MS Excel and basic in the neighbourhood and took additional computer skills to 230 employees. ACCOMPLISHED protective measures. IN 2015

Owing to the responsible attitudes of the employer, employees and trade unions, Przemysław social effects of the redundancies in the O THE DIVERSITY CHARTER Płachetka, Nowa Dęba Division were minimised. Fur- Since 22 May 2015, we have been among HR Manager, the signatories of the Diversity Charter. thermore, restructuring exercises carried Poland out in other areas were successful and the The international initiative promoted by part-time employment pattern could be the European Commission brings together terminated earlier than planned. companies which follow a policy of equal treatment and equal opportunities and take proactive measures to support social COMPOSITION OF POLPHARMA cohesion and equality by engaging them- GROUP GOVERNANCE BODIES selves in the promotion of diversity of the (2014): workforce, business partners and social BBYY GENDERGENDER partners. The constantly growing group of Charter signatories spans companies from a wide range of sectors, representing most 228%8% 772%2% European countries, including 119 Polish BBYY AAGEGE undertakings (as at 28 October 2015). 35% aged 30 to 50 65% aged 51 ≥

58 Polpharma Group Corporate Social Responsibility Report 2013–2014 59 Polpharma Group Corporate Social Responsibility Report 2013–2014 10. we care about the environment Taste the World: Diversity with a Pinch of Salt e are committed to ensuring of our manufacturing processes, managing The implementation of sustainable Everyone is different. This holds true even development is based on setting and that we grow Polpharma Group our energy, water and pollutant emissions in the kitchen. This diversity can be clearly achieving of objectives. In 2009, we set in harmony, respecting the reasonably and ensuring the safe use of seen in Taste the World (Posmakuj Świata), W long-term objectives for the period from needs of stakeholders, being mindful of chemicals. a unique cookbook published in a joint 2010 to 2014 in our Starogard facility. human life and health and of the environ- effort by two units: Brand PR and Interna- They involved the reduction of energy ment. We consider the environmental We additionally optimise the transporta- tional Markets. The book contains selected consumption and water withdrawal, impact of our business at every link of the tion of our products to customers. Al- recipes contributed by 40 Polpharma volatile organic compounds as well value chain. Meeting of environmental though our impact on waste generated by employees from 17 countries. It has been as minimising waste and use of PVC standards is one of the requirements that end consumers is limited, we successively published in three languages (Polish, Eng- packaging. We have accomplished most we impose on our suppliers. We analyse introduce recycled packaging materials or lish and Russian), in printed and electronic of our objectives. The minimisation of versions. The recipes are formulated in such a range of environmental aspects at the downsize the packaging to minimise our PVC in packaging, however, remains an a way that each of them tells a story rather 10.stage of product and technology develop- impact at the end of the value chain. unattainable challenge, because this kind than being a simple list of ingredients. ment. We keep improving the effectiveness of packaging material offers the best The book features awesome and appetising protection of medicinal product proper- pictures of the dishes. ties. In 2014, we formulated long-term objectives for all Polpharma Group com- EFNI – for the Promotion of Diversity The project was recognised by the jury panies in Poland for the period from 2015 of the International Business Award 2014 to 2020. Relying on our experience from As one Poland’s largest companies, we The European Forum for New Ideas WE CARE ABOUT THE ENVIRONMENT feel responsible for the developmental is one of few places where not only (Stevie Awards). The book received the the fi rst stage, we defi ned objectives challenges ahead of us, including the issue key economic and social issues are Gold Stevie Award in the Other – Public which were mostly a continuation from The activities of Polpharma Group in the Detailed guidance on operating activities of population ageing. We want to make discussed, but practical solutions are Relations category, and was additionally the previous period. The new objectives area of sustainable development are taking into account the environmental it a subject of public debate, as this way also presented to overcome or at nominated as one of top three projects involve the increased use of recycled based on the Integrated Occupational context is provided in ‘declarations’ we will be able to come up with solutions least minimise the effects of undesir- to the Golden Paperclip Award (Złote packaging materials, increased volume of Health and Safety and Environment which oblige us to: more quickly and turn a problem which able occurrences. Recommendations Spinacze) in the Internal Communications waste undergoing recovery or recycling following from the debate suggest Management System conforming to • ensure the continuous optimisation processes, and reduced CO emissions is now faced by entire Europe into an category. 2 decision-makers how to address key ISO 14001 (environmental manage- and streamlining of technological and opportunity for Poland to become more from passenger transport. The values set challenges. ment), OHSAS 18001 and PN-N-18001 auxiliary processes (» the Green Process competitive and escape the middle-income for particular objectives do not account The success of our publication, measured (OHS management) and PN-EN 17025 Declaration), growth trap. for production volume, as the achieve- Population ageing is undoubtedly not only by the number of readers but also (quality management for testing labora- • minimise the consumption and arduous- ment of our targets is driven by a range one of those challenges. Therefore, by the prestigious awards, demonstrates tories) standards. The policies imple- ness of solvents (» the Solvent of additional factors, such as the types Promotion and creative use of diversity is during the subsequent EFNI editions how much we value the cultural diver- mented within that system include the Management Declaration), of products manufactured or weather defi nitely a solution. Therefore, we put this in 2013 and 2014, we devoted a lot of sity of our organisation, which builds on Environmental Sustainability Policy, • minimise generated waste and maximise conditions. I am convinced that with the issue forward during key debates on the attention to the consequences of that diverse passions, traditions and customs the Occupational Health and Safety solvent recycling (» the Waste commitment of our staff, we will achieve future of Poland carried out on the occa- phenomenon and discussion on solu- of our employees from different regions of Policy and the Laboratory Management Management Declaration), our objectives in the next reconciliation sion of the European Forum for New Ideas tions. Reinforcement and promotion of the world. The indirect project objective Policy. • promote the use of public transport, period, too. cyclically held in Sopot since 2011. In 2013, a culture of diversity could definitely was very important, too. We wanted the cycling, safe and green transport of goods we acted as the partner of a panel entitled be a remedy, encouraging experienced employees to get to know each other and (» the Green Transport Declaration). Grażyna Kaczyńska, “Europe 60+ Ageing society as a challenge employees to stay active for as long as we encouraged them to engage in a joint possible, for the benefit of themselves action, so far from our everyday routine. Manager of the for development”. A year later, during and the company, and thus supporting With that fantastic experience, we can tap Sustainable the same EFNI event, we supported the the development of competences of on the potential of our diverse international Development and delivery of the session “How to exploit the the young generation of employees. team even better. Environmental diversity policy and new phenomena in the Protection Unit, labour market to strengthen the competi- Polpharma SA tiveness of a business?”. Magdalena Rzeszotalska, Corporate Monika Jasłowska, Communication Head of Brand and CSR Manager, Management, Polpharma SA Polpharma Group

60 Polpharma Group Corporate Social Responsibility Report 2013–2014 61 Polpharma Group Corporate Social Responsibility Report 2013–2014 INITIATIVES ENTERED FOR ENVIRONMENTAL OBJECTIVES AND THEIR ACCOMPLISHMENT initiatives THE GREEN PROCESS AWARD IN 2014 AS COMPARED TO 2013 IN THE STAROGARD GDAŃSKI For many years, Polpharma employees FACILITY have been engaged in process improve-

Key initiatives taken in 2013 and 2014 chilled water from a chiller (reduced S E

ment in the environmental context. S L G ) E A

to mitigate the environmental impacts withdrawal of tap water), A 0 V I R T I 0

In 2008, we presented the fi rst Green C E T N 0 B ‘ A of products and services: • optimisation of the cooling system in N Electricity consumption Heat consumption A I A M T

Chemistry (Zielona Chemia) award in the N V

I L F N U

• reduction of ammonium nitrogen the IV Fluids facility (electricity savings D I

was reduced by 604 MWh was reduced by 6718 GJ P N N NUMBER O OF I INITIATIVES F FINANCIAL A ADVANTAGES area of chemical synthesis in Starogard ‘000) ( (PLN discharges into waste water in the of 340 MWh and heat savings of 470 GJ (1.7%), to (2.4%), to Gdański, in the framework of initiatives Piracetam manufacturing process by 75%, annually), . proposed for the Sustainable 22010010 5 34,661 MWh 281,749 GJ. • an innovative manufacturing technology • refi ning of the Awanafi l technology 339393 We owe those savings mostly Development Programme. We owe the reduction mostly employed for Enalaprilat, which only uses and Topiramat process (quantities of 22011011 1111 1 226363 to upgrading exercises under In subsequent years, the programme to organisational measures water, hydrochloric acid and hydroxide methylene chloride used in the synthesis 22012012 1166 1 998686 the Energy-Saving Programme. covered Polpharma Group in Poland as implemented as part of the (the use of organic solvents is eliminated), reduced by ~17%, solvent use and waste a whole and its remaining industrial divi- 22013013 1144 2 613 The withdrawal of deep Energy-Saving Programme. • optimisation of the compressed air output reduced by ~11%) sions together with the R&D function. 22014014 1166 4 359 groundwater increased The use of solvents This way, the award was renamed to system, • innovative technical solutions in equip- 3 by 49 906 m , (16%) to amounted to Green Process (Zielony Proces). • reduced ammonium nitrogen levels in ment and pipeline insulation (heat losses 3 treated waste water discharged into reduced by ~2600 GJ in Starogard and . Currently, sustainable process design is 357,594 m 1121 tonnes, the Wierzyca River, Nowa Dęba), The increase arises from increasing by 0.8. The a foundation of the company’s opera- • introduction of low-weight paperboard • extension of tank lifetime (deep ground- Owing to the introduction of low-weight the product range being increase arises from the tional improvement. Group employees and of the option to use leafl et paper water withdrawal reduced by approx. paperboard, we reduced the use of paper- manufactured. product range being across all functions and organisational levels demonstrate strong environmental with grammage reduced from 45 g to 918,000 litres and washing agent use board in packaging by 91.8 tonnes annually. manufactured. The Alaska Plus paperboard will save 1564 The volume of solid waste awareness. Each business aspect is 40 g, by approx. 450 litres per annum). trees every year as well as 23,000,000 litres reached • reduction of electricity consumption in planned considering the reduction of of water and 460,000 kWh of electricity in the Solid Forms building owing to the 697 tonnes, adverse environmental impacts. The the paper manufacturing process, and it will number of ‘green’ initiatives confi rms optimisation of chilled water pumps, marking a 5% increase, which eliminate 18.5 tonnes of CO2 emissions into arises from product range the commitment of our employees. I am • closing of the compressor cooling water the atmosphere by reducing the need for being manufactured. convinced that the implementation of system and cooling of compressors using transport. the sustainable development concept contributes to the improvement of pro- cess effi ciency and more rational use of TOTAL ENVIRONMENTAL PROTECTION EXPENDITURES AND INVESTMENTS natural resources, raising the awareness 2013 2014 The achievement of our environmental of responsible business activities. objectives, understood as minimising our TYPE OF EXPENDITURE (PLN) environmental footprint, prevention and Fees: ensuring the safety of our processes requires continuing investments. Over the last years, Environmental fees 701 519 701 519 our major expenditure at Polpharma Group Bogdan Maślanek Abstraction of surface water or groundwater 1 194 117 1 194 117 has been incurred to upgrade fi re protection systems and implement the initiatives of the Director of the Gas or dust emissions into the air 1 759 274 1 759 274 API Facility, Sustainable Development Programme, such Waste treatment 3 412 344 3 412 344 Polpharma SA as the reduction of energy consumption or Cost of sewage treatment, including cost of restoration 4 533 868 4 533 868 improvement of manufacturing processes. in connection with spills disclosed under EN23 The remaining expenditure is related with Cost of sewage services and water purchase 2 406 576 2 406 576 the alignment of ongoing activities to the Testing and measurements of emissions into the air, noise 627 186 627 186 applicable legal requirements. emissions, water and sewage quality, water tables in wells Management expenses 1 086 145 1 086 145 TOTAL EXPENDITURE 15 721 029 15 721 029 TOTAL INVESTMENTS 4 486 500 3 860 142

62 Polpharma Group Corporate Social Responsibility Report 2013–2014 63 Polpharma Group Corporate Social Responsibility Report 2013–2014 REDUCTION OF ENERGY CONSUMPTION energy Energy management in a large organisa- tion such as Polpharma is extremely Task Savings Jan–Dec Plan for 2014 ENERGY CONSUMPTION WITHIN THE ORGANISATION complex and it depends on many 2014 [MWh] [MWh] factors, such as the restrictive legal ORGANIZATIONAL MEASURES (O) provisions regulating the manufacturing 1.1. Polpharma SA. Starogard Gdański 2013 2014 of pharmaceuticals, which require the 596 321 TOTAL FUEL CONSUMPTION* / USE (SCOPE 1) use of energy-intensive air conditioning Monitoring of shutdowns: lighting, utility systems, machinery 312 205 FROM NON-RENEWABLE SOURCES IN (OWN OR PURCHASED) TOTAL systems, or the increasing environmental Optimization of the compressed air system (master controller) 284 116 IN CJ BY FUEL TYPE requirements that are hard to reconcile TECHNICAL MEASURES (T) Coal 00in some respects. We install new systems 2.1. Polpharma SA. Starogard Gdański 745 908 Natural and coke oven gas 63 423 52 025 reducing emissions into the air which often increase energy consumption. Modernization of the cooling system in the IV Fluids facility 105 280 Heating oil 2 033 2 240 However, owing to a number of initia- Installation of an absorption chiller in the Solid Forms facility (incl. in B2014) 503 500 Liquid fuel 105 258 106 369 tives taken as part of the Energy-Saving Upgrade of the iced water system in the Solid Forms facility 137 87 Other (specify) 00Programme, which has been in place at Free cooling system on administration premises and multi-tier warehouse 041 TOTAL 170 714 160 634 Polpharma since 2009, we manage to maintain a downward trend. In 2014, we *Energy consumption is understood as generation and use for production and business used 34.66 GWh of electricity in Staro- gard Gdański, 1.7% less than the year before, and 281,749 GJ of heat, which was 2.4% less. Aside from technical and water and wastewater management

TOTAL ENERGY CONSUMED/USED PURCHASED technological solutions, internal audits AND GENERATED (ELECTRICITY, HEAT, COOLING AND STEAM) are a very effective tool in the optimisa- IN GJ tion of energy consumption, and so are Saving of water, one of the most valuable In 2014, as compared to 2010, we managed ENERGY GENERATION organisational measures taken to raise natural resources, is a permanent to reduce the total withdrawal of river In 2014, we undertook a new project in the energy awareness of staff. Electricity 00 feature of responsible management in the water and deep groundwater by more than cooperation with the Gdańsk University Group. Rational water use is supported by 25% (from 2977 to 2216 m3). of Technology, which includes analyses of Heating Medard Krzyżyński, 00 a number of initiatives taken in relation to the content of APIs in process and treated Head of the Cooling 00 manufacturing, cooling, fi re protection, as Industrial wastewater and sewage gener- wastewater. It is an innovative project, as Department of Steam 00 Systems and well as sewage processes. We quickly ad- ated in Starogard Gdański are treated by there are no relevant legal requirements in ENERGY PURCHASE Automation, dress any spills or failures and we improve an on-site treatment plant. Owing to our place at the moment. Being aware of the Electricity and the performance of our water system. activities, some of them carried out in detrimental impact of those substances on Electricity 218 682 222 444 Telecommunications The implemented solutions are accompa- cooperation with the Gdańsk University of the environment, we have decided to take Heating 313 106 321 085 Infrastructure nied by education campaigns supporting Technology, we have managed to reduce measures to minimise their emissions into Cooling 00 Management at environmentally conscious employee at- the quantity of ammonium nitrogen in the aquatic environment. Polpharma SA titudes, such as Stop Running the Tap treated wastewater by 75% over the last Steam 00 (Nie Lej Wody). 5 years. The wastewater generated by other TOTAL 531 788 543 529 Polpharma Group companies fl ows The facility in Starogard Gdański has its to municipal treatment plants. TOTAL ENERGY CONSUMPTION WITHIN THE ORGANIZATION own river water intake and four deep IN GJ groundwater wells. The other Polpharma Total energy consumption within the organization 702 502 704 163 Group companies use tap water.

64 Polpharma Group Corporate Social Responsibility Report 2013–2014 65 Polpharma Group Corporate Social Responsibility Report 2013–2014 TOTAL WATER WITHDRAWAL BY SOURCE substance management and process mass efficiency 2013 2014 WATER WITHDRAWAL BY SOURCE TOTAL (m3) Chemical substances, including organic • evaluating the chemicals used in process- metric (PMI) developed by the American Surface water, including water from wetlands 00 solvents, are used in the manufacturing es already at the stage of design, research Chemical Society. Rivers 1 738 039 1 850 534 of drugs and pharmaceutical substances. and development. Lakes 00 Key environmental measures in this area The metric measures the relationship be- include: The use of solvents depends on the type of tween materials used to produce a certain Ground water 00 • elimination of chlorinated solvents product being manufactured and has been quantity of a product. Maximisation of the Rainwater collected directly and stored by the organization 00 and substances with noxious properties stable for the last few years. use of materials reduces the emissions of Waste water from another organization 00 from manufacturing processes, pollutants to each environmental compart- Municipal water supplies 213 741 203 873 • reduction of solvent use, Since 2009, we have been monitoring the ment • maximising solvent regeneration performance of chemical and pharmaceuti- Deep groundwater 318 167 366 283 processes, cal activities using a process mass intensity Other source (specify) 00 TOTAL WATER WITHDRAWAL FROM ALL IDENTIFIED SOURCES 2 269 947 2 420 690

The data is calculated based on meter readings and invoices. PROCESS MASS INTENSITY (PMI) [RAW MATERIALS INPUT (KG) / PRODUCT OUTPUT (KG)] The process mass effi ciency of pharmaceutical manufacturing in Starogard Gdański is improv- TOTAL WATER DISCHARGE BY QUALITY AND DESTINATION 247 244 ing by the year, while in the chemical manu- 216 223 183 facturing area it depends on the type of APIs produced. Tracking of the metric allows to take 2013 2014 measures to improve the process mass intensity, 59 60 51 53 64 DESTINATION OF DISCHARGE TOTAL (m3) CHEMICALS for example by reducing the use of water or PHARMACEUTICALS increasing the share of regenerated solvents. Wastewater discharged to surface waters (lake, river, etc.) 2 377 866 2 261 855 2010 2011 2012 2013 2014 Wastewater discharged to sewers 210 790 198 302 Wastewater removed from the organization via truck to treatment facilities 00 Wastewater discharged to ground water 00 MATERIALS USED BY WEIGHT OR VOLUME Wastewater discharged over land 00 TOTAL WATER DISCHARGE 2 588 656 2 460 157 2013 2014 2013 2014 NON-RENEWABLE MATERIALS TOTAL TOTAL Materials used for drug manufacturing [kg] 6 049 351 6 124 057 TOTAL NON-RENEWABLE 13 464 584 15 680 331 MATERIALS USED [kg] Packaging materials used [kg] 3 588 950 5 710 747 TOTAL NON-RENEWABLE 1 977 896 1 520 223 Solvents used [kg] 1 316 228 1 318 572 MATERIALS USED [m3] Total paper used by weight (other than pack- 32 978 18 085 TOTAL NON-RENEWABLE 2 905 282 2 933 864 aging paper, e.g. offi ce paper) [kg] MATERIALS USED [l] Diesel fuel [l] 2 711 562 2 767 643 Diesel fuel [kg] 2 278 759 2 324 641 Petrol [l] 193 720 166 221 Petrol [kg] 145 518 125 929 Natural gas [m3] 1 977 896 1 520 223 Heating oil [kg] 52 800 58 300

66 Polpharma Group Corporate Social Responsibility Report 2013–2014 67 Polpharma Group Corporate Social Responsibility Report 2013–2014 waste management The increasing legal demands on the edukacja ekologiczna pracowników quality of pharmaceuticals, their packag- i otoczenia PERCENTAGE OF RECYCLED INPUT MATERIALS USED ing and leafl ets result in growing waste TO MANUFACTURE volumes, generated both during manu- facturing processes and by the patients. We believe that environmental education and interactions with environmental It is a key challenge for Polpharma Group is an important aspect of the responsibility O GREEN TICKETS organisations. 2013 2014 to keep looking for new solutions to for the environment, raising the awareness On 1 January 2014, we introduced subsidies TOTAL (KG) maximise the volume of recovered or and promoting environmentally conscious for those employees of the Pharmaceutical The meeting was attended by environ- recycled waste. We reduce the volumes attitudes in our employees and local com- Works in Starogard Gdański who used public mental protection experts from several Total materials used by weight or volume 13 464 579 15 680 331 of waste owing to the involvement of munities. transportation. When they show a copy of Pomeranian companies. We discussed such Total recycled input materials used by weight or volume 610 718 776 367 our employees in the initiatives of the a commuter pass for buses or trains bearing items as packaging placed on the market, Solvent regeneration [kg] 2 375 173 2 318 616 Sustainable Development Programme, Aside from the Sustainable Development their name, they receive 20 bonus points in industrial accidents, carbon footprint, good Percentage of recycled input materials used to manufacture 5% 5% which includes the implementation of Programme and the Energy-Saving Pro- the MyBenefi t cafeteria system. Next year, practices and initiatives reducing the envi- low-waste technologies and more ef- gramme, we carry out a range of initiatives we are going to implement this practice ronmental nuisance caused by businesses. fi cient processes. As much as 64% of the and projects in our facilities and offi ces with in more locations in Poland. 92 employees waste generated by the Polpharma facil- a focus on building a culture of environmen- opted for this commuting solution in 2014. Awards and Honours ity in Starogard Gdański was recovered or tal awareness in many dimensions: The feeling that we can make a real differ- recycled in 2014. This portion of waste • the Green Week (Zielony Tydzień), Green Local Communities ence to the environment is our greatest TOTAL WEIGHT OF WASTE BY TYPE AND DISPOSAL METHOD included plastic, recycled paper, glass and marked by practical advice on how to be We want to make local communities more satisfaction. However, we have to admit composite packaging, as well as steel, eco-friendly every day, sensitive to the issues of environmental that we are happy about the awards demolition waste, reaction waste and • Green IT (Zielone IT), a project promoting protection. Joint commitment can bring demonstrating that our commitment to waste solvents. It is defi nitely a success 2013 2014 the rational use of electric and electronic truly signifi cant effects, which is demon- environmental protection is recognised and that we managed to reduce the volume equipment, strated by our long-standing projects: valued. WASTE DISPOSAL METHOD TOTAL of landfi lled waste to 1%. We achieved • tele- and video conferencing systems • We are a partner of the European Mobility Recycling 1 834 1 868 this owing to a consistent search for new instead of business travel, Week in Starogard Gdański. In parallel, we In 2013–2014 we earned a number of Incineration 392 439 recycling, recovery and disposal options. • electronic document workfl ow, including organise events to promote sustainable awards, including a honourable mention Landfi ll 358 138 invoices, transport in other locations. in the 3rd edition of the Environmentally • use of double side and black and white • Next to health promotion, environmental Responsible Business competition (Ekood- Other (e.g. dissolution in a treatment plant, 527 452 printing, education is the main axis of the annual powiedzialni w biznesie). We were also third party disposal) • collection of waste light bulbs, batteries, Polpharma Open Day. We use this event awarded the honourable title of the Patron Dorota Gomuła, Recovery, including energy recovery 229 471 CDs, printer cartridges, expired drugs to encourage people to cycle or to recycle of Ecological Education (Mecenas Edukacji Environmental Reuse not applicable not applicable brought by our employees, waste. The Open Day is also an opportu- Ekologicznej) in 2013 and 2014 by the Protection Expert, Ekologia i Rynek monthly. Polpharma S.A. Composting not applicable not applicable Polpharma SA • active participation in the Waste-Less Day nity to exchange waste paper and other (Dzień bez śmiecenia) and in the interna- waste to a sapling or an eco-themed Pharmaceutical Works in Starogard Gdański On-site storage not applicable not applicable tional Clean Up the World campaign, souvenir. and Polpharma Trade Offi ce in Warsaw (other – specify) not applicable not applicable • the Second Life of the Product (Drugie • We organise conferences, meetings for received the Bicycle Friendly Certifi cate Total weight of waste [t] 3 340 3 367 życie produktu) campaign, schools and ecology-themed competi- (Przyjazny Rowerom) in 2014. In addition, • the Let’s Go Cycling (Wszyscy na rowery) tions. Trade Offi ce was also awarded the Green TYPE OF WASTE TOTAL programme, rewarding employees for bike Offi ce Certifi cate (Zielone Biuro), which commuting, Moreover, we share our expertise with attests to the company’s environmentally- Weight of hazardous waste [t] 676 679 • Green Tickets (Zielone Bilety) (reward- other companies in our region. In 2014, friendly approach to facility management Weight of non-hazardous waste [t] 2 663 2 687 ing the use of public transport by bonus we organised the Let’s Talk About the and commitment to environmental protec- TOTAL WEIGHT OF WASTE [T] 3 339 3365 points in the MyBenefi t scheme), Environment meeting (Porozmawiajmy tion. Both certifi cates were awarded by the • inclusion of environmental education o środowisku), which was a continuation Environmental Partnership Foundation. in the WIEM induction training, of similar meetings initiated by the LOTOS • safety and ecology updates on the Group. The objective of the event was to intranet. share information and experience concern- ing the implementation of the environmen- tal law, cooperation with state authorities

68 Polpharma Group Corporate Social Responsibility Report 2013–2014 69 Polpharma Group Corporate Social Responsibility Report 2013–2014 11. we build a sustainable supply chain SUPPLY CHAIN UNDER SCRUTINY Building a sustainable supply chain is Various corporate functions participated e are committed to ensuring Those assumptions formed the basis for an important element of Polpharma in the efforts to develop the sustainable that our products are a syn- the design of a new system of cooperation Group’s comprehensive approach to supply chain strategy and Polpharma onym of top quality and safety. with suppliers – the sustainable supply MANUFACTURERS OF MACHINERY, EQUIPMENT, W social responsibility. We believe that INPUT MATERIALS AND PACKAGING Group Supplier Code of Conduct, from Therefore, we only cooperate with the best chain strategy. ensuring that our suppliers meet ad- Quality through OHS to Environment suppliers, who can meet our strict quality ditional requirements concerning respect LOGISTICS and Compliance. We additionally invited CENTRES requirements, as confi rmed by current Polpharma Group Supplier Code of Con- for human rights, labour practices or our Polish and foreign suppliers audit fi ndings. We impose equally strict duct is an important component of that environmental protection is a must for to participate in a dialogue concerning requirements on ourselves when we act system. Project work started in autumn a company which relies on ethics in its the planned solutions. An interesting as a product or service supplier for other 2014, and the Code was adopted in 2015. TRANSPORT business. Polpharma Group Supplier COMPANIES feature involved screening of our companies. Code of Conduct is the fi rst step towards cooperating companies from all areas One of the initial stages of the design of the continuous improvement of our sup- of procurement – manufacturing materi- We want to create a feeling of co-responsi- the Code involved the analysis of suppli- ply chain. Compliance with the Code is als, non-manufacturing materials and bility within our supply chain, not only with ers in terms of potential corporate social an important criterion in the evaluation MANUFACTURING services, or technical and engineering PROVIDERS OF NON- TRADE OFFICE respect to the end product, but also for the responsibility risks. 1572 suppliers were and selection of partners for cooperation. FACILITIES procurement. The analysis allowed us to highest ethical standards and harmonious evaluated in total from the perspective of Inviting our suppliers to join the circle of -MANUFACTURING, estimate the actual and potential risks development of all actors in the life cycle both current and potential risks. MARKETING AND businesses which set the standards for ENGINEERING associated with our suppliers in a range 11.of our products, while considering the ethics and responsibility, we support the SERVICES of CSR areas. On that basis, we de- needs of stakeholders. promulgation of the best practices in this veloped the sustainable supply chain TRANSPORT COMPANIES area, in Poland and globally. We hope strategy and communicated it to our that those activities will contribute to employees and business partners in 2015. raising standards in the supply chains of From the very beginning, we thought our partner companies, too. long-term about the effects that we O COMMON ETHICAL We additionally expect our suppliers wanted to achieve – to improve the man- PHARMACEUTICAL WHOLESALERS STANDARDS to proactively promote the sustain- Bożenna agement quality of our suppliers while Polpharma Group Supplier Code able development concept among their Kozakiewicz, minimising the risks in the supply chain of Conduct is an expression of our stakeholders and to verify the activities of Vice President of on our side. Therefore, raising supplier strategic approach to a sustainable their employees and subsuppliers in that the Management TRANSPORT awareness and supplier education have supply chain. respect. The implementation of the Code Board of Polpharma COMPANIES always been critical. We did not want SA and Member of was initiated in 2015. The process consists to impose our standards on suppliers, so the Management Our suppliers are obliged to sign an of the following steps: we invited them to cooperate, and the Board of Polpharma • communicating information to suppli- communication of new requirements was acknowledgement that they have read Trade Offi ce and understood the Code and that ers and signing of the Code of Conduct HOSPITAL PHARMACIES promptly followed by workshops and PHARMACIES they intend to respect its provisions. acknowledgement, PATIENTS education meetings. The acknowledgement of the Code and • supplier education activities (classroom compliance with its provisions are also or online workshops, information and ANALYSIS OF SUPPLIER Elżbieta Czarnocka, the preconditions for cooperation with training material and a knowledge base CSR RISK Director of the Non-Manufacturing our Group. The Code outlines the most for suppliers in a dedicated section Risk analysis areas for suppliers: Materials important requirements for Polpharma of Polpharma’s website which is now • violation of employee rights, and Services Group suppliers in the area of: under development), • violation of human rights, Procurement Unit • management and ethics, • self-evaluation in the form of an online • adverse community impact, • adverse environmental impact. at Polpharma • employment conditions and employee questionnaire allowing suppliers to Group rights, evaluate the degree to which they have TRANSPORT • occupational health and safety, implemented the rules of the Code of COMPANIES • product safety and quality, Conduct, • tests on humans and animals, • improvement and reviews (internal and • impact on the environment external audits). DISPOSAL COMPANIES

70 Polpharma Group Corporate Social Responsibility Report 2013–2014 71 Polpharma Group Corporate Social Responsibility Report 2013–2014 innovation and advancing knowledge

We improve our organisation, respond to key medical challenges and provide space for the advancement of knowledge by implementing innovative solutions and cooperating with scientists.

72 Polpharma Group Corporate Social Responsibility Report 2013–2014 73 Polpharma Group Corporate Social Responsibility Report 2013–2014 innovation

and advancing Sebastian Szymanek, Member of the Management Board of Polpharma SA and Polpharma Trade Offi ce, knowledge General Manager in Poland For many years, Polpharma has been engaged in the development of Polish science and medicine. Close cooperation with the scientifi c community helps us develop innovative drugs and improve the existing products and manufacturing technologies. We share our Seeking to overcome the challenges posed by modern medicine and pharmacy, we focus on innovation, continuous improvement knowledge on the latest advancements in medicine and our long-term experience with doctors and pharmacists, supporting them in and advancement of knowledge. We keep developing our R&D facilities and we implement innovative solutions. helping patients. We invest approx. PLN 170 million in R&D activities in Poland every year. We reinforce the culture of innovation, where employees The position of a leading pharmaceutical company in Poland makes us particularly responsible for the development of pharmacy in share their ideas and are not afraid of taking the inherent risks of the innovation process. Poland. We support initiatives creating a friendly climate for science and innovation, and we help talented Polish scientists maximise their potential. We would like Polish scientists to act as a growth driver for Poland, without having to look for career opportunities Developing cooperation with universities and scientifi c institutions, we bridge science with business. We perceive synergistic abroad. Therefore, we create stable employment for highly-qualifi ed specialists and we keep improving the culture of innovation within cooperation and supporting the most talented Polish scientists as a chance to deliver innovative solutions that allow us to serve the company. the patients and the society even better. We also believe that it is our responsibility to support the education of medical and We reinvest a major part of our profi t in advanced technologies and new product developments, including biologics. In accordance with pharmaceutical professionals. In 2013 and 2014 we organised or supported 570 events: conferences, training, workshops, live surgery the OECD classifi cation, the pharmaceutical industry is one of the three most innovative sectors of the economy. We are proud of our streamings.Moreover, we develop innovative tools based on new technologies to facilitate the daily jobs of doctors and pharmacists. signifi cant contribution in this respect.

ddoctors use our DrWidget OUR SUCCESSES mmobile application series, such doctorsd took part more than more than employee ideas were recognised grants totalling more than aas the Medicines Database (Baza in conferences organised as innovations in the Innovation PLN 1.3 million were awarded by 30,000 Leków) application which con- 15,000 by Polpharma in 2013 29 4 Award programme the Polpharma Scientifi c Foundation ttains more than 15,000 descrip- aand 2014. ttions of medicinal products.

OUR COMMITMENTS

12. We implement innovative 13. We bridge science with business. 14. We educate medical • Through the activities of the Polpharma Scientifi c Foundation solutions. and pharmaceutical professionals. (grant competitions and scholarships), we supported research projects of particular importance for the development KEY METRICS of medicine and pharmacy. • We created development opportunities in Poland for excellent • We will reinforce an internal culture which • We will appoint an action coordinator • We will maintain the high level of expertise Polish scientists. Not only do we retain talents in Poland, but supports innovation, knowledge sharing, in our company to quickly evaluate of the lectures given as part of the European mutual inspiration and rewarding of the innovative projects proposed to Polpharma Educational Programme, reviewed by we also contribute to the returns of those who have decided best ideas put forward by employees – by universities and research institutes. workshop participants. to take their chance abroad. 30% increase in the number of grassroots • Support for research in the fi elds of • We shared advanced knowledge and the latest medical initiatives. pharmacy and medicine provided by the KEY ACTIVITIES IN 2013–2014: insights with doctors, pharmacists, scientists and students • We will put EU resources obtained by the Polpharma Scientifi c Foundation will through regular and comprehensive education programmes company to effective use. focus on young scientists. • We initiated work in our Biotechnology Division in Gdańsk (the European Educational Programme, the Knowledge Pharm). • We will establish partnerships with • The Polpharma Scientifi c Foundation will to develop biologics, drugs that are the future of medicine. • We created and provided advanced work tools for doctors other operators in Poland and abroad to promulgate the research outcomes of its • We improved existing drugs, refi ning the manufacturing (such as the DrWidget platform). successfully implement innovative solutions grant benefi ciaries in a periodical. and advanced therapies, including biologics. technologies and improving the comfort of use, which • We will actively participate in the efforts translates into better therapeutic compliance. to design a sectoral programme of support for innovation development in the • We encouraged our employees to come up with innovative pharmaceutical industry. ideas, rewarding the best ones with Innovation Awards.

74 Polpharma Group Corporate Social Responsibility Report 2013–2014 75 Polpharma Group Corporate Social Responsibility Report 2013–2014 POLPHARMA GROUP INNOVATION MAP 12. we implement innovative solutions TYPES OF INNOVATION:

ur strategy is to reinvest profi ts We seek to ensure that creativity, curiosity and Evaluating the ideas, we consider fi nancial SIGNIFICANTLY IMPROVED PRODUCT: from drug sales in innovative enthusiasm are common across all functions, advantages, the potential to add value in innovative formulation Two APIs in a single tablet Osolutions and development of rather than only in the R&D department. the future, creativity, systemic approach Chewing tablets products needed by patients. Seven R&D We place emphasis on the effective fl ow of and knowledge productivity. In 2013 and new administration route Modifi ed release injections Orodispersible tablets administered once a month

facilities of Polpharma employ more than ENHANCING /

information between our units involved in 2014, we approved 29 out of 41 initia- TECHNOLOGY or every three months 400 top specialists who come up with 30 innovative processes, especially between R&D, tives proposed. The fi nancial value of the modifi ed composition to 40 new solutions every year. Biologics technical and marketing teams. ideas put forward by our employees in that better taste are one of our priorities, offering hope to period totalled approx. PLN 1 million and it is Ophthalmic medicines without patients suffering from serious illnesses. We offer our employees the opportunity for growing over time, starting from successful new dosages irritating preservatives Our Biotechnology Division in the Gdańsk ongoing improvement of their qualifi cations implementation. Masking the bitter taste Science and Technology Park is the most in order to be able to complete the most of pediatric drugs advanced research centre of its kind in ambitious projects (for more information, see In the Share the Idea programme (Podziel Poland. pp. 52 to 54). We reward thinking out-of- się pomysłem), we encourage sales and SIGNIFICANTLY IMPROVED THERAPEUTIC METHOD: SIGNIFICANTLY IMPROVED PROCESS: the-box, empowerment and any initiatives marketing employees to suggest innovative new synthesis pathway We cultivate a culture of creativity, which increasing the innovation level and competi- solutions for even more sustained customer new route of administration forms a natural foundation for innovation. for the API concerned tiveness of our business. relationships. In 2014, we implemented Emulsions We reinforce a climate where employees are fi xed hours of consultations between general new dosages for injections not afraid of the risk associated with innova- We have had an internal Innovation Bureau practitioners and specialists (Thursdays with More effective and environmentally safe tion, and they are recognised for being open in place since 2007 and we give Innovation specialists – Czwartki ze specjalistami) and method of synthesis for substances used 12.and ready to challenge the status quo. Awards to employees who come up with the computer skills training for doctors aged 50+ in osteoporosis treatment most valuable initiatives. (Everyone can do it – Każdy potrafi ). UNIQUE SYSTEMS supporting: work performance tracking sales forecasting innovation has many names inventory control in distribution channels As the author and leader of the innovation work and testing management at laboratories

programme at Polpharma Group, I am very ORGANISATIONAL Innovation is understood not only as innovation in Poland, but also within our proud of our outcomes so far. Since the investments in state-of-the-art laborato- company. establishment of the Innovation Bureau in out-of-the-box ADVERTISING CAMPAIGNS ries or development of new medicines, but 2007, we have developed 360 staff initia- innovative EDUCATION CAMPAIGNS also as never-ending everyday improve- We place emphasis on dialogue, partner- tives, of which 206 have been regarded as ment of therapies provided to our patients. ships and establishment of advanced breakthroughs in the improvement of our SOFTWARE AND APPLICATIONS supporting patients to follow medical advice correctly MARKETING This kind of innovation, called incremental platforms for cooperation with the scien- processes, technologies and organisational effective use of SOCIAL MEDIA in patient communication innovation, manifests itself in a continuous tifi c community. Between 2010 and 2015, growth. Aside from the signifi cant effect on CONFERENCES on an unprecedented scale and USEFUL TOOLS supporting the work advancement of manufacturing processes, Polish Polpharma Group companies applied our fi nancial performance (more than 2% of and professional development of doctors and pharmacists new methods of substance synthesis, for protection for 23 inventions concerning EBITDA), the programme contributed to the increased commitment of our employees reduction of adverse reactions or improve- API synthesis (10 patent applications) and innovative SALES SUPPORT TOOLS to the achievement of business objectives, ment of application forms to increase fi nal-form manufacturing technologies and transfer of knowledge between departments the comfort of patients. We additionally dosage (13 applications). During the same and talent development. It was a milestone EFFECTS OF INNOVATION: develop technological, marketing, organ- period, we obtained eight patents, of which in the development of the culture of in- isational and enhancing innovations which two cover APIs and six cover fi nal-form novation across all functions, which – in my make our organisation a better place and drugs. opinion – is of critical value for the long-term help us operate on the market and serve growth of our organisation. improved product safety lower costs of production, our patients more and more successfully. Inventions relating to: imatinib (smaller Marzio Mercuri, and reduced adverse reactions favourable impact on the environment, tablets), tianeptine (more reproducible Head of the increased comfort of drug use and improved So understood, innovation is an impor- release profi le), olopatadine (reduced eye improved work organisation and effectiveness, Innovation correct following medical advice by patients tant component of our CSR strategy. In irritation) and combination of ramipril and Bureau, Technical more effective communication with patients higher effi cacy of treatment, accordance with that strategy, we want to indapamide (dosing regimen that requires Operations Offi cer and the medical and pharmaceutical community increase the potential for use of innova- fewer tablets) are particularly important for at Polpharma tion, mostly by reinforcing the culture of the comfort of patients. Group

76 Polpharma Group Corporate Social Responsibility Report 2013–2014 77 Polpharma Group Corporate Social Responsibility Report 2013–2014 In 2014, in response to the needs of the Not only do we retain talents, but we also Scientifi c Advisory Board Awards for Innovation medical community and patients, we contribute to the returns of those who Taking up a job with the Biotechnology The possibility of confronting innovative Already for 80 years we have been proving We make substantial investments in worked on a new shape for ACARD tablets. have decided to take their chance abroad. Division in Gdańsk was not just a regu- ideas with the current state of knowledge that it is good to believe in the advance- new product developments. Our core The heart shape reminds patients to take lar step on my career journey – it was a plays a key role in research and develop- ment of science, to have the courage to focus is on generic drugs, which provide the tablets on a regular basis, supporting big leap forward. When I completed my ment activities. We are able to access change the world and to follow the highest access to advanced therapies to a wide therapeutic compliance. The new tablets doctoral dissertation in 2007, working as an up-to-date information and scientifi c standards of quality. We are happy that group of patients. We are also the only assistant lecturer at the Nicolaus Coper- have been available since 2015. advancements owing to cooperation with our innovative activities are acknowledged manufacturer in Poland with a large scale We are proud of the fact that Polpharma nicus University in Toruń, I decided to go the scientifi c community. For many years, and appreciated. The following honours are production of APIs, the pharmaceutical located its laboratory, the most ad- to Ireland. I worked for the pharmaceutical The Biotechnology Division in Gdańsk – our our API Facility Research and Development particularly important: substances necessary to manufacture vanced biotechnology centre in Poland, industry for seven years and I learned about innovation showpiece The state-of-the-art Department which designs and refi nes • Award of the President of the Republic medications. in the Gdańsk Technogy and Science the reality of leading drug manufacturers or biotechnology centre of Polpharma in the API manufacturing technologies has been of Poland in the Innovation category Park. The company invests in innovative developers. During all that time, I dreamt The success of the API business demon- Gdańsk Science and Technology Park is leveraging the experience of scientists from (2013) for the development of innovative technologies and creates jobs for highly that one day I would go back to Poland. strates our innovativeness not only in engaged in the development and produc- qualifi ed specialists, encouraging them Establishing the Biotechnology Division, top Polish universities and scientifi c technologies and launch of manufacturing terms of technology, but also in the fi eld tion of biologics, which are the future of to stay in Poland. Polpharma became a gateway not only for institutions, such as the Gdańsk University of a series of osteoporosis drug APIs, of organisation. We have switched from medicine in the fi ght against severe and It can also serve as an example of my return to Poland, but also to the world of Technology, Łódź University of Technol- • First place among large companies on the high-volume, simple and unprofi table chronic illnesses. successful cooperation between the of biologics. I was asking myself, could such ogy, the Institute of Organic Chemistry List of 500 most innovative companies manufacturing to advanced substances business and scientifi c communities. The complex products be actually developed in of the Polish Academy of Science, etc., in Poland in 2011, in a ranking prepared manufactured relying on state-of-the- Opened in 2012, the Centre is the most in- Gdansk Life Sciences Center, our joint Poland? It seemed quite unreal. Now I have on the basis of cooperation agreements, by the Institute of Economics of the Pol- art technologies. Together with the novative facility of this kind in Poland. It of- initiative, will enable the development of the feeling that I am involved in something grant agreements and consortia. ish Academy of Sciences (in 2013), scientifi c community, we improve our fers a unique chance to the most talented innovative areas proposed by young sci- outstanding, an exceptional and unique • The Innowator Wprost award for the processes and develop brand new syn- young scientists to work with recognised entists, contributing to the development project from the perspective of the entire In order to further advance the transfer of Biotechnology Division in Gdańsk in the thesis pathways that are more effective biotechnology experts and to be in touch of Pomerania and Polish knowledge- Poland. the most recent knowledge, we established Science category (2014) for the creation and environmentally sound. Examples with the world’s latest technologies. based economy. the Scientifi c Advisory Board (SAB) in the of the most advanced biotechnology could include the substances used in On an area of 2600 m2, the Centre accom- API Facility in May 2014, with varying centre in Poland in the Gdańsk Science the treatment of erectile dysfunctions modates R&D laboratories and plants for composition depending on the themes of and Technology Park, or osteoporosis, based on innovation Tomasz Welerowicz, the production of biological medicines in projects under development. Professors • First place among large companies in award-winning technologies. Analytics and Quality accordance with the standards of GMP Teresa Kamińska, Control Coordinator, recognised in the Polish and international the 1st edition of the Innovation Initia- (Good Manufacturing Practice). Today, the President of the Polpharma SA scientifi c community accepted our invita- tor competition (Inicjator Innowacji) Centre already has 60 top specialists and is Pomeranian Special Biotechnology tions to cooperate on that basis. Members of the Newsweek magazine. still expanding (as at 2015). In accordance Economic Zone Division in Gdańsk of the Board deliver cyclical workshops and with the motto of the Biotechnology Divi- seminars for the team of the API Facility RATIONALE FROM THE Bogdan Maślanek, Director sion, ‘Our Future Is Here’, we offer young Research and Development Department. NEWSWEEK COMPETITION JURY of the API Facility, Polish scientists the opportunity to pursue The engineers working in the department Aside from focusing on the development Polpharma SA their scientifi c and career ambitions here, PERCENTAGE OF YOUNG SCIENTISTS (BELOW 35) are also able to quickly contact an expert in of its products, Polpharma launches social, in Poland. Several talented researchers in IN THE BIOTECHNOLOGY DIVISION a given fi eld by email or telephone. marketing and organisational innovation the fi eld of biotechnology have already de- We additionally place a lot on emphasis projects every year. We are granting this MEMBERS OF THE API TEAM SCIENTIFIC ADVISORY BOARD cided to return to Poland and pursue their DDECEC 22013013 DDECEC 22013013 on delivering the best services to patients award for the consistent approach to the careers with Polpharma Group. and doctors on the basis of the most recent creation and fostering of innovation. We TOTAL EMPLOYMENT 2211 4477 • Prof. Janusz Rachoń medical knowledge. To this end, we attend appreciate the well-thought-out structure (1st and 2nd edition) Innovation to attract the best of the best 1133 2288 regular Advisory Board sessions with top of innovation management and the activities AGED UP TO 35 (INCLUSIVE) • Prof. Karol Lesław Grela Our company is one of the top R&D inves- specialists and opinion leaders in a given supporting the development of an innova- (1st and 2nd edition) 661,90%1,90% 559,57%9,57% tors in Poland. According to a report pub- AGED UP TO 35 (INCLUSIVE) fi eld of medicine. Owing to the meetings, tive corporate culture where innovators are • Prof. Piotr Kiełbasiński (1st edition) lished in 2013 by the Institute of Econom- we are able to learn about the latest thera- sought for and motivated. We would like to • Prof. Andrzej W. Lipkowski (1st edition) ics of the Polish Academy of Sciences, we peutic recommendations and solutions especially acknowledge Polpharma for its ap- • Prof. Jacek Młynarski (2nd edition) ranked 5th among 795 Polish companies in which can be consistently implemented. In proach to the open innovation model, for its terms of R&D expenditure. Owing to that, 2013 and 2014, we had 19 Advisory Board high awareness of the fact that cooperation we provide an opportunity for develop- sessions on a dozen or so therapeutic areas, in support of their immediate environment ment to excellent Polish scientists and the such as allergology, gastroenterology, brings mutual and very valuable benefi ts. most talented graduates. gynaecology, neurology, ophthalmology, Here science meets business, giving a perfect dermatology, cardiology and diabetology. example of how to leverage synergies.

78 Polpharma Group Corporate Social Responsibility Report 2013–2014 79 Polpharma Group Corporate Social Responsibility Report 2013–2014 13. we bridge science with business

e actively participate in the Together with our partners, we have most important initiatives, taken effective measures to ensure that Building an innovation-friendly environ- The Polpharma Scientifi c Foundation is en- to continue and develop their scientifi c Patient needs have always been a priority Wconferences and meetings the Pomorskie Province is covered by ment together with governmental and gaged in the provision of long-term support research. Implementation of 51 projects has to Polpharma. The Polpharma Scientifi c where, together with other operators from ‘smart specialisation’ as a region to build non-governmental organisations offers for Polish science. In accordance with our been completed and their results have been Foundation stems from that philosophy. different sectors, we look for the answer for its competitive advantage on the basis of space for the implementation of innova- motto, ‘Helping the People of Science’, published in renowned scientifi c journals The main objective of the Foundation is the question how to make innovation the advanced technologies, as a country where tive projects. Favourable fi scal and legal we participate in the development of with a high impact factor. to fi nance research projects of excep- foundation of growth in Poland. Our ex- the knowledge and creativity of scientists conditions and a system of subsidies pharmaceutical and medical sciences by tional importance for the development perts support the activities of the National translate into products and services serving help companies of all sizes invest more fi nancing research in those fi elds. Furthermore, the Foundation supports the of medicine and pharmacy. We organise Centre for Research and Development, the the society. With that in mind, we want to in research and development, imple- most talented PhD students by means of a competition every year which attracts Ministry of the Economy and the Coalition bridge science with business, initiating and ment high-risk projects and thus look Already for 14 years, we have organised a scholarship scheme carried out since really good projects, demonstrating that for Polish Innovation. engaging ourselves in a range of activities for innovative solutions to give them the a grant competition for scientists engaged 2006. In fi ve editions of our competition we have excellent scientists in Poland to support effective knowledge sharing and competitive edge. in medical and pharmaceutical research. held every two years, we have granted 37 who are prepared to carry out outstand- to contribute to increased innovation in According to data from the Central Sta- Accepting and taking the risk associated study scholarships totalling 370,000 zloty. ing research. Grants go to authors of Poland. (“Medical technologies in the fi eld tistical Offi ce (GUS), 2014 was a record- with fundamental research, which is the For ten years, we have sponsored the prizes works that are best rated by reviewers 13. breaking year in terms of the increase in and the Scientifi c Council of the Founda- of diseases of affl uence and ageing”). most common type of research we provide in the prestigious All-Poland Competi- research and development expenditure fi nancing for, we create the right conditions tion for MSc Theses from Pharmaceutical tion. in the business enterprise sector. for talented researchers to do their jobs. Departments which has been organised by The activities of the Foundation are Businesses allocated more than PLN We care about innovative, courageous and the Polish Pharmaceutical Society for over a testimony to Polpharma’s responsibil- 7.5 billion to R&D activities, 19.7% more visionary projects. 40 years. ity for the condition of Polish science, working together for than in 2013. Therefore, the trilateral which immediately translates into the cooperation between business, science The Scientifi c Council, composed of scien- In 2012, the Foundation launched a new quality of life and health of the general the future of polish science and authorities is already paying off. tifi c experts on pharmacy and medicine, programme – the Recommended Grant – public. We are the only private party Involvement in such initiatives offers cooperates with the Management Board with the objective to provide co-fi nancing in Poland which has provided fi nancial a chance to reinforce the position of the of the Foundation. Those persons perform to scientifi c research carried out by young support for medical and pharmaceutical On our own account and in partnerships, ship programmes and projects addressed Polish pharmaceutical sector, but it also their functions pro bono publico, and their scientists. In 2014, two grants totalling research already for 14 years. Most of the we carry out programmes supporting the to Polish students at universities abroad, entails a great deal of responsibility for recommendations as regards the selection 100,000 zloty were received by the winners rewarded projects involve fundamental development of Polish science, promoting • cooperation with student learning the future of the Polish R&D activities. of projects for fi nancing are fully indepen- of a competition held by the Polish Oph- research aimed at exploring the mecha- inventions and commercialisation of in- circles – joint projects, knowledge dent and based on grounds of merit. Only thalmological Society. nisms by which diseases are caused. This novative ideas serving the society. sharing. the best projects are rewarded, those best is the fi rst step towards the discovery of new medicines and diagnostic methods, Monika rated by reviewers, giving hope for the More information on the activities of the Lamparska-Przybysz, which we hope can be used to fi ght We support young scientists at various development of original new solutions. Foundation and projects covered by its sup- Funding previously incurable diseases. stages of their careers. Moreover, we In the thirteen editions of the competition port can be found in the Annual Report of Development stimulate future talents, promoting science held so far, we have allocated almost 16.5 the Foundation published in mid-2015. among young people as an interesting idea Manager, Polpharma SA million zloty to 62 teams, helping them for life. Bożenna Płatos, SUPPORT PROVIDED BY THE POLPHARMA SCIENTIFIC FOUNDATION Our key activities in this area include: IN 2013 AND 2014 Manager of • fi nancing of scientifi c research in the the Polpharma Scientifi c fi elds of medicine and pharmacy; grant TYPE OF ASSISTANCE 2013 2014 Foundation competitions and scholarship pro- Value of grants awarded in research project competitions PLN 325,200 PLN 977,250 grammes of the Polpharma Scientifi c Number of grants awarded 1 3 Foundation are addressed to scientists Number of projects reviewed 16 22 aged below 35, Scholarship competition (award in 2015) 19 applications • discovering and promoting talents – Countrywide PTFarm contest for the best Master thesis 3 prizes (totalling 3 prizes (totalling through our own initiatives and sponsor- for students of pharmaceutical faculties PLN 5000) PLN 5000) ships: (“Eureka DGP! Discovering Polish Recommended grant 2 grants (totalling Inventions”, “Supertalents in Medicine” PLN 100,000) of the Puls Medycyny magazine), TOTAL AMOUNT OF ASSISTANCE PLN 330,200 PLN 1,082,250 • offering career opportunities to young people – by means of graduate trainee-

80 Polpharma Group Corporate Social Responsibility Report 2013–2014 81 Polpharma Group Corporate Social Responsibility Report 2013–2014 ACCOMPLISHED We help turn ideas into realistic the Wrocław University of Technology and IN 2015 solutions Nicolaus Copernicus University in Toruń. In the Pomorskie Province, otherwise Polpharma was the leader of a success- I am full of appreciation for the initia- The young market economy in Poland has The award was granted for “Diagnostic than in other provinces, we adopted ful campaign aimed at making medical tive of the Pomeranian Special Eco- not developed fully effective mechanisms tests for the identifi cation of bacterial a unique bottom-up partnership-based technologies in the fi eld of diseases of nomic Zone carried out in cooperation yet to fi nance innovative ideas devised by strains and their production methods”. affl uence and ageing the smart spe- process for the defi nition of smart O GDANSK LIFE SCIENCES with Polpharma. The engagement of Polish scientists. Therefore, we are willing The invention allows to choose a suitable specialisations, with regional authorities cialisation of the Pomorskie Province. CENTER: WORKING TOGETHER a Polish company experienced in the to engage in activities bridging that gap. antibiotic for a patient much faster, which selecting the proposals with the highest The shared goal called for understanding FOR THE INNOVATIVE commercialisation of innovative ideas is essential and often life-critical in the case development potential from among all between a hundred or so local opera- DEVELOPMENT OF THE REGION greatly complements the knowledge Start up with us! of bacterial infections. In the 2nd edition, entries using an open and competitive tors. It is noteworthy that the Pomorskie The year 2015 saw the inauguration of an and scientifi c competence developed We were a partner of Zacznij.biz, a compe- the fi rst prize was awarded to a team from formula. The competitive procedure Province was one of few regions where the important Pomeranian project which we by Pomeranian universities. I hope that tition organised by the Lewiatan Confed- the Jagiellonian University for the inven- employed to select the specialisations specialisation was chosen using a bottom- had worked on in the preceding months the activities of the Gdansk Life Sciences eration and Lewiatan Business Angels. The tion “Nested method for the detection of triggered a very active entrepreneurial up approach. together with the Pomeranian Special Center will translate into real success and competitors, owners of high-tech micro bacteria and fungi” for fast and inexpensive discovery process, engaging various part- Economic Zone: the Gdansk Life Sciences development of innovation, especially in enterprises, scientists and students, had diagnostics of sepsis. ners from the region in the cooperation, The overarching goal of the initiative is to Center, a new jointly established unit will our region. For me, it is a challenge and the opportunity to show their ideas to who represented the business communi- establish a platform for cooperation cover- support the development and commercial- a honour to chair the Scientifi c Council, potential investors and to obtain funding ty, science, business support institutions ing the following areas: ization of valuable research projects in the which hosts the elite of Polish scientists. to develop and implement new technolo- O SMART SPECIALISATION and NGOs. Entities critically important • integrated programmes for the preven- fi elds of biotechnology, medicine and pre- The establishment of the Centre is gies. The participants additionally attended IN POMERANIA to building cooperation between science tion and monitoring of therapy in dis- ventive medicine. The task of the business a great success in itself, but time-con- workshops on effective commercialisation The new fi nancial perspective of the Euro- with business were engaged in direct eases of affl uence (including monitoring accelerator in Gdańsk is to turn as many suming and laborious efforts are neces- of ideas. pean Union for 2014–2020 envisages a new cooperation with the interested partners. of correct following medical advice by projects as possible into real businesses. sary to make full use of its capacity. breakdown of allocations from the EU co- They included Polpharma, which took patients), supported by ICT and tele- Authors of innovative ideas representing The Golden Scalpel (Złoty Skalpel) hesion funds. ‘Smart specialisations’ will be up the role of a leader in the specialisa- medicine solutions, universities and research institutes will fi nd Prof. Krzysztof Since 2014, we have been a partner of the rewarded. Quoting the European Commis- tion “Medical technologies in the fi eld • innovative care systems for disabled and comprehensive support in the Gdansk Life Bielawski, Director Golden Scalpel competition organised by sion: “smart specialisation is about identi- of diseases of affl uence and ageing”. elderly patients – health monitoring, Sciences Center: access to expertise, busi- of the Technology Puls Medycyny, an independent medical fying the unique characteristics and assets We appreciate the contribution of equipment improving the quality of life, ness mentoring, assistance in obtaining ap- Transfer Centre Polpharma in the development of journal. The competition has rewarded of each country and region, highlighting home telemedicine, propriate funding. On our part, we ensure of the Intercolle- innovativeness in Pomerania and its remarkable innovators in Polish health care each region’s competitive advantages, and • innovative therapeutic solutions sup- the possibility of turning ideas into reality giate Faculty of engagement in the establishment of Biotechnology of for 8 years. In the 6th edition, the fi rst prize rallying regional stakeholders and resources ported by the application of biotechnol- on a non-profi t basis in our laboratories intersectoral partnerships. We believe the University and the study grant funded by Polpharma around an excellence-driven vision of their ogy and innovative analysis and synthe- and we contribute valuable know-how that owing to a strong integration of the of Gdańsk and the went to the Hemodynamics Team of future”. The selection of a smart specialisa- sis – follow-on biologics and biobetters, arising from international presence which communities participating in the design Medical University the European Health Centre in Otwock. tion also means “strengthening regional modern generic drugs, theranostics, is necessary to commercialise projects of smart economic specialisations, many of Gdańsk The team led by Prof. Adam Torbicki was innovation systems, maximising knowl- personalised therapies, outside of Poland. new and innovative projects, products the third one globally, after Japan and edge fl ows and spreading the benefi ts of • new materials applying chemistry, bio- and initiatives will emerge and achieve Norway, to implement balloon pulmo- innovation throughout the entire regional technology and nanotechnology in the The Science and Business Council is a leading and supraregional status once nary angioplasty for patients with chronic economy”. prevention of diseases and regenerative they are commercialised. responsible for the review of the projects thromboembolic pulmonary hypertension medicine. submitted. Its members include outstand- who had not qualifi ed for cardiac surgeries In June 2011, the Council of the European ing scientists and experienced business beforehand. Union adopted a conclusion that Member The development of this smart specialisa- representatives. The Council is chaired States should perceive health policy not tion in Pomerania is additionally fuelled by by Prof. Krzysztof Bielawski, Director of Eureka DGP! Discovering Polish only as a source of expenditure, but also the Black Pearls LQT Fund established in the Technology Transfer Centre of the Inventions as an investment and a contributor to Mieczysław Struk, 2015 in the framework of a project carried Intercollegiate Faculty of Biotechnology of We also engage in initiatives which support economic growth. This emphasises the Marshal of the out by Black Pearls Investments and the the University of Gdańsk and the Medical inventiveness at Polish universities. We importance of the civilisation challenge Pomorskie Province National Centre for Research and Devel- University of Gdańsk. supported two editions (2013/2014 and posed by ageing of European societies. opment, which has a budget of PLN 20 mil- 2014/2015) of the Eureka DGP! Discovering Declarations of EU decision-makers are lion for allocations to promising projects in The Gdansk Life Sciences Center will closely Polish Inventions competition organised by followed by actual EU funds allocated to the fi eld of life quality technologies. cooperate with organisations working Dziennik. Gazeta Prawna magazine, fund- activities and projects offering hope for towards the increase of innovation and com- ing study grants for the winners (30,000 signifi cant improvements in preventive petitiveness in Poland, such as the Foun- zloty in each edition). The winners of the care and treatment, including diseases of dation for Polish Science or the National fi rst edition were a scientifi c team from affl uence. Centre for Research and Development.

82 Polpharma Group Corporate Social Responsibility Report 2013–2014 83 Polpharma Group Corporate Social Responsibility Report 2013–2014 14. we educate medical and pharmaceutical professionals

Being the largest pharmaceutical has reached thousands of Polish doctors in 2016, concerning the prescription of company in Poland, we want to for 13 years, In our opinion, the role of a leader entails medications by midwives. I am deeply convinced that the European Bshare the knowledge and experience • providing students with the opportunity obligations both towards the society and Educational Programme brings new of our experts to doctors and pharmacists to contrast their academic learning with towards scientifi c and medical communi- A series of three ultrasound workshops training quality for doctors, pharmacists throughout Poland. We engage in the the practice of the pharmaceutical indus- ties. With that in mind, we created the was delivered by Dr Tomasz Roszkowski, and nurses. It combines theory and education and development of the medical try by means of the Knowledge Pharm a renowned gynaecologist, based on his European Educational Programme O THE EUROPEAN practice, with an emphasis on the latter. and pharmaceutical community in many education programme, carried out since 13 years ago. Since then, already more own concept. Ultrasound workshops deliv- EDUCATIONAL PROGRAMME – This belief is supported by a great deal respects. The activities of particular impor- 2007, than 20,000 doctors and pharmacists ered by three top Polish ultrasound experts KNOWLEDGE IN A NUTSHELL of feedback offered by EEP participants. tance are: • development and provision to doctors of took part in EEP conferences, learn- were also held as part of the EEP, attracting Our proprietary European Educational The results of the EEP training strategy • organisation and supporting of confer- innovative working tools, such as the ing about the latest advancements of a total of 400 participants, who had the Programme has been reaching doctors are a great success to both Polpharma ences, workshops and debates which DrWidget which includes fi ve applications medicine. We are aware how diffi cult opportunity to see live examinations and from all over Poland with updates on the and the excellent lecturers. They include: offer the attendees (doctors, pharmacists, supporting all operating systems, used by and demanding the jobs of a doctor and listen to a lecture on the legal aspects of condition and advancements of medicine Prof. Zembala, Prof. Skarżyński, Prof. scientists and students) opportunities to approx. 30,000 doctors in Poland, pharmacist are in the today’s world. retention of ultrasound scan records. and pharmacy for more than 13 years. Kuna, Prof. Filipiak, Prof. Narkiewicz, enhance their knowledge on the latest • carrying out training programmes for Patients expect more and more thorough What makes EEP special is the exception- Prof. Stępień, achievements and research results, foreign students, mostly from Kazakh- help from the health care system, forcing We additionally held an educational work- ally large audience (more than 20,000 Prof. Skrzypulec-Plinta, Prof. Kaszuba, to 14.• sharing knowledge through the Euro- stan, enabling them to improve compe- doctors not only to continuously expand shop where we examined 22–24 weeks doctors from all over Poland in 13 years), name just some. This innovative strategy pean Educational Programme, which tence and develop scientifi c their knowledge, but also to improve pregnant patients using a state-of-the-art who appreciate the attractive formula of allows to stay focused on the achieve- their communication skills. Polpharma ultrasound machine. hands-on workshops and the careful selec- ment of the main objective, which is strives to pursue those needs and tion of meeting themes. to raise the broadly defi ned quality of respond to them, delivering a wide range Furthermore, we had the Alert Karat work- medical services. The learning from the of conferences, workshops and training shop for doctors, devoted to fi rst aid in Top experts from relevant fi elds take part training courses allows to get more job courses. medical emergencies. With the Get Ready satisfaction, measured by diagnostic Knowledge-Based Partnership Practical demonstrations – in the fi eld in the preparation of the EEP scheme. In the for a Shock campaign (for more informa- and therapeutic success. This, in turn, In 2013 and 2014, we organised more than ofdermatology, gynaeocology, or even live recent years, the Programme has focused tion, see p. 19), we reached a wide group of increases patient confi dence in doctors, 180 national events for the medical com- eye surgeries – are a permanent feature of on the improvement of knowledge in the doctors, general practitioners, allergists and pharmacists and nurses/educators. munity: specialist conferences, congresses, EEP meetings for doctors. Medicine is con- Agata Łapińska, fi elds of cardiology, gastroenterology, neu- nurses with anaphylaxis expertise, including competitions, education workshops in stantly developing, and the same applies Rx Marketing rology, ophthalmology, dermatology and Director, the principles of giving fi rst aid. We ad- Prof. Józef a range of specialisations, such as cardiol- to imaging technologies, such as echocar- gynaeocology. Since 2012, we have been Polpharma ditionally developed the fi rst anaphylaxis Drzewoski, ogy, gastroenterology, neurology, gyn- diography or electrocardiography. We try organising national conferences for general Trade Offi ce algorithms for doctors in the history of the Internal Medicine, aeocology, allergology, dermatology and to respond to the needs of doctors and we practitioners as part of the EEP. During Polish medicine. Surveys have shown an Diabetology ophthalmology. organise workshops in those fi elds. the meetings, they are told about the key immense level of ignorance on that subject and Clinical highlights of medicine advancements ‘in Pharmacology which is even more dangerous consider- Since 2002, we have been developing the In 2013 and 2014, we additionally organ- a nutshell’. The workshops are extremely Clinic of the ing that only a quick and proper response European Educational Programme (EEP), ised two editions of endoscopy workshops popular and are attended by approx. 800 Medical University offers a chance to save someone’s health featuring cyclical free scientifi c conferences for gastroenterologists, in cooperation with NUMBER OF CONFERENCES doctors on average. We have also held EEP of Łódź. Scientifi c ORGANISED IN 2013 AND 2014 or even life. The experts taking part in the and workshops for doctors. Moreover, we the CMKP Hospital, under the direction of meetings for ophthalmologists since 2013. patron of EEP campaign shared the view that clear and supported more than 380 important com- Prof. Jarosław Reguła, the national gastro- for 12 years 22013013 22014014 simple procedures had to be prepared and munity events. enterology consultant. Live Surgery disseminated. The new algorithms show Conferences organised as part of the IINN POLANDPOLAND (TOTAL)(TOTAL) 223636 333131 in a clear and graphical way the fi rst steps Holding our meetings in various regions of In the framework of EEP meetings for European Educational Programme are also that should be taken in the case of anaphy- Poland, from the biggest agglomerations to gynaecologists and dermatologists, we had OORGANISEDRGANISED an opportunity to participate in live surger- EEP FOR GENERAL BBYY POLPHARMAPOLPHARMA 9922 8899 laxis. The experts developed three versions small towns, we share our knowledge with dermatoscopy and ultrasound workshops. ies. In 2013, 450 doctors who came to PRACTITIONERS of the algorithm: for general practitioners, IN 2013 AND 2014 a very wide medical and pharmaceutical We invited gynaecologists to the Women’s SSUPPORTEDUPPORTED Jachranka could watch a cataract removal, allergists and patients. The algorithms are audience. Health University – education meetings BBYY POLPHARMAPOLPHARMA 114444 224343 while a year later, phthalmologists visiting distributed to doctors and all participants on the risk of HSV infections in pregnant the Ossa resort ‘assisted’ in two surger- nationwide conferences of the anaphylaxis fi rst aid workshop. 3 What makes our educational activities women and newborns, and midwives to ies performed by teams led by Prod. Jacek Szafl ik from the Public Ophthalmic Teach- different is their very hands-on nature. participate in fi ve editions of the Polpharma 2400 doctors Workshop participants can watch the lat- Midwives’ Academy dedicated to innova- ing Hospital in Warsaw. est diagnostics or treatment solutions in tive contraception and the legal aspects of – average lecture merit score action, presented by top specialists. the act of law which is to become effective 4,45 (on a scale from 1 to 5)

84 Polpharma Group Corporate Social Responsibility Report 2013–2014 85 Polpharma Group Corporate Social Responsibility Report 2013–2014 Offering Digital Support questions to lecturers via a moderated POLPHARMA’S EDUCATION In Black and White The www.farmacjapraktyczna.pl website is KNOWLEDGE PHARM We are committed to providing the most chat window. AND EXPERTISE WEBSITES We bring the latest insights closer to doc- a compendium of knowledge in the fi eld IN FIGURES: FOR DOCTORS AND up-to-date medical knowledge to medical PHARMACISTS tors by means of a wide range of publica- of pharmaceutical care, applicable law and and pharmaceutical professionals. There- In our education and expertise portals, such tions, books and brochures released with the practical operation of pharmacies. 5 conferences in 2013 and 2014 fore, in parallel to our ‘live’ events, we share as www.leczpaznokcie.pl or www.abcmi- www.abcmigrena.pl/dlalekarzy our support. knowledge in the digital space – all year grena.pl, we created separate sections for An educational website about migraine conferences since the beginning round, in a convenient and practical man- doctors and pharmacists, where they will treatment addressed to specialists, in 19 of the programme ner. Our www.polpharma.tv website offers fi nd complete and up-to-date informa- particular neurologists and general practi- live streams from major events. During tion on individual diseases and effective tioners. Doctors can also learn about the Support from the Start the interviews, virtual participants can ask therapies. most recent advancements in neurology and We would like young scientists, soon-to- 449 participants in 2013 and 2014 headache treatment, or put their knowledge be doctors and pharmacists to enter the to the test by participating in e-learning ses- labour market not only with in-depth sions and competitions. 2179 participants from 10 Polish In 2013 and 2014, we supported the knowledge taken out from university, but medical universities since the beginning publication of several scientifi c works also with hands-on information which is of the programme • DrWidget Interakcje – (interactions) www.leczpaznokcie.pl/dla-lekarzy written by most recognised specialists. essential to understand the specifi c nature – provides information on dangerous An online guide for specialists – gynaecolo- They included: “Atlas patologii nowo- of our industry. Since 2007, we have been interactions between combinations of gists and dermatologists – on fungal infec- tions and foot and nail diseases. Doctors can tworów skóry”, “Wybrane aspekty prawne carrying out the Knowledge Pharm, drugs; it also contains warnings about Polpharma makes a difference by sup- also learn about the most recent advance- w ginekologii dziecięcej”, “Neurologia a proprietary programme consisting of drug use, porting the development of medical ments in dermatology and treatment of tom 1”, “Pierwsza pomoc okulistyczna”, a series of conferences for pharmacy stu- DrWidget Never Sleeps • DrWidget CalcMed – medical calcula- sciences in Poland. The academic com- fungal infections, or put their knowledge to “Antykoncepcja Vademecum”, “Problemy dents and (separately) medicine students. DrWidget (www.DrWidget.pl) is our fl ag- tors linked to a drug database which munity is glad that a private company the test by participating in e-learning ses- kardiologiczne w praktyce lekarza pod- We organise the meetings in cooperation ship solution, a continually developed allow to calculate dosage depending sions and competitions. is willing to help students, to give them stawowej opieki zdrowotnej”, “Genialna with local and regional authorities as well medical information platform supporting on age, weight, as well as BMI, average the opportunity to share their accom- maszyna Biografi a serca”, “Stany nagłe. as student organisations, including Młoda doctors and pharmacists in their jobs, also blood pressure, LDL or basal metabolic www.DrWidget.pl plishments with the public and to have Podstawowe procedury zabiegowe”, Farmacja (Young Pharmacists) – the larg- as a series of mobile applications. DrWidget rate, A hands-on website offering a range of useful scientifi c discussions with professionals. “Wielka Interna. Gastroenterologia est association of pharmacy students in is a constantly updated medical informa- • DrWidget Normy i Skale – (reference tools for every doctor. The site includes cur- We would like the private sector to give część 1”, “Interna Szczeklika 2014/2015” Poland. 19 conferences have been held so tion resource accessible from any device ranges and scales) – a clear presentation rent drug indexes with a convenient search as much support to universities as in function, medical calculators, a tool to check or “Wybrane aspekty boreliozy z Lyme”. far, attended by more than 2000 students (computer, tablet, smartphone) which of medical reference ranges and scales does in other countries. Such support drug interactions or useful standards and from 10 medical universities in Poland. In includes the following applications: commonly used in medicine, means investing in the development scales. All functions are additionally available Among dozens of brochures and education 2013 and 2014, we had 5 conferences with • DrWidget Baza Leków – pdrug data- • DrWidget Ewuś – allows to quickly of the country, especially in the medical as a series of mobile applications. pamphlets published in 2013 and 2014, 449 attendees. base) – more than 15,000 medicinal check if a patient is entitled to free fi eld. Polpharma excels in it. some address such issues as the irritable products described in great detail; the health care, www.polpharma.tv bowel syndrome (IBS), ulcers, fungal infec- The International Conference application allows to easily check the in- • DrWidget ICD-10 – an extensive da- An online service with free video content for tions of the skin and nails, or glaucoma. of Student Scientifi c Circles dications for use of a medicinal product, tabase containing a set of diseases and medical specialists and general practitioners. The Polpharma Scientifi c Foundation, in We have been cooperating with the Prof. Marek its price, copayment level or relevant related health problems according to It features cyclical streaming of lectures turn, publishes Postępy Polskiej Medycyny student scientifi c circles of the Medical Krawczyk, information for reimbursable drugs, the ICD-10 classifi cation and the related delivered by outstanding specialists in Rector of the i Farmacji. Zeszyty Naukowej Fundacji University of Warsaw for 12 years. We are drugs and APIs registered in Poland. particular scientifi c fi elds, and the remaining Medical University content is available on a VOD basis. Polpharmy, a scientifi c magazine giving a partner for scientifi c camps in Starogard of Warsaw an overview of research papers based on Gdański and the accompanying interna- We have also developed specialist propri- • Dyslipidemia algorithms, created to www.farmacjapraktyczna.pl research projects fi nanced by the Founda- tional conferences held on our premises. etary applications for doctors: educate doctors on the diagnosis and A portal for front-line pharmacists, phar- tion. Three volumes have been published The future doctors from Poland, but also Aside from the Knowledge Pharm, • Cardiology calculators, auxiliary treat- treatment of dyslipidemia in cardio- macy managers and owners. It features so far, and the fourth one is in preparation. from Belarus and Moldova, attend English- Polpharma supported 19 Polish and ment algorithms for patients with acute vascular risk patients, including the specialist papers on drugs and diseases, language lectures given by outstanding international scientifi c conferences, pharmaceutical care, as well as legal and coronary syndromes, cardiac insuffi - assessment of indications for statin The range of educational publications professors and specialists. They are also of- congresses and meetings organised pharmacy administration advice. The web- by university students and medical ciency, atrial fi brillation and pulmonary treatment, provision of target LDL-C site has 17,700 unique users on average. is completed by Farmacja Praktyczna, fered the opportunity to present their own organisations in 2013 and 2014. embolism, levels, optimum statin dosage, schedule The Farmacja Praktyczna website is the a monthly published since 2007 for Pol- accomplishments. The level of expertise of • Pulmonary Algorithms, with auxiliary of blood tests and procedures to follow second best-known specialised online ser- pharma Trade Offi ce. For many years, the the young attendees is best refl ected by treatment algorithms for patients with in case of suspected complications in vice for pharmacists, excluding websites magazine has been the leader of the press the fact that the audience includes many asthma, COPD, pneumonia, nicotine statin treatment of offi cial authorities. segment addressed to pharmacists. future PhD students with scholarships addition, sinusitis, infl uenza and obstruc- from the Medical University of Warsaw. tive sleep apnea,

86 Polpharma Group Corporate Social Responsibility Report 2013–2014 87 Polpharma Group Corporate Social Responsibility Report 2013–2014 gri content index

Reporting External Reporting External Indicator Indicator description range Pages assurance Indicator Indicator description range Pages assurance STRATEGY AND ANALYSIS STAKEHOLDER ENGAGEMENT G4-1 Statement from the most senior decision-maker complete 4-5 yes G4-24 List of stakeholder groups engaged by the organization complete 11 yes

G4-2 Description of key impacts, risks, and opportunities complete 4-5 yes G4-25 Identifi cation and selection of stakeholders with whom to engage complete 10 yes ORGANIZATIONAL PROFILE G4-26 Approach to stakeholder engagement complete 10 yes G4-3 Name of the organization complete 2 yes G4-27 Key topics and concerns that have been raised through stakeholder engagement complete 9, 10 yes G4-4 Primary brands, products, and services complete 2 yes REPORT PROFILE G4-5 Location of the organization’s headquarters complete 3 yes G4-28 Reporting period complete 1 yes G4-6 Number of countries where the organization operates, and names of countries complete 3 yes G4-29 Date of most recent previous report complete 1 yes G4-7 Nature of ownership and legal form complete 3 yes G4-30 Reporting cycle complete 1 yes G4-8 Markets served complete 3 yes G4-31 Contact point complete 1 yes G4-9 Scale of the organization complete 2-3 yes G4-32 GRI content index complete 88-91 yes G4-10 total number of employees by region, age, gender and employment contract complete 52 yes G4-33 Assurance complete 92 yes G4-11 Percentage of total employees covered by collective bargaining agreements complete 55 yes GOVERNANCE STRUCTURE AND COMPOSITION G4-12 The organization’s supply chain complete 71 yes G4-34 Governance structure of the organization complete 11 yes G4-13 Signifi cant changes during the reporting period complete 1 yes ETHICS AND INTEGRITY G4-14 Precautionary approach complete 11 yes G4-56 Values, principles, standards and norms of behavior such as codes of conduct complete 36,38-39 yes G4-15 Externally developed initiatives to which the organization subscribes complete 10 yes and codes of ethics or which it endorses G4-57 Internal and external mechanisms for seeking advice on ethical and lawful complete 40 yes G4-16 Memberships of associations complete 10 yes behavior, and matters related to organizational integrity, such as helplines IDENTIFIED MATERIAL ASPECTS AND BOUNDARIES or advice lines G4-17 Entities included in the organization’s consolidated fi nancial statements partial 2 yes G4-58 Internal and external mechanisms for reporting concerns about unethical complete 40 yes G4-18 Process for defi ning the report content complete 8 yes or unlawful behavior, and matters related to organizational integrity ECONOMIC INDICATORS (EC) G4-19 Material aspects identifi ed in the process for defi ning report content complete 9 yes G4-20 Scope and materiality of identifi ed aspects for all entities within the organization complete 9 yes EC-DMA Management approach (for economic performance) partial 2 yes G4-21 Scope and materiality of identifi ed aspects outside of the organization complete 9 yes G4-EC1 Direct economic value generated and distributed partial 2, 16 yes G4-22 Restatements of information provided in previous reports, and the reasons complete 1 yes for such restatements G4-23 Signifi cant changes from previous reporting periods complete 1 yes

88 Polpharma Group Corporate Social Responsibility Report 2013–2014 89 Polpharma Group Corporate Social Responsibility Report 2013–2014 Reporting External Reporting External Indicator Indicator description range Pages assurance Indicator Indicator description range Pages assurance ENVIRONMENTAL INDICATORS (EN) LA-DMA Management approach (for diversity and equal opportunity) complete 59 yes EN-DMA Management approach (for materials) complete 61, 67 yes G4-LA12 Composition of governance bodies and breakdown of employees per employee complete 12, 59 yes G4-EN1 Materials used by weight or volume complete 67 yes category according to gender, age group, minority group membership, and other indicators of diversity G4-EN2 Percentage of recycled input materials used to manufacture the organization’s complete 68 yes primary products and services SOCIETY INDICATORS (SO) EN-DMA Management approach (for energy consumption) complete 64 yes SO-DMA Management approach (for local communities) complete 27, 34 yes G4-EN3 Energy consumption within the organisation complete 64 yes G4-SO1 Percentage of operations with implemented local community engagement, complete 27 yes impact assessments, and development programs G4-EN6 Reduction of energy consumption complete 65 yes SOCIETY INDICATORS FOR PRODUCT RESPONSIBILITY (PR) EN-DMA Management approach (for water withdrawal) complete 65 yes PR-DMA Management approach (for product labeling and customer health and safety) complete 43-44 yes G4-EN8 Total water withdrawal by source complete 66 yes G4-PR1 Percentage of signifi cant product and service categories for which health and complete 43 yes EN-DMA Management approach (for effl uents and waste) complete 65, 68 yes safety impacts are assessed for improvement G4-EN22 Total water discharge by quality and destination complete 66 yes G4-PR2 Total number of incidents of non-compliance with regulations and voluntary complete 45 yes G4-EN23 Total weight of waste by type and disposal method complete 68 yes codes concerning the health and safety impacts of products and services during EN-DMA Management approach (for impacts of products and services) complete 61-62 yes their life cycle, by type of outcomes G4-EN27 Extent of impact mitigation of environmental impacts of products and services complete 63 yes PR-DMA Management approach (for product and service labeling) complete 41, 46 yes EN-DMA Management approach (for compliance) complete 61-62 yes G4-PR3 Type of product and service information required by the organization’s procedures complete 46 yes G4-EN29 Monetary value of signifi cant fi nes and total number of non-monetary sanctions complete 61 yes for product and service information and labeling, and percentage of signifi cant for non¬-compliance with environmental laws and regulations product and service categories subject to such information requirements EN-DMA Management approach (for environmental expenditures) complete 61, 63 yes PR-DMA Management approach (for marketing communications) complete 41 yes G4-EN31 Total environmental protection expenditures and investments complete 63 yes G4-PR7 Total number of incidents of non-compliance with regulations and voluntary complete 42 yes codes concerning marketing communications, including advertising, promotion, SOCIAL INDICATORS: LABOR PRACTICES AND DECENT WORK (LA) and sponsorship, by type of outcomes LA-DMA Management approach (for employment) complete 51 yes PR-DMA Management approach (for compliance) complete 42 yes G4-PR9 Monetary value of signifi cant fi nes for non-compliance with laws and regulations complete 42 yes G4-LA1 Total number and rates of new employee hires and employee turnover complete 53 yes concerning the provision and use of products and services by age group, gender and region G4-LA2 Benefi ts provided to full-time employees that are not provided to temporary complete 55 yes or part-time employees, by signifi cant locations of operation LA-DMA Management approach (for occupational health and safety) complete 47, 49 yes G4-LA6 Type of injury and rates of injury, occupational diseases, lost days, and complete 50 yes absenteeism, and total number of work-related fatalities, by region and by gender LA-DMA Management approach (for training and education) complete 52, 54 yes G4-LA9 Average hours of training per year per employee by gender, and by employee complete 54 yes category G4-LA10 Programs for skills management and lifelong learning that support the continued complete 54 yes em¬ployability of employees and assist them in managing career endings G4-LA11 Percentage of employees receiving regular performance and career development complete 55 yes reviews, by gender

90 Polpharma Group Corporate Social Responsibility Report 2013–2014 91 Polpharma Group Corporate Social Responsibility Report 2013–2014 92 Polpharma Group Corporate Social Responsibility Report 2013–2014 CSR HISTORY AT POLPHARMA GROUP

2009 Launch of the Solution to Forgetfulness (Rozwiązanie na zapominanie) campaign addressed to people whose loved ones are starting to have memory problems

2008 Publication of the first Polish monograph on therapeutic compliance and doctor- -patient cooperation In chronic diseases by the Polpharma Scientific Foundation

2008 Launch of It’s a Shame not to Ask – Pregnancy without Herpes (Wstyd nie zapytać – ciąża bez opryszczki) – an education campaign addressed to pregnant women and those planning to start a family

2008 First edition of the Green Process (Zielony Proces) competition which rewards environmental initiatives of employees

2008 Implementation of the Green Chemistry (Zielona Chemia) policy, which is a We are presenting you with the second CSR report drawn up by our company in commitment to consider the environment already at the stage of design of products accordance with the Global Reporting Initiative guidance. This time, the report and manufacturing technologies outlines the achievements of Polpharma Group as a whole in 2013 and 2014 and 2008 Initiation of the Knowledge Pharm (Pharma Wiedzy) programme for medicine the Group’s corporate social responsibility strategy until 2018. and pharmacy students from all Polish universities 2008 Publication of the first environmental report The report was drawn up in parallel to the strategy, and in consequence the group of people involved in the process for several months was very large. We are 2007 Obtaining the ISO 14001 environmental certificate and OHSAS 18001 occupational health and safety certificate very grateful to all employees across Polpharma Group locations in Poland who supported the process of collection of data and material and co-authored the 2004 Obtaining the ‚Integrated permit’, which confirms that the company meets EU report. Special credit goes to individual function leaders, who contributed their requirements on Integrated pollution prevention and control advice and experience at each stage of work on the strategy and the report. 2003 The first title of the Friend of Polish Cardiology awarded to Polpharma We would also like to say thank you to our stakeholders – partners, associates and by the Polish Cardiac Society representatives of a number of important organisations and entities, whose inputs 2002 Launch of our European Educational Programme aimed at providing knowledge can be found in the report. on the latest advancements In medicine and pharmacy to doctors and pharmacists

2002 Inauguration of Polscreen: the Polish Programme for the Prevention of Coronary Finally, we would like to thank SGS and the team led by Ms Małgorzata Greszta, Disease, which was the largest population-based study In the world. Approx. 730.000 who supported us with their advice in the strategy and report development process, patients were examined as part of the Polscreen programme from 2002 to 2005 and Deloitte for the review of the data disclosed in the report. 2001 Establishment of the Foundation for the Development of Polish Pharmacy and

Magdalena Rzeszotalska 2000 Polpharma decides to sponsor Polpharma Starogard Gdański. a men’s basketball team

2000 Privatisation of Polpharma based on Polish capital and the beginning of a shift In the company’s mindset on Its role within the society

Graphics and desktop publishing: Olga Figurska, lunatikot Photographs on page 33: The Starak Family Foundation | photo: M. Jędrzejewski